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1 ABSTRACT  
Malaria is an endemic disease across sub-Saharan Africa. P. falciparum is the most 
lethal species of the parasite and is responsible for over 400 000 deaths in the region. 
There is no effective vaccine for malaria. Early diagnosis remains key to ensure that 
the correct treatment for the disease can be administrated. Rapid diagnostic tests 
(RDT’s) are an attractive alternative to light microscopy for the diagnosis of a malaria 
infection. RDT’s have weaknesses such as the reagents are not stable. Therefore, this 
study looked at ways to improve RDT’s.   
Differential scanning fluorimetry (DSF) was used  to study the thermal stability 
of recombinant Plasmodium falciparum glyceraldehyde-3-phosphate dehydrogenase 
(rPfGAPDH), lactate dehydrogenase (rPfLDH) and Histidine Rich Protein-2 (rPfHRP-
2) and found that rPfGAPDH had the highest melting temperature (Tm; 55°C), while a 
Tm could not be obtained for rPfHRP-2. Chloroquine and quinine were shown to interact 
with rPfLDH and rPfGAPDH using DSF. The drug-protein interactions were also shown 
in silico with docking studies. Anti-rPfLDH IgY and anti-rPfHRP-2 IgY antibodies were 
evaluated using DSF in the presence of the respective antigens. A higher Tm was 
obtained in the presence of the antigen, indicating binding of antigen to the antibody 
at pH 4. 
RDT’s are often exposed to high ambient temperatures which can cause the 
antibodies to degrade. Cold chain storage facilities are not always available to store 
RDT’s. Heat stable antibodies may aid in improving the stability of RDT’s. The 
thermodynamic parameters of antibodies from chickens, mice, rabbits and crocodiles 
were compared . Chicken IgY was found to be the most stable having a ΔµG of 71.48 
Kjmol-1 (±0.32); ΔµS = 1.47 (± 0.01) Kj.mol-1.K-1; ΔµH = 508 Kj.mol-1 (2.08) and Tm 
73.75°C (±0.2). The Tm of freshly isolated chicken IgY and IgY stored from 1990 were 
compared and found to have similar a Tm confirming the IgY molecule is a stable 
molecule.  
Different conjugating methods were compared for the conjugation of HRPC to 
chicken anti-rabbit serum albumin IgY and the glutaraldehyde method was found to be 
the most efficient conjugating method. The conjugate detected 20 ng of rabbit serum 
albumin.  
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Storage of low concentrations of HRPC was found to lose activity in a short 
period of time. Therefore, an aqueous-organic solvent buffer with methanol and Ca2+ 
was developed and was able to store HRPC for three months with 70% activity.   
The second part of the study was to develop a diagnostic test for a P. falciparum 
infection by detecting rPfHRP-2. Two Copper-based assays were developed based on 
the high affinity histidine residues in PfHRP-2 have for copper (Cu). The first assay 
depends on reducing Cu2+ to Cu+ which inhibits horseradish peroxidase activity. The 
presence of rPfHRP-2 binds to and removes Cu+ allowing HRPC to maintain high 
activity. This assay detected 100 ng of rPfHRP-2 in solution. The second assay 
involves Cu2+ catalysing the oxidation of tetramethylbenzidine (TMB). The Presence of 
rPfHRP-2 prevents TMB oxidation by binding and removing Cu2+, leading to a 
suppressed oxidised TMB signal. Neither assay worked in an ELISA based format.  
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CHAPTER 1: Literature review  
1.1. Introduction of malaria related to humans  
There are five species of malaria parasite that infect humans they are; Plasmodium 
falciparum, vivax, ovale, malariae and knowlsei (Snow et al., 2005). The infection from 
Plasmodium falciparum is the most lethal and is responsible for the largest number of deaths 
(Geleta and ketema, (2016). Malaria parasites are transmitted by the female Anopheles 
mosquito to a human with a single bite. The World Health Organisation (WHO) predicts that 
3.3 billion people are at risk of contracting the disease across the globe. Areas with the highest 
malaria burden are Southeast Asia, South America and Africa. In 2015 there were 214 million 
malaria cases of which over 80% (171.2 million) were from Africa and 438 000 deaths of which, 
over 90% (394 200) were from Africa (WHO, 2015b). 
1.2. The life cycle of the malaria parasite 
The malaria life cycle occurs in two hosts, the female Anopheles mosquitos and 
humans (Figure 1.1). A human host is infected when a female Anopheles mosquito carrying a 
Plasmodium malaria infection bites a human for a blood meal, the sporozoites are injected into 
the human (Kebaier et al., 2009). The sporozoites migrate through the lymphatic system or by 
the blood system usually via active gliding motility whereby the sporozoites move towards the 
liver, pass through the Kuppfer cells and enter hepatocytes. This marks the beginning of the 
liver stage of the malaria infection (Kebaier et al., 2009; Cowman and Crabb, 2006). 
Within hepatocytes, sporozoites differentiate and divide into mature hepatic schizonts 
which burst open and release thousands of merozoites. Merozoites invade red blood cells 
(RBC) via protein-protein interaction called the actin-myosin motor (Keeley and Soldati, 2004), 
to start the blood stage of the malaria life cycle. Within RBC asexual reproduction occurs 
whereby the merozoites go through a 48-hour replication cycle, going through ring, trophozoite, 
and schizont stages that finally lead to the formation  of 16-32 daughter merozoites that are 
released when the RBC ruptures. Uninfected RBC can be infected by the daughter merozoites 
(Cowman and Crabb, 2006). During RBC rupture, a malaria patient’s symptoms are 
headaches, sore muscle and joints and fatigue, which develops into fever and vomiting. A P. 
falciparum infection may worsen to severe and cerebral malaria (Reyburn, 2010). 
 The sexual stage of P. falciparum occurs in the blood of the human host, where male 
and female gametocytes are formed. The gametocytes are ingested by a female Anopheles 
mosquito when it feeds for a blood meal (Cowman and Crabb, 2006). Gametocytes develop 
into gametes in the mosquito's gut, then into a zygote which moves into the mosquito’s midgut 
and develops into an ookinete and finally into an oocyst which releases sporozoites that can 
enter into the salivary gland of the mosquito. 
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Figure 1.1: A cartoon representation of a P. falciparum malaria infection in a human host. The 
human host is infected with sporozoites from a female Anopheles mosquito (A). Sporozoites 
migrate to the liver via the blood or lymphatic system (B). Sporozoites invading the hepatocytes 
(beginning of the liver stage) differentiation into merozoites (C). Merozoites infecting RBC mark 
the beginning of the parasites asexual life cycle (D). Following sexual stage of the life cycle in the 
blood a female anopheles mosquito feeds on a blood meal containing male and female gametes 
(E). (Figure adapted from Cowman and Crabb, 2006). 
1.3. Malaria in South Africa 
In South Africa the number of malaria cases are much lower than neighbouring 
countries, with 20 malaria infections per 100 000 individuals. Most of the infections are from P. 
falciparum malaria (Manana et al., 2018). The disease is an endemic in three of South Africa’s 
nine provinces (Limpopo, Mpumalanga, and KwaZulu-Natal) and higher transmission is 
associated with rainy weather. In the 2015/2016 season, there were  6 385 reported cases of 
malaria with 58 deaths, which increased in the 2016/2017 season to 9 478 infections and 76 
deaths (Malaria in South Africa, http://www.nicd.ac.za/wp-content/uploads/2017/05/Malaria-
update.pdf). The primary defence in households in malaria-endemic areas is the use of long-
lasting residual insecticides.  
However, there has been insecticide resistance to deltamethrin (pyrethroid), DDT 
(organochlorine) and bendiocarb (carbamate) (Brooke et al., 2015). 
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 An alternative approach to aid in eradicating malaria from South Africa that is currently 
being considered is the use of the sterile insect technique (Manana et al., 2018; Munhenga et 
al., 2011). Until there is a vaccine developed against malaria infections, RDT’s and correct 
anti-malaria drugs remain critical to saving lives.  
1.4. Cerebral malaria 
Cerebral malaria is the most lethal form of malaria and caused by a P. falciparum 
infection which is responsible for the most malaria deaths globally. Around 20% of CM infected 
patients do not survive and children under the age of five, living in sub-Saharan Africa are at 
highest risk (Ghazanfari et al., 2018; Christensen and Eslick, 2015). About 25% of patients 
who survive a CM infection often have neurological disorders such as epilepsy, attention deficit 
hyperactivity disorder (ADHD), lower intelligence quotient (IQ) and other neurodisabilities 
(Christensen and Eslick, 2015). 
The exact mechanism for CM is not entirely understood and ideas of the CM 
mechanism are based on post-mortem studies on the brains of CM victims. One of the ideas 
was that the sequestration of the parasites were due to parasitized red blood cells (pRBC) 
adhering to the erythrocyte cell surface by P. falciparum erythrocytes membrane protein-1 
(PfEMP-1) binding to ligands on CD36 cells (Craig and Scherf, 2001; Kraemer and Smith, 
2006), endothelial protein C receptor (EPCR; Newbold et al., 1997), or intercellular adhesion 
molecule 1 (ICAM-1; Chakravorty and Craig, 2005). The adherence of pRBC leads to the 
infected RBC’s blocking blood vessels which results in reduced blood flow, which may result 
in the patient going into a coma or death. Some studies have reported a positive correlation 
between the number of pRBC and patients going into a coma (Silamut et al., 1999; Ponsford 
et al., 2011). However, in a review by Ghazanfari et al., (2018) it was argued that several 
factors must be involved for developing CM.   
P. falciparum is the only species of malaria that produces histidine rich protein-2 
(PfHRP-2) and this has led to speculation that PfHRP-2 may be involved in the progression of 
P. falciparum malaria  to CM. Various studies have reported that higher concentrations of 
PfHRP-2 is associated with a malaria progression to CM (Park et al., 2017; Fox et al., 2013; 
Rubach et al., 2012; Seydel et al., 2012). The ranges of PfHRP-2 concentrations from patients 
in the different studies were 2684 ng/ml (1092 – 5537 ng/ml) for CM and 929 ng/ml (379 – 
2735 ng/ml) severe malaria anaemia ( Park et al., 2017); 7833 ng/ml (± 2.5 ng/ml) for CM and 
421 ng/ml (± 9 ng/ml) for an uncomplicated malaria infection (Fox et al., 2013); 1008 ng/ml 
(342 – 2572 ng/ml Interquartile range (IQR)) for CM, 465 ng/ml (36 -1432 ng/ml IQR) for 
uncomplicated infections and 4000 ng/ml (1194.5 – 5287.3 ng/ml) for victims of CM  
(Rubach et al., 2012); 12 800 ng/ml (± 7057 ng/ml) from CM infected patients; 1028 
ng/ml (±2970 ng/ml) for malaria infected patients; 6367 ng/ml (± 3862 ng/ml) for retinopathy 
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CM positive patients and 1539 ng/ml (± 2032 ng/ml) retinopathy CM negative patients (Seydel 
et al., 2012).  
It could be argued that the increased concentrations of PfHRP-2 may be due to a higher 
parasite biomass, however, Seydel et al., (2012) showed that even though a CM patient has 
a 5-fold higher PfHRP-2 concentration, the parasites had a concentration of 2.03 fg/ml for CM 
retinopathy negative patients, while parasites for CM retinopathy positive patients were 2.46 
fg/ml. This therefore indicated that even though the parasite biomasses were similar, the higher 
concentration of PfHRP-2 was associated to patients with CM. 
All these studies have highlighted the correlation between PfHRP-2 and the 
development of CM. However, some of the studies had conflicting results. Manning et al., 
(2011) reported PfHRP-2 concentrations for uncomplicated malaria infections (77 – 1114 
ng/ml) were at a similar range to severe malaria (113 – 1113 ng/ml). It is important to note that 
CM patients were not compared, and the study was conducted in Papa New Guinea (PNG), 
while studies mentioned prior were all done in sub-Saharan Africa where CM is most 
prominent.  
 Further evidence suggesting PfHRP-2 may play a role in the development of CM was 
provided by Pal et al., (2016) in an in vitro and in an in vivo model (Pal et al., 2017). The in 
vitro model used the human cerebral microvascular endothelial cell line (hCMEC/D3) and 
measured its transendothelial electric resistance (TEER) in the presence of P falciparum 3D7 
parasitized RBC (HRP-2 positive); Dd2 parasitized RBC (HRP-2 negative); Dd2 parasitized 
RBC (supplemented with HRP-2). Results showed 3D7 RBC and Dd2 HRP-2 supplemented 
RBC caused the TEER resistance to decrease while the Dd2 RBC showed no substantial 
change in resistance. Poly L-His and the two main PfHRP-2 fragments were supplemented 
with Dd2 and there was no significant change in the resistance of the TEER. The result was 
due to the triggering of the endothelial cell inflammasome causing junctional protein 
rearrangement, which makes the endothelial cell more permeable causing leakage and 
decrease resistance showed by the TEER.  Furthermore, rPfHRP-2 treatment of hCMEC/D3 
upregulated ICAM-1 and vascular cell adhesion protein-1 (VCAM-1) which have been shown 
to bind PfEMP-1. PfEMP-1 is thought to play a role in the development of CM (Craig and 
Scherf, 2001). Pal et al., (2017) showed when PfHRP-2 was spiked into P. berghei infected 
mice, PfHRP-2 was able to pass the blood brain barrier (BBB) and the mice died six days 
earlier when PfHRP-2 was present compared to mice infected with  P. berghi and spiked with 
BSA.  
 There is some evidence suggesting PfHRP-2 may play a role in the progression of an 
uncomplicated malaria infection to a CM infection. To date, there is no reliable diagnosis for a 
CM infection.  
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Currently, if a patient is living in a malaria endemic area and goes into a coma, they 
are diagnosed with CM and diagnosis is revaluated if the antimalaria drug treatment does not 
work.  
The gold standard for confirming a CM infection is if a post-mortem on the brain tissue 
of an infected patient shows sequestration of parasites (Seydel et al., 2012). Therefore, if a 
rapid, low cost, reliable detection system could be optimised for determining PfHRP-2 
concentrations, one could potentially diagnose the likelihood of a patient's infection 
progressing to a CM infection.   
1.5.  Malaria diagnosis methods: 
1.5.1. Light microscopy to diagnose a malaria infection 
Light microscopy is a common method used to diagnose malaria and there are two 
types of samples used: a thick or thin blood film. Thick blood film should be used first to 
diagnose if a patient is infected.  
Thick blood films use 1 – 2 drops of blood smeared (20 – 30 layers thick) over 1.5 to 2 
cm in diameter. A hypotonic solution is used to lyse the erythrocytes, and the cell contents are 
released including different stages of the malaria parasite stain. Thick blood film is more 
sensitive for detecting a malaria infection. An infection is determined by counting either 500 
parasites or 1000 white blood cells (WBC). If the WBC count is not previously determined, 
assume 8000 WBC per µl of blood (Garcia and Isenberg, 2007; Mathinson and Pritt, 2017).  
In a thin blood film, erythrocytes are stained in and fixed with absolute methanol and it 
can be used to diagnose the species of malaria (Garcia and Isenberg, 2007; Mathinson and 
Pritt, 2017).  
Typical stain dyes are used for both thick and thin blood films are Giemsa, Wright stain 
or a Giemsa-Wright stain, all the stains, stain DNA. The Giemsa stain is recommended as all 
cytoplasmic material is stained and can be viewed easily, making malaria species identification 
possible (Moody, 2002). Examination of slides is recommended at 100 x magnification with oil 
immersion of 100 – 300 fields depending on the area, as more fields should be viewed where 
the disease is less prevalent (Ochola et al., 2006).  
Light microscopy remains the gold standard to diagnose a malaria infection due to 
advantages such as sensitivity, species identity and low cost. The drawbacks are that 
sensitivity depends on the microscopist or that mixed infections can be missed (P. knowlesi; 
Singh and Daneshvar, 2013).  
Fluorescence microscopy is an alternative to light microscopy, however, only offers a 
qualitative measure of the parasite progression, therefore %parasitaemia cannot be 
calculated. The two main fluorophores of fluorescence microscopy used are acridine orange 
and benzothiocarboxypurine both work by staining DNA.  
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Acridine orange stains DNA of living and dead parasites and is toxic, therefore may 
overestimate the severity of an infection. Benzothiocarboxypurine can stain only living parasite 
DNA since it is actively adsorbed (Moody, 2002). 
1.5.2. Nucleic acid method to detect malaria  
The Polymerase chain reaction (PCR) is used to determine a malaria infection in a 
laboratory environment. Two commonly used PCR methods are quantitative PCR and nested 
PCR. Typically, the technique works by obtaining a suspected patient’s blood sample, after 
which, nucleic acids are extracted. Reagents are added including the primers to amplify the 
target nucleic acid sequence. The targeted genes are the 18s small subunit ribosomal gene. 
The amplicon is then visualised by fluorescence, the turbidity of the solution or UV visualisation 
of the band on an agarose gel (Vasoo and Pritt, 2013; Buppan et al., 2010).  
The advantages of PCR are: its sensitivity, as  0.02 to 20 parasites per µl of blood can 
be identified; nested-PCR can identify different species of infection; a mixed malaria infection 
and is less subjective than light microscopy (Vasoo and Pritt, 2013; Mathinson and Pritt, 2017). 
The drawbacks of PCR are: its cost factor as a laboratory is required and the method requires 
skilled personnel (Mathinson and Pritt, 2017).   
1.5.3. Aptamers used to diagnose a malaria infection 
Aptamers are biorecognition oligonucleotide chains (made up of either DNA or RNA)  
that are used for the capture of specific molecules depending on their properties (Ragavan et 
al., 2018). The method is used to find aptamers that are  systematic evolution of ligands by 
exponential enrichment (SELEX) which screen between 1012-1015 nucleotide random regions 
from a library. Jain et al., (2016) reported the use of an aptamer (P38) conjugated to gold 
nanoparticles that were used to diagnose a malaria P. falciparum infection by detecting PfLDH. 
The P38 aptamer was shown to detect PfLDH and none of the human LDH (hLDHA and 
hLDHB). The Kd was 0.35 µM and a PfLDH limit of detection 281 ± 11 pM. Other studies that 
have looked at aptamers as a diagnostic tool for malaria were reported by Lee et al., (2012); 
Cheung et al., (2013) and Frith et al., (2018). 
1.5.4. Serology to detect malaria  
Serology is the detection of antibodies. Serology is not used for malaria diagnosis as 
antibodies take at least a week after the infection to be detected and may last up to 12 months 
post infection. Therefore, past and current infections cannot be differentiated. Serology is used 
is in the screening of blood donors and testing febrile patients (Mathinson and Pritt, 2017). 
1.5.5. Biosensors and optical assays for malaria diagnosis 
Biosensors include electrochemical sensors, immunosensors, and optical sensors, 
colorimetric biosensors, fluorescence sensors, surface plasmon resonance sensors, surface-
enhanced Raman spectroscopy, quartz crystal microbalance sensors, lab-on-a-chip  
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and microfluidic devices, paper-based sensors, cell phone-based sensors, optical 
imaging and miscellaneous sensors. Even though these are beyond the scope of the current 
review, a review by Ragavan et al., (2018) covered these malaria diagnostic assays.  
1.5.6. Malaria rapid diagnostic tests to detect malaria  
Malaria rapid diagnostic tests (MRDT’s) are a popular alternative to light microscopy in 
remote malaria endemic areas (Cheng et al., 2014). The technique is simple to perform, and 
low level of expertise needed. The basic concept of an RDT is shown in Figure 1.2.  
 
Figure 1.2: A cartoon representation of an RDT. (Figure adapted from Murray et al., 2008). 
An RDT utilises a lateral flow immunochromatographic system on a nitrocellulose-
based platform. A blood spot is added to the lysing agent. The lysed parasite material flows 
through the nitrocellulose via capillary action and passes a set of capture antibodies 
(represented by 1 and 2; Figure 1.2). Within an RDT a second set of antibodies are present, 
known as detector antibodies and usually have gold nano particles conjugated to them. If the 
parasite’s antigen is present the detector antibodies will bind to the antigens and once the 
parasite antigen is captured at positions 1 or 2, a coloured line will form, indicating a positive 
infection. A control line shows the RDT is working and typically the most commonly used 
antigens are PfHRP-2 for P. falciparum and LDH and aldolase to diagnose different infections 
or pan infections depending on the RDT (Murray et al., 2008).  
For RDT PfHRP-2  is the antigen most commonly detected (WHO, 2015b; Cheng et 
al., 2014). Generally, PfHRP-2 based RDT are more stable and have higher sensitivity than 
RDT’s detecting LDH and aldolase (WHO, 2015b). RDT’s are easy to use, and personnel 
require minimum training, results are available in under 30 minutes and a laboratory is not 
necessary. 
RDT’s are less sensitive compared to light microscopy and the WHO recommends 
RDT’s to be used in combination with a separate diagnostic method like light microscopy 
(Mathinson and Pritt, 2017).  
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Another major problem with RDT’s is its variation in sensitivity and selectivity due to 
batch variation and the antibodies on the nitrocellulose strip degrade when exposed to high 
ambient temperatures in areas where the RDT’s are stored (Jimenez et al., 2017).    
1.5.7. Diagnosis of cerebral malaria  
To date, there is no rapid diagnosis method for CM. Reports have stated about 25% of 
deaths initially diagnosed with CM were due to other causes (Taylor et al., 2004).  Retinopathy 
is been looked at as a possible technique which can be used for the diagnosis of CM infection. 
This is due to CM infected patients having retinal whitening, and retinal vessels appear orange 
rather than red due to parasite infected erythrocytes, which cause polymerisation of 
hemoglobin into hemozoin (Beare et al., 2006).  However, Seydel et al., (2012) highlighted that 
retinopathy is relatively challenging and is not appropriate for use in remote locations. 
1.6. An alternative to retinopathy for CM rapid diagnosis 
Due to the complexity and lack of understanding of CM, a rapid diagnostic is difficult to 
develop. To date, a possible marker for severe malaria or a CM infection is tracking HRP-2 
concentrations in the blood (Seydel et al., 2012; Dvorin, 2017; Sinha et al., 2015). Dvorin, 
(2017) suggested a two-part diagnosis method based on the detection of HRP-2 and 
endothelial protein C receptor binding transcripts using PCR. The current most common 
method used to quantify PfHRP-2 concentrations is ELISA, but reagents and equipment are 
not readily available in the remote malaria endemic areas (Desakorn et al., 1997; Kim et al., 
2016). Sinha et al., (2015) evaluated the use of RDT’s as semi quantitative HRP-2 detectors, 
Paracheck®  was found to work best, although the plasma had to be separated from the sample 
as the threshold of HRP-2 was reached below the HRP-2 limit of detection. There is a need 
for a diagnostic method to detect and quantify HRP-2 as a potential indicator of severe malaria. 
1.7. The structure of HRP-2 
P. falciparum Histidine rich protein-2 is a 30 kDA water soluble protein that was first 
discovered by Wellems and Howard, (1986). HRP-2 is only expressed by P. falciparum malaria 
where it is expressed in two stages, the blood stage and the gametocyte stage (Howard et al., 
1986; Hayward et al., 2000). Some HRP-2 is released into the blood when the blood stage 
schizont is developing, and most is released when the infected erythrocyte ruptures (Howard 
et al., 1986). HRP-2 can be present  in concentrations greater than 1 µg/ml in the blood and 
may persist for up to a month after a P. falciparum malaria infection has been resolved 
(Dondorp et al., 2005). 
HRP-2 has an unusual amino acid composition where 87% of the protein consists of 
histidine (35%), alanine (40%) and aspartic acid (12%) (Wellems and Howard, 1986). A 3D 
crystal structure has not been resolved for HRP-2.  
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The AHHAAD repeats occurring throughout the amino acid sequence of the protein 
and the 309 amino acid sequence is shown in Figure 1.3.   
 
Figure 1.3: The amino acid sequence of PfHRP-2. (P90582-1). 
1.8. Function of HRP-2 
The exact function of HRP-2 is unknown. Benedetti et al., (2003) showed HRP-2 is 
similar to hisactophilin in the sense that both proteins can bind actin at acidic pH (Shown using 
circular dichroism spectra). HRP-2 also binds phosphatidyl- inositol 4,3 biphosphate (PIP2) in 
an α- helical conformation, which is typical to an actin binding protein. By binding actin, the 
secondary structure formed stabilises actin-filaments, and this could stabilise infected 
erythrocytes and aid in the cytoskeleton changes during knob formation.  
Das et al., (2006) showed HRP-2 might play a role in the supersession of the host’s 
immune system by binding to T-cells and B-cells.  Sullivan et al., (1996) and Choi et al., (1999) 
demonstrated HRP-2 aids in heme binding (50 molecules of heme per molecule of HRP-2) and 
polymerization of toxic heme into non-toxic hemozoin. However, Nakatani et al., (2014) 
suggested heme detoxification protein aids the parasite with heme detoxification.  
Ndonwi et al., (2011) showed HRP-2 acts as a procoagulant by binding heparin with 
high affinity, therefore, preventing antithrombin activity. Interestingly when HRP-2 was in the 
presence of Zn2+, or Cu2+ HRP-2 had a higher binding affinity for heparin. The 51 His-His-Ala 
repeat regions on HRP-2 allow the protein to bind to metal cations. HRP-2 affinity for metal 
ions was first reported by Panton et al., (1989). Panton et al., (1989) showed PfHRP-2 needed 
450 mM imidazole to be removed off a Cu2+ matrix, while only 300 mM imidazole was needed 
to elute PfHRP-2 of a Zn2+ matrix. This indicated PfHRP-2 binds with higher affinity to Cu2+. 
According to Bauer et al., 2017; Co2+ and Zn2+ had the highest KON but the lowest KD, 
whereas Cu2+ had the lowest KON and the highest KD, therefore the proteins affinity is higher 
for Co2+ and Zn2+ than for Cu2+.  
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1.9. P. falciparum isolates lacking the HRP-2 gene 
Even though most RDT’s rely on the detection of HRP-2 to diagnose a P. falciparum 
malaria infection (Lee et al., 2006), isolates lacking HRP-2 have recently been reported.  
The first reported area affected was the Peruvian Amazon basin (Gamboa et al., 2010). 
Several studies have since then reported HRP-2 and HRP-3 deletions in isolates from India 
(Kumar et al., 2013), Brazil and Bolivia (Viana et al., 2017), Mali (Koita et al., 2012);  Senegal 
(Wurtz et al., 2013) and Kenya (Beshir et al., 2017).  
The genes for HRP-2 and HRP-3 are located on chromosomes 8 (HRP-2) and 13 
(HRP-3) therefore, gene deletions are assumed to be due to independent events. In Brazil and 
Bolivia HRP-3 gene deletions are more common (Viana et al., 2017).  
1.10. Current state of malaria diagnosis 
Light microscopy is the gold standard for diagnosing a malaria infection, however, it 
cannot diagnosed if a P. falciparum infected patients malaria infection will progress to CM. 
Many biosensors and optical assays are being developed for the rapid detection and 
quantification of HRP-2 but none of them are recommended by WHO.    
1.11. Copper binding to histidine residues 
A study done by Zhao and Waite, (2006) showed histidine residues of  the Mcfp-4-
sequence  peptide (a histidine rich protein) bound more Cu ions than any other metal ion tested 
using mass spectroscopy (Figure 1.4).    
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Figure 1.4: A mass spectrum illustrating the binding of Fe3+, Ni2+, Zn2+, Co2+ and Cu2+ to Mcfp-4-. 
The result of showed 11 Cu2+ bound per 8 histidine residues. Knowing HRP-2 has a high affinity for Cu, 
an assay could potentially be developed and used to detect and quantify HRP-2 based on its high affinity 
for Cu ions. (Figure adapted from Zhao and Waite, 2006). 
1.12. Introduction of HRPC  
Horseradish peroxidase (HRP; E.C1.11.1.7) is a plant peroxidase which is present in 
the roots of the horseradish plant (Armoracia Rusticana). There are at least 15 peroxidase 
isoenzymes with isoenzyme C (HRPC) being the most abundant and widely studied (Hoyle, 
1977; Veitich, 2004). HRPC is part of the type 3 peroxidase superfamily of heme containing 
oxidoreductases enzymes. The oxidoreductases catalyse the oxidation of various 
chromogenic organic compounds usually with high enzyme activity in the presence of 
hydrogen peroxide (H2O2) or sodium perborate (Zhao et al., 2015). HRPC is used in various 
fields like, biotechnology (Azevedo et al., 2003), immunodiagnostics (Krieg and Halbhuber, 
2003), biomedical applications such as aiding in cancer treatment (Wardman, 2002), 
wastewater treatment (Alemzadeh and Nejati, 2009) and detection of Cu in water samples 
(Xianyu et al., 2013).  
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1.13. Structure of HRPC 
HRPC is made up of 308 amino acids and a total molecular weight of 44 kDa. Gajhede 
et al., (1997) resolved the X-ray crystal structure of HRPC at 2.15Å (Figure 1.5). The main 
features of the HRPC molecule indicate most of the protein is made up of α- helices, the blue 
circles represent the Ca2+ ions in the distal and proximal region and the iron (III) protoporphyrin 
IX or heme group is indicated in red.  
There are 13 α-helices, and α-helices A-J are common in most peroxidases, while there 
is an additional three a-helices  D’, F’ and F” unique to HRPC. The function of the additional 3 
α-helices is not understood but it is suspected that helices D’, F’ and F”  may aid the catalytic 
efficiency of HRPC by keeping reactive intermediates within the hemes active site, therefore 
aiding in the oxidation of substrates.  
HRPC is a glycoprotein with a total carbohydrate content of between 18 – 22%. The 
carbohydrates are in the form of glycans (mannose, xylose, fucose, and N-acetylglucosamine) 
that are bound to the loops of the α- helices distributed across the protein (Gajhede et al., 
1997).  HRPC has nine potential glycosylation sites of which eight are glycosylated via N-linked 
amide bonds to asparagine residues. 
The amide bond motif is Asn-X (any amino acid)-Ser/Thr (Asn13, Asn57, Asn158, 
Asn186, Asn198, Asn214, Asn255 and Asn268; Veitch, 2004; Welinder, 1979). The glycans 
point away from HRPC and their role is to aid the enzyme to maintain its conformation and 
improve solubility. Smith et al., (1990) found that glycans were removed from HRPC, the 
enzyme precipitated in aqueous-saline buffer. This further confirmed the importance of the 
glycans for HRPC.   
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Figure 1.5: The 3D X-ray structure of horseradish peroxidase done at 2.15 Å using x-ray 
crystallography. The 3D structure shows a stick model in red that represents the heme, above the 
heme is a distal domain and below the heme is the proximal domain, both contain a calcium atom shown 
as a blue sphere. The α helices are shown by purple ribbons and the β sheets are shown in yellow. 
(Brookhaven accession code 1H5A). (Veitch, 2004). 
The active site of HRPC houses two metal ions, Ca2+  and a Fe3+ in the heme centre. 
There are two Ca2+ atoms per HRPC molecule. They are situated on either side of the heme 
in the distal region (above the heme) and proximal region (below the heme) respectively.  
The distal calcium atom is in a seven-coordinate state and is formed with an oxygen 
ligand set. The oxygen ligand set is formed by Asp43, Asp50, Ser52 side chains and Asp43, 
Val46 and Gky48 carbonyl groups (Gajhede et al., 1997).  
The proximal calcium atom has seven-coordinate bonds with Asp222, Asp230, Thr171, 
Thr225 side chains and Thr171, Thr225 and Ile225 carbonyl groups. Ca2+ helps maintain the 
heme pocket structure (Gajhede et al., 1997; Veitch, 2004). Howes et al., (2001) showed that 
the proximal Ca2+ atom is more often lost resulting in a conformational change in HRPC active 
site, therefore, substrates bind less efficient in the heme pocket. The Fe3+ centre plays a role 
in the oxidation of substrates.    
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The solvent access channel is located toward the right side of the heme edge and has 
a hydrophobic outer edge because of three Phe68, Phe142 and Phe179 residues and a C18 
methyl group. The inner layer of the solvent channel is positively charged, and this is due to 
the distal Arg38. Of the Phe residues, Phe179 is the most important of the three Phe due to its 
position (closest to the heme) that allows stereoselectivity of substrates entering the active 
site. This helps with rapid transfer of electrons to oxidise a substrate (Gajhede et al., 1997; 
Azevedo et al., 2003).  
Important amino acids in the catalytic mechanism are summarised in Table 1.1. 
Table 1.1: Amino acids important to the catalytic mechanism of HRPC. 
Amino acid        Function 
Arginine 38  ● Found in the distal region 
● Helps to maintain the reactive intermediate from compound 
1, by promoting H+ and stabilise reactive intermediates.  
Phenylalanine 41 ● Prevents substrates from binding to compound 1  
Histidine 42 ● Found in the distal region 
● Binds the first substrates H+ in compound 1 formation  
● Provides 1 H+ for the formation of H2O, when heme 
regenerated  
Asparagine 70 ● Binds to His42 to maintain its alkaline nature, when 
participating in compound 1 formation.   
Proline 139       May assist proton transfer when forming compound 2 
Gajhede et al., (1997); Azevedo et al., (2003); Veitich, (2004) 
1.14. HRPC mechanism  
The reaction mechanism of HRPC is important to look at in order to understand how 
HRPC functions and is explained in Figures 1.6-1.8.  
 
Figure 1.6: The mechanism formation of compound 1, Fe4+- oxoferryl. The Fe3+ in HRPC active site 
is oxidised by H2O2 with the aid of His42 and Arg38 (Veitch and Smith, 2000). 
17 
An H2O2 molecule enters the HRPC active site through the solvent access channel and 
binds to Fe3+ by the α-oxygen while the distal His42 abstracts a H+ from the H2O2 and the distal 
Arg38 stabilises the reactive β-oxygen. A highly reactive intermediate form called compound 
0 that through hetroclyclic cleavage becomes compound 1 (Figure 1.6). The result is Fe3+ is 
now Fe4+=O which is reactive to substrates (phenol represents the substrate in the 
mechanism). 
 Phenol enters the active site and is oxidised, firstly B: removes an H+ from the OH 
group of the phenol. The H+ is then attached to the distal His42 (intermediate not shown), and 
the now reactive phenolic substrate radical is stabilised by distal Arg38. The His42 donates 
the abstracted  H+ to the oxyferryl heme and compound 2 is formed (Figure 1.7). 
 
Figure 1.7: The reduction of compound 1 by phenol into compound 2. B represents a protein that 
abstracts H+ from phenol that will be taken up by distal His42 (Veitch and Smith, 2000). 
Finally, a second phenol can enter and is oxidised (Figure 1.8).  
 
Figure 1.8: A new phenol substrates H+ is abstracted by B. There is formation of H2O and 
regeneration of the active site (Veitch and Smith, 2000). 
The distal His42 binds to the α- O on the oxyferryl heme, which then has two H+ bound 
forming a H2O molecule displaced by the heme.  
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The heme centre returns to the original state with after the oxidation of two phenols and 
two H2O molecules from the H2O2. The overall reaction can be summarised as: 
        (1) 
Whereby the AH represents any chromogenic substrate. The overall reaction illustrates 
a single HRPC molecule oxidises two molecules of a substrate.  
1.15. HRPC substrates  
HRPC oxidises a large range of chromogenic and fluorometric substrates including 
2,20-Azino-di(3-ethylbenzothiazolin-6-sulfonate (ABTS); Benzidine (4,40-Diaminobiphenyl); 
3,30-Diaminobenzidine (DAB); Guaiacol (2-Methoxyphenol) Pyrogallol (1,2,3-
Trihidroxybenzene); Phenol; 3,3,5,5-Tetramethylbenzidine (TMB), to just name a few (Veitch 
and Smith, 2000). Of all substrates, the focus in the study was on TMB. TMB is an endpoint 
chromogenic substrate used in several biochemical techniques. The substrate is hydrophobic 
therefore it needs to be dissolved in an organic solvent like DMSO. TMB is popular due to its 
low toxicity and high sensitivity (Bos et al., 1981). Spectrophotometric analysis of TMB shows 
it has two peaks at 370 nm and 650 nm, this is where the diamine forms (oxidised TMB and is 
bright blue in colour; Figure 1.9) if a concentrated acid is added a second H+ from TMB is lost 
and the diamine becomes a diimine that absorbs at 450 nm (Figure 1.9; Josephy et al., 1982). 
Assays using metal ions like Cu2+ and nanoparticles use TMB as the chromogen of choice (Shi 
et al., 2016; Fu et al., 2018). 
 
 
Figure 1.9: Resulting products for the oxidation of TMB. The TMB molecule before oxidation (A). 
Diamine form of TMB after it has been oxidised by HRPC (B). The addition of a concentrated acid leads 
to formation of Diimine (C). (Figure adapted from Josephy et al., 1982).   
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1.16. Inhibitors of HRPC 
There are several known inhibitors of HRPC such as L-cysteine and other thiol-based 
compounds (Sariri et al., 2006), EDTA, sodium azide (Ortiz de Montellano et al., 1988) and 
several metal ions. Keyhani et al., (2003) and (2005) has reported the inhibitory effects of Cd2+ 
and Ni2+ on HRPC activity. This  was of environmental importance as both heavy metals are 
released from pollutants and interact with plant life. Ni2+ and Cd2+ both showed kinetic inhibition 
of peroxidase activity. Han et al., (2008) reported the inhibition of HRPC by Co2+ in a dose 
dependent manner and Moyo, (2014) reported the use of HRPC as a biosensor for the 
detection of Zn2+, based on the inhibition of HRPC by Zn2+. The most potent of the inhibitors 
reported was Cu+. Detection of Cu was used in an assay to detect Cu concentrations in water 
(Xianyu et al., 2013). Of all the metal ions reported, none were competitive inhibitors of HRPC.   
1.17. Advances of HRPC in biotechnology 
There are several assays which use HRPC as a reporter enzyme and the uses of the 
enzyme in biotechnology was reviewed by Azevedo et al., (2003). A potential new method in 
which HRPC could be used for the detection of compounds or other proteins could be based 
on their binding affinities to metal ions. One such assay has been described by Shi et al., 
(2016) whereby Cu+ was incubated in a sample with pyrophosphate. Pyrophosphate binds 
Cu+. Therefore, if HRPC was inhibited, it meant the absence of pyrophosphate and the amount 
of HRPC activity correlated to pyrophosphate concentration.    
1.18. Peroxidase like activity of Cu2+ and Fe3+ 
Nanotechnology is evolving and developing. Nanoparticles with peroxidase- like activity 
is an avenue researched to potentially replace enzymes (Gao et al., 2007; Wang et al., 2017).
  Wu et al., (2014)  reported that Fe3+ ions possess peroxidase- like activity indicating 
that within nanoparticles the peroxidase like activity was not only due to the nature of the 
nanoparticle but the Fe3+ ions as well. Similarly, Cu2+ has also been shown to possess 
peroxidase like activity (Shan et al., 2016). Interestingly both metal ions are involved in Fenton 
chemistry.  
 Fenton chemistry involves a metal ion transferring an electron (e-) to an oxidant like 
H2O2. This breaks up H2O2 into two OH• molecules that are highly reactive. The OH• can attack 
and oxidise chromogenic substrates like TMB into a diamine (Figure 1.9). The addition of NaCl 
to a H2O2 mixture forms more reactive intermediates called reactive chloride species (RCl-; 
Wardman and Candeias, 1996; Shan et al., 2016). This well characterised interaction has since 
been used for the detection of molecules which bind Fe3+ and Cu2+ such as L-cysteine and L-
histidine in urine (Wu et al., 2014; Xu et al., 2015); Uric acid (Lu et al; 2017) and dopamine 
(Wang et al., 2017). These assays indicate that there is promise around the peroxidase- like 
activity metal ion assays and this could potentially be used in a diagnostic assay. 
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1.19. Introduction to differential scanning fluorometry 
Differential scanning calorimetry (DSC) is commonly used to determine the thermal and 
thermodynamic stability of proteins in the field of life sciences (Bruylants et al., 2005). Methods 
such as surface plasma resonance (SPR) and isothermal calorimetry are methods used in 
determining protein-protein interactions and drug-protein interactions. However, a shortfall of 
these techniques is that they do not have high throughput capability for screening drug and 
fragment-based libraries. Therefore, the screening of small molecules is labour intensive, and 
the techniques require expensive machinery (Lo et al., 2004; Redhead et al., 2017).   
An assay was developed by Pantoliano et al., (2001) to reduce the labour required for 
drug discovery screening while still remaining economical. The assay was called the thermal 
shift assay which is now more commonly referred to as differential scanning fluorometry (DSF). 
For DSF a protein sample is heated at a constant temperature in the presence and absence 
of a drug molecule. A hydrophobic dye, known as a fluorophore which is usually SYPRO 
Orange is present in the mixture. The fluorophore binds specifically to hydrophobic amino acid 
residues and fluoresces upon binding.  
From the fluorescence signal the proteins melting temperature (Tm) is extrapolated. The 
Tm is an indication of when 50% of a protein has unfolded and higher Tm values generally 
correlates to more stable protein (Pantoliano et al., 2001 Niesen et al., 2007).  
If the drug molecule present in the mixture binds to the protein the drug can stabilise 
the protein and increase the proteins Tm. Generally, a 2°C increase in Tm for a protein in the 
presence of a drug is considered a protein-drug interaction. A drug may sometimes bind to a 
protein and reduce its stability. The drug is then not regarded as a potential drug to study 
further, since the drug may be binding non-specifically to the protein  (Niesen et al., 2007; 
McMahon et al., 2014; Huynh and Partch, 2015).   
 DSF has become a widely used biophysical technique due to its various applications 
in drug discovery (McMahon et al., 2014); extraction of thermodynamic properties of proteins 
(Wright et al., 2017); optimising of buffers for protein stability and protein purification (Crowther 
et al., 2010; Huynh and Partch, 2015); Measure of protein-protein interactions (Douse et al., 
2015). DSF can be used to screen hundreds of compounds in a single day, the reagents are 
inexpensive, low concentrations of proteins are used 1 – 5 µM (Niesen et al., 2007) and the 
equipment  required is an RT-qPCR machine. DSF has been applied to be used in cultured 
cells and tissue samples to show in vivo drug-protein interactions, the assay is called cellular 
thermal shift assay (CETSA; Jafari et al., 2014).     
 DSF has some shortfalls when determining  a protein Tm and drug-protein interactions.  
Not all proteins are suitable candidates for analysis using DSF, different transition curves of 
proteins unfolding are illustrated in Figure 1.10.  
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The green line is an indication of a protein well suited for DSF analysis, the initial 
fluorescence is low, and denaturation is indicated by a sharp transition with increasing 
temperature. The yellow line indicates an intermediate thermodenaturation curve, the initial 
fluorescence is high, but a transition still occurs. Typically, an intermediate transition is present 
for proteins that are in sub-optimal buffer conditions, are partially denatured or may have 
surface hydrophobic patches, which leads the fluorophore binding at lower temperatures 
(before the protein unfolds due to an increased temperature) and fluorescence. The red line 
shows the absence of a transition and from the profile a Tm cannot be obtained, generally this 
is due to a completely denatured protein, a buffer containing surfactants, or the protein is an 
enzyme with a large solvent access, therefore allowing the dye to enter the hydrophobic core 
(Niesen et al., 2007; Crowther et al., 2010; Reinhard et al., 2013).  
 
Figure 1.10: An arbitrary DSF fluorescence curve showing the transition of thermal denaturation 
of a good, intermediate and bad protein candidate.  (Figure adapted from Reinhard et al., 2013). 
It is suspected about 20% of recombinant proteins do not produce transitions when 
evaluated using DSF, due to the nature of the protein or incorrect purification conditions. A 
concern raised by Redhead et al., (2017) and Wright et al., (2017) was that by only measuring 
the protein’s Tm as a parameter to determine the protein’s stability or to determine if a small 
molecule can be considered a potential drug is just a qualitative measure. Both studies 
suggested using DSF data but by using ΔµG energy rather than Tm as a more quantitative 
measure.    
 Some studies have successfully used DSF as a primary fragment-based drug 
discovery screening tool with success.  
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Major and Smith, (2011) screened a 600 compound FBDD library against myoinositol-
3-phosphate synthase form Trypanasoma brucei and had a 6% hit rate. Hudson et al., (2012) 
screened a 665 compound FBDD library and had 66 matches of which 40% were validated by 
NMR. Redhead et al., (2015) showed SPR and DSF had a good correlation of results when 
identifying small molecules against kinase p38a. Even though some compounds may interfere 
with DSF screening due to the interactions with the fluorophore, DSF should be considered as 
a primary or secondary screen for interrogating small molecules for drug discovery (McMahon 
et al., 2014). Well established methods such as NMR and electro paramagnetic resonance 
(EPR) have also been shown to have conflicting data when interrogating small molecules for 
drug discovery (McMahon et al., 2014).  
Several studies have used DSF as a method to screen monoclonal antibodies to find 
the most stable antibody. An interesting observation from these studies was that DSF had a 
good correlation with DSC when determining the Tm of the proteins (He et al., 2010; Menzen 
and Friess, 2013; King et al., 2011). In summary a protein’s Tm has been shown to successfully 
identify drug candidates and has been used successfully to determine a proteins stability. 
1.20. Using DSF as a method to determine the thermal stability of proteins that could 
be used as malaria diagnostic reagents 
Currently, RDT’s are an attractive alternative to light microscopy but should be used in 
conjunction with other malaria diagnostic methods like light microscopy (Jimenez et al., 2017). 
This is due to limitations such as variance in sensitivity per batch of RDT. Sometimes RDT’s 
give false positive results due to the antibodies on the test strip losing activity because of high 
ambient temperatures in areas where the RDT’s are stored. Mouse monoclonal antibodies are 
used in the tests which can cross react with rheumatoid factor giving false positive (Iqbal et al., 
2000). If RDT’s could detect below 100 parasites per µl, this will aid in the diagnosis of malaria 
infected patients and will allow individuals to receive treatment faster, resulting in more lives 
being saved.  
1.21. Advantages of polyclonal chicken IgY antibodies in biotechnology  
Polyclonal chicken IgY antibodies are often used in biochemical techniques. Chicken 
IgY is cheap to produce, the antibodies can be obtained and purified using non-invasive 
methods (Schade et al., 1996), there is very little cross reactivity with mammalian IgG and IgY 
does not recognise rheumatoid factor. Chicken IgY is stable up to 60°C and 70°C in the 
presence of sugars (30% sucrose, trehalose or lactose; Jaradat and Marquardt, 2000).  The 
advantage of  chicken IgY has been recognised by the European Centre for the Validation of 
Alternate Method (ECVAM). They suggested that chicken IgY antibodies should be looked at 
to replace the use of mouse monoclonal IgG antibodies (Schade et al., 1996; Terzolo et al., 
2003). 
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 These benefits suggest chicken IgY antibodies have the potential to be used in RDT’s 
and should be further investigated as an avenue to address the limitations of RDT’s.  
1.22. PfGAPDH as a potential biomarker for diagnosis a P. falciparum malaria infection 
Since some malaria isolates are lacking PfHRP-2 (Gamboa et al., 2010), protein 
diagnostic markers are being analysed for their potential. Krause et al., (2017) showed 
PfGAPDH has the potential to be used a P. falciparum diagnostic marker as the protein exists 
in a 4 -6-fold higher concentration than PfLDH in parasite lysate.   
Detection of malaria biomarkers that are more stable and are present in higher 
concentrations in infected patients would overcome the limitation of PfLDH, which it is found 
in low concentrations and RDT’s detecting PfLDH lack sensitivity. However, further research 
still needs to be conducted.  
1.23. Problem statement 
Malaria related deaths have decreased in the last decade through vector control 
strategies like long-lasting insecticidal nets and indoor residual spraying, and the use of RDT’s 
allowing patients to receive appropriate treatment. More work still needs to be done to reduce 
the number of malaria related deaths. There is no rapid diagnosis method for a CM infection 
and CM results in 20% of infected patients dying and a further 25% with permanent 
neurological disorders. There is a link between a P. falciparum infection leading to CM and the 
concentration of the PfHRP-2 protein.  
Malaria RDT’s do not need skilled personnel to diagnose an infection and are 
economical. However, due to HRP-2 gene deletions and antibodies degrading under high 
ambient storage temperatures, RDT’s are recommended to be used in conjunction with a 
second diagnostic method like light microscopy.   
Hypothesis:  
Chicken IgY antibodies are more stable than the more commonly used mammal IgG 
molecules. Therefore, chicken IgY should be studied for its potential as diagnostic reagent.  
The second hypothesis was to show that PfHRP-2 can be detected by measuring its 
ability to bind Cu ions. 
1.24. Aims 
The first aim was to measure the thermal stability of common diagnostic target proteins 
rPfHRP-2 and rPfLDH and compare them to the thermal stability of rPfGAPDH (a potential 
diagnostic protein). DSF will also be used to show protein-protein interactions (PfHRP-2 and 
rPfLDH interaction with  their respective antibodies) and  rPfLDH and rPfGAPDH interaction 
with anti-malaria drugs. 
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In silico methods will be used to show the interaction of anti-malarial drugs with rPfLDH 
and rPfGAPDH. This can show the amino acids interacting with anti-malarial drugs and provide 
insight into important functional groups new anti-malarial drugs require.  
The second aim was to determine the thermal stability of chicken IgY antibodies and 
compare it to the antibodies from other species (Chapter 3). The third aim was to develop a 
detection and quantification method for PfHRP-2 by creating two competition assays with Cu 
and PfHRP-2.  
 
The first assay is based on a competition assay between HRPC and Cu+ for rPfHRP-2 
and the second assay is based on Cu2+ Fenton chemistry (Chapter 4). 
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2. CHAPTER 2: Recombinant expression and purification of P. 
falciparum HRP-2, LDH and GAPDH; differential scanning 
fluorometry analysis of recombinant protein, chicken IgY 
antibodies; rPfLDH and rPfGAPDH with anti-malarial drugs 
2.1.  Introduction  
Recombinant protein expression is by far the most widely used technique to obtain high 
(mg) yields of a protein, which avoids the need to continuously purify proteins from large 
amounts of animal or plant based material (Rosano and Ceccarelli, 2014). Recombinant 
protein expression has the added advantage of producing large quantities of proteins that 
would otherwise be difficult to obtain due to their low concentrations in nature (Rosano and 
Ceccarelli, 2014). There are various expression hosts such as plant (Krainer and Glieder, 
2015); fish (Davidson et al., 2003); filamentous fungi; yeast and, bacteria (Demain and 
Vaishnav, 2009). All expression hosts have their own advantages and disadvantages and an 
ideal host is selected according to experimental needs. The bacteria host Escherichia coli (E. 
coli) BL21 DE3 is the most widely used expression host (Rosano and Ceccarelli, 2014). 
There are numerous advantages that favour using E. coli (BL21) DE3 as an expression 
host such as: Its rapid growth rate kinetics resulting in high-density cell cultures in short periods 
of time. The media used to grow the bacterial cultures are economical (Sezonov et al., 2007). 
Competent  E. coli (BL21)  cells can be transformed with plasmid vectors in just 5 minutes 
(Pope and Kent, 1996). The host bacteria have the lacUV5 promoter which controls T7 RNA 
polymerase expression and this controls expression of genes coded for by the T7 promoter. 
The E.coli BL21 (DE3) strain is deficient in the Lon protease and ompT proteases. (Gottesman, 
1996; Grodberg and Dunn, 1988), therefore, protease inhibitors are not required.  
The two plasmid vectors used here were the pET(15b) and pKK223-3, which express 
fusion proteins with a hexa-his tag. The hexa-his tag allows for a single purification step of 
recombinant protein (≥ 95%) from a cell lysate. The recombinant protein can be used for 
immunisation of animals to raise antibodies. Chicken IgY antibodies are an attractive source 
of antibodies as high yields can be purified using non-invasive techniques (Schade et al., 
1996).   
Differential scanning fluorometry (DSF) is a popular assay used to determine the 
biophysical properties of proteins (Niesen et al., 2007). DSF measures the melting temperature 
(Tm) of a protein with the aid of a fluorescent dye typically SYPRO Orange (Niesen et al., 2007). 
The Tm value is an indication of when 50% of a protein has unfolded.  
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The principle of the DSF assay is a protein sample is heated at a ramp temperature 
from 25°C to 90°C (Pantoliano et al., 2001; Matulis et al., 2005). As a protein is heated the 
protein’s stability decreases and it begins to unfold, it causes the hydrophobic core amino acids 
to be exposed, which in turn interacts with the fluorescent dye (Pantoliano et al., 2001). 
DSF has been used in various studies and protocols. The studies range from looking 
at various biophysical properties of proteins, such as their thermodynamic properties (Wright 
et al., 2017) to high throughput thermal scanning (HTTS; Lavinder et al., 2009). HTTS uses 
DSF to screen if ligands bind to a protein as is often used as a primary screen in the field of 
drug discovery. The theory is that if a drug binds to a protein, the protein is stabilised, and 
there will be a shift in the Tm. However, DSF can show if a drug destabilises the protein, then, 
the Tm is reduced (Cimmperman et al., 2008; Lavinder et al., 2009 McMahon et al., 2014).  
Other studies looked at calculating the binding constant of ligands to proteins (Vivoli et al., 
2014), screening for optimal buffers (Vedadi et al., 2006; Ericsson et al., 2006; Crowther et al., 
2010) and protein-protein interactions (Layton and Hellinga, 2011).  
DSF has several advantages, such as equipment and reagents are economical  (Lo et 
al., 2004), and the assay has a short run time (McMahon et al., 2014). The disadvantages of 
DSF are that some proteins do not produce melt curves that show transitions, therefore a Tm 
cannot be determined (Crowther et al., 2010). Attempts have been made to get around this by 
using thiol-specific fluoroprobes (Vedadi et al., 2010; Hofmann et al., 2016).  
P. falciparum HRP-2, LDH, GAPDH were recombinantly expressed and affinity purified. 
DSF analysis was performed on the three antigens to determine their stability and interactions 
with different drugs in silico.    
2.2. Materials and Methods 
2.2.1. Materials (Chemicals and equipment) 
All common reagents, buffers, salts and SDS-PAGE reagents were purchased from 
Sigma and Merck. Recombinant protein expression reagents (Yeast extract, tryptone)  were 
purchased from Sigma-Aldrich-Fluka (Steinheim, Germany). Antibodies purchased from 
Novagen (Damstadt, Germany; excluding chicken IgY antibodies). Protein molecular weight 
marker, containing: 116 kDa β-galactosidase; 66.2 kDa bovine serum albumin; 45 kDa 
ovalbumin; 35 kDa lactate dehydrogenase; 25 kDa REase Bsp981; 18.4 kDa β-lactoglobulin 
and 14.4 kDa lysozyme (Vilinius, Lithuania). SYPRO Orange (Sigma). 
Bovine serum albumin (BSA) was purchased from Roche (Mannheim, Germany). Maxi 
Sorp™ 96-well ELISA plates were from Nunc products (Roskilde, Denmark). PCR-X clear 
tubes (Star labs; Germany). Ni2+-NTA agarose (Qiagen). 
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AvantiTM J-26 XPI and AllegraTM X-22R centrifuges from Beckman Coulter 
(California, USA); UV-1800 Shimadzu spectrophotometer from Shimadzu corporation (Kyoto, 
Japan); pH meter from HANNA instruments;  Corbett Research PCR Rotorgene 6000 and 
VersaMax™ ELISA plate reader was purchased from Molecular Devices Corporation 
(California, USA). 
2.2.2. Recombinant expression and purification of PfHRP-2; PfLDH and PfGAPDH 
Glycerol stocks of E. coli (BL21) DE3 bacterial cells transformed with either the pET-
15(b) vector coding for rPfHRP-2 or rPfGAPDH or the pKK223-3 vector coding for rPfLDH, 
were used. The glycerol stocks were used to 3-way streak a LB agar plate (1% (w/v) tryptone; 
0.5 % (w/v) yeast extract; 85 mM NaCl; 11 mM glucose; 1.5% (w/v) bacto-agar prepared in 
dH2O and autoclaved) which was incubated overnight at 37°C. A single colony was used to 
inoculate 10 ml of 2 x YT (1.6% (w/v) Tryptone; 1.0% (w/v) bacto yeast; 0.5% NaCl; 50 µg/ml 
ampicillin) and grown overnight at 37°C with agitation (200 RPM).  
A sample of the culture was diluted 1:100 in fresh terrific broth (TB media; 1.2% (w/v) 
tryptone, 2.4% (w/v) yeast extract, 0.4% (v/v) glycerol, 0.17 M KH2PO4, 0.72 M K2HPO4; 50 
µg/µl ampicillin) and grown at 37°C with agitation (200 RPM) until the cultures reached an O.D 
of 0.5-0.6 for rPfHRP-2. The culture was then supplemented with 1 mM lactose (lactose was 
used since it has previously been shown inhouse to increase the expression of rPfHRP-2)  and 
grown overnight at 37°C with agitation (200 RPM). For rPfLDH and rPfGAPDH  cultures were 
grown overnight at 37°C. 
2.2.3.  Ni2+-NTA affinity purification of rPfHRP-2, rPfLDH and rPfGAPDH  
After expression of all three proteins, the cells were harvested by centrifugation (5000 
x g; 10 min; 4°C), the supernatant was decanted, and the pellet was resuspended in wash 
buffer (50mM NaH2PO4; 300 mM NaCl; 20 mM imidazole) at 20% of the original cell cultures 
volume. The cells were lysed by sonication (6 x 45 sec at 20% amplitude). 
The insoluble cell material was pelleted by centrifugation (12 000 x g; 20 min; 4°C) and 
the supernatant contained the recombinant protein. A Ni2+-NTA resin was equilibrated with 
wash buffer and used to affinity purify recombinant proteins. The supernatant fraction was 
incubated with the resin for an hour at RT on an end over end rotor.  
The lysates and Ni2+-matrices were poured into a 10 ml Bio-Rad affinity matrix column. 
For rPfLDH and rPfGAPDH E. coli (BL21) DE3 proteins were washed away with wash buffer 
(50mM NaH2PO4; 300 mM NaCl; 20 mM imidazole) and the recombinant protein was eluted 
with elution buffer (50mM NaH2PO4; 300 mM NaCl; 250 mM imidazole).  
For rPfHRP-2, two wash steps were required, buffer 1 (50mM NaH2PO4; 300 mM NaCl; 
20 mM imidazole) and wash buffer 2 (50mM NaH2PO4; 300 mM NaCl; 250 mM imidazole). 
rPfHRP-2 was eluted with 500 mM imidazole. 
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2.2.4. SDS-PAGE  
The protein samples purity was determined by running the samples on a 12.5% 
reducing SDS-PAGE gels that were stained with Coomassie brilliant blue R-250 for analysis 
(Laemmli, 1970). The gels were run at 20 mA. 
2.2.5. Western blotting  
The western blotting procedure was followed as per Towbin et al., (1979). In brief, 
electrophoresis on an SDS-PAGE gel, the protein was transferred to the nitrocellulose paper 
overnight at 20 mA and proteins were visualised by staining with Ponceau S (0.1% (w/v) 
Ponceau S, 15% (v/v) acetic acid).  
The nitrocellulose membrane was blocked with (5% (w/v) low fat milk powder in TBS-
Tween-20 (20 mM Tris-HCl buffer; 200 mM NaCl; pH 7.4); 0.1% Tween-20)) for an 1 h at RT. 
Primary antibody solutions (either monoclonal mouse anti-His-tag IgG (1/6000) or polyclonal 
chicken ant-rPfHRP-2 IgY (1 µg/ml); made up in 0.5%(w/v) BSA-PBS)  were added and 
incubated at RT for 2 h. A secondary antibody (either goat anti-mouse IgG-HRPO (1/6000) or 
rabbit anti-chicken IgG-HRPO (1/10 000) in 0.5%(w/v) BSA-PBS) was added and incubated at 
RT for 1 h. After each incubation the nitrocellulose was washed (3 x 5 min) using TBS-Tween 
20 (0.1% (w/v)). Finally, proteins recognised by the antibodies were visualised using 4-chloro-
1-naphthol·H2O2 substrate (0.06% (w/v) 4-chloro-1-naphthol, 0.1% (v/v) methanol and 
0.0015% (v/v) H2O2 in TBS) in the dark. 
2.2.6.  Bradford protein determination  
The Bradford method was used to determine protein concentration (Bradford, 1976). 
Concentrations of unknown protein samples were calculated from a BSA (Bradford standard 
curve) standard curve 0 -50 µg and was measured at 595 nm.  
2.2.7.  Isolation of anti-rPfHRP-2 IgY from chicken eggs  
Eggs from chickens immunised with antigen were collected and stored at 4°C. Anti-
rPfHRP-2 IgY was purified by the method described by Polson et al., (1985).  
2.2.8. Affinity purification of anti-rPfHRP-2 IgY  
Anti-rPfHRP-2 IgY was affinity purified using an rPfHRP-2-AminoLinkTm matrix 
(Qoronfleh et al., 2003). 
2.2.9.  Indirect ELISA for determining the LOD of rPfHRP-2 detected using anti-
rPfHRP-2 
rPfHRP-2 was diluted in PBS (pH 7.0) at various concentrations and pipetted into wells 
of Nunc Maxi SorpTm 96 well ELISA plates and incubated overnight at 4°C. All steps were done 
at 37°C. Wells were blocked with 150 µl BSA-PBS 0.5% (w/v) for 1 h. 
29 
 rPfHRP-2 (75 ng in BSA-PBS 0.5%(w/v) was added to each well and incubated for 2 
h, (100 µl) rabbit anti-chicken IgG-HRPO (1/10 000 in BSA-PBS 0.5%(w/v) was added for 1 h. 
Wash steps were performed before each incubation step using PBS-Tween 20 (0.1%(v/v)). 
150 µl of substrate (TMB (426 µM); H2O2 (1.176 mM in citrate-phosphate buffer (150 mM; pH 
5.0)). After an hour the plates were read at 652 nm (VersamaxTm microplate reader). 
The controls were: no rPfHRP-2 coat, no blocking, no anti-rPfHRP-2 IgY coat and no 
rabbit anti-chicken IgY coat. All results were corrected for background by subtracting the 
relevant controls.  
2.2.10. Standard protein thermodenaturation differential scanning fluorometry  assay                                              
to measure the Tm of proteins 
The assay described by Niesen et al., (2007) with minor modifications was followed. 
Protein at 2.5 µg was typically used unless otherwise stated in  7.5 µl AMT buffer (200 mM Na-
acetate buffer; 200 mM MES and 400 mM Tris-HCl; pH 4-9), 7.5 µl dH2O and 10x SYPRO 
Orange.  
The assay was run in xtra-clear qPCR tubes (Star labs) in a Rotor-Gene 6000 RT-PCR 
machine (Corbett). The condition parameters set were high resolution melt (HRM) which has 
an ƛexcitation  = 460 nm and an ƛemission at 510 nm, which was used to measure the SYPRO 
Orange fluoresce probe. A temperature range of 25°C to 95°C was used with a ramp 
temperature of 0.3°C/sec.  
Proteins tested in the assay were carbonic anhydrase; rPfHRP-2; anti-rPfHRP-2 IgY; 
rPfLDH; anti-rPfLDH IgY, rPfLDH; rPyLDH; anti-rPfLDH IgY raised against a common epitope 
(APGKSDKEWNRDDL) and rPyLDH. 
2.2.11.  Measuring antigen-antibody interactions 
The standard conditions were used to measure protein-protein interactions. Varying 
concentration of proteins were used. rPfHRP-2 (1 µg) and anti-rPfHRP-2 IgY (4 µg) were pre 
incubated at 37°C for 2 h, rPfLDH (1 µg) and anti-rPfLDH IgY (1, 2, 3, 4 µg; against the whole 
protein) was incubated at 4°C or 37°C for 2 h, rPfLDH (1 µg) and rPyLDH (1 µg) and anti-
rPfLDH IgY (1 or 4 µg; against the common peptide) were incubated for 2 h at 37°C. All 
incubations were done at pH values of 4, 7 and 9 in AMT buffer and then SYPRO Orange was 
added and DSF analysis was carried out. 
2.2.12. DSF analysis of anti-malaria drugs with rPfLDH and rPfGAPDH 
1 mM anti-malaria drugs (chloroquine, pyrimethamine, amodiaquine and quinine) were 
incubated with both rPfLDH and rPfGAPDH at 4°C for 30 min in AMT buffer (pH 6.0) followed 
by SYPRO Orange and DSF analysis was carried out under the standard assay. 
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2.2.13. Processing DSF data 
Rotor-gene series 6000 software was used to capture fluorescence data from the 
thermodenaturation of proteins. The change in fluorescence/ change in temperature (dF/dT) 
was calculated and the dF/dT data was plotted against temperature and the highest dF/dT 
point on each peak was referred to as the Tm.   
2.2.14.  In silico methods showing chloroquine and quinine interacted with rPfLDH and 
rPfGAPDH  
Molecular docking studies were carried out using the Schrodinger molecular docking 
suite (Schrodinger 2018-2). Chloroquine and quinine binding to rPfLDH (PDB 1CET) and 
rPfGAPDH (PDH 1WYG) were docked. The docking studies were followed as described by 
Kumar et al., (2015) where the default setting of the Schrodinger software was used. Protein 
was prepared by bringing the protein to its correct conformation, as sometimes when being 
crystallised, certain amino acid residues may be left out, bond lengths may be incorrect, and 
various other abnormalities are resolved. Thereafter, either chloroquine or quinine was drawn 
using the Maestro 2D work space to draw small molecules. The current bound ligand was 
removed, and the new drawn ligand was prepared. A grid was drawn around the site at which 
the previous ligand was bound. The grid determines the area analysed for binding sites, a grid 
of 15 Å2 was used and a scan was performed to determine if binding had occurred. Validation 
by redocking was carried out. The validation was performed by removing the original ligand 
from either PfLDH and PfGAPDH. The receptor (binding site) was then prepared in the 
absence of the ligand, this was to bring the protein back to its native state. Then the ligand 
initially removed was docked once again to confirm the ligand bound in the same conformation 
as the x-ray crystallography structure depicts. 
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2.3. Results    
2.3.1. Expression and purification of recombinant proteins from E. coli BL21 (DE3) 
PfHRP-2 was recombinantly expressed as a His-tag fusion protein from the gene 
cloned into  a pET-15(b) plasmid in an E. coli Bl21 (DE3) bacterial host. The recombinant 
protein was affinity purified using a Ni2+ chelate chromatography matrix. An SDS-PAGE and a 
western blot illustrating the steps for purification of rPfHRP-2  as shown in Figures 2.1A and 
B.  
(A)                                                                             (B)                   
 
Figure 2.1: Recombinant expression and Ni2+-chelate affinity purification of PfHRP-2 analysed by 
SDS-PAGE and western blottting. PfHRP-2 was expressed in E. coli BL21(DE3) cells as a His6-tag 
fusion protein and was purified using Ni2+-chelate affinity chromatography. Each step of the purification 
was analysed on a 12.5% reducing SDS-PAGE gel (A) and proteins on a duplicate gel were 
electrophoretically transferred to nitrocellulose and probed with anti-His tag mouse monoclonal antibody 
and a secondary goat anti-mouse-HRPC antibody (B). Molecular weight marker (Mw); E. coli BL21 
(DE3) untransformed cell lysate (lane 1); cell culture pellet (lane 2); cell lysate supernatant (lane 3); 
rPfHRP-2 unbound fraction (lane 4); 20 mM imidazole wash sample (lane 5); 250 mM imidazole wash 
sample (lane 6); eluents 1-3 with 500 mM imidazole (lanes 7 -9). The SDS-PAGE gel was stained with 
Coomassie brilliant blue R-250. 
Untransformed E. coli BL21 (DE3) lysates showed that rPfHRP-2 was not expressed 
by the host cells alone. rPfHRP-2 was isolated as a 54 kDa protein band (Figure 2.1A lanes 7-
9) and ran as a doublet. The fusion protein is 24 kDa larger than the expected size of PfHRP-
2, which is 30 kDa (Ndonwi et al., 2011). An additional 250 mM wash step had to be included 
to remove contaminating proteins that were found to have a high binding affinity for the Ni2+-
NTA resin (Figure 2.1A lane 6).  
To confirm the identity of the expressed His-tagged rPfHRP-2, a western blot was 
performed (Figure 2.1B) and probed with mouse anti-His tag IgG antibody. No proteins were 
detected by the antibody in the E.coli BL21(DE3) untransformed cell lysate. Transformed E. 
coli cells had bands of 54 kDa detected (Figure 2.1B; lanes 2 and 3), which indicated that 
rPfHRP-2 was present in the starting sample and lysate. rPfHRP-2 was eluted over three 
fractions including proteins bands appearing above the 116 kDa protein marker were detected 
in (Figure 2.1B lanes 7 to 9), which could potentially be  protein aggregates. 
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2.3.2. Detecting rPfHRP-2 using anti-rPfHRP-2 IgY  
An observation was noticed in Figure 2.1A where several proteins in lane 6 had a high 
affinity for the Ni2+-NTA resin. The 250 mM wash (Figure 2.1, lane 6) was diluted by the large 
volume of buffer therefore in a separate purification, individual fractions of each purification 
step were collected and run on an SDS-PAGE gel and western blot (Figure 2.2A and B). 
(A)                                                                                       (B) 
 
Figure 2.2: Recombinant expression and Ni2+-chelate affinity purification of PfHRP-2 analysed by 
SDS-PAGE and western blotting. PfHRP-2 was expressed in E.coli BL21(DE3) cells as a His6-tag 
fusion protein and was purified using Ni2+-NTA chelate affinity chromatography. Each step of the 
purification was analysed on a 12.5% reducing SDS-PAGE gel (A) and proteins on a duplicate gel were 
electrophoretically transferred to a nitrocellulose and probed with polyclonal chicken anti-rPfHRP-2 IgY 
and a secondary mouse anti-rabbit-HRPC IgG (B).  Molecular weight marker (Mw); E. coli BL21(DE3) 
untransformed cell lysate (lane 1); cell culture pellet (lane 2); cell lysate supernatant (lane 3); rPfHRP-2 
unbound fraction (lane 4); 20 mM imidazole wash sample (lane 5); 250 mM imidazole wash samples 
(lane 6-8); eluents 1-6 with 500 mM imidazole (lanes 9 -14). The SDS-PAGE gel was stained with 
Coomassie brilliant blue R-250. 
The pattern and samples for lanes 1 to 5 (Figure 2.2A) were the same as Figure 2.1A. 
The difference was in the running of the 3 250 mM imidazole wash steps (lanes 6 to 8). There 
are about 18 proteins (proteins) that were not eluted by the 20 mM imidazole wash (lane 5), 
indicating their high affinity for the Ni2+-NTA resin.  
All proteins were not detected by the mouse monoclonal anti-His-tag IgG (Figure 2.1B) 
or the chicken polyclonal anti-rPfHRP-2 IgY (Figure 2.2B) except for rPfHRP-2. Figure 2.2B 
also had a single band that was detected in lanes 1 to 5 which was larger than rPfHRP-2, 
however, this protein was removed in the wash steps and there was no detection in lanes 9 to 
14. Similarly, aggregated and degraded rPfHRP-2 is detected both above and below the 54 
kDa rPfHRP-2 band as well as bands above 116 kDa (Figure 2.2B). 
2.3.3. Expression and purification of recombinant PfLDH 
PfLDH was recombinantly expressed as a His-tag fusion protein from the gene cloned 
into the pKK-233-3 plasmid in an E. coli BL21 (DE3) bacterial host.  
33 
The recombinant protein was affinity purified using a Ni2+-chelate chromatography 
matrix. An SDS-PAGE gel and western blot were used to track the expression and purification 
of rPfLDH (Figures 2.3A and B). 
(A)                                                                           (B) 
 
Figure 2.3: Recombinant expression and Ni2+-chelate affinity purification of PfLDH analysed by 
SDS-PAGE and western blotting. rPfLDH was expressed in E.coli BL21(DE3) cells as a His6-tag fusion 
protein and was purified using Ni2+-chelate affinity chromatography. Each step of the purification was 
analysed on a 12.5% reducing SDS-PAGE gel (A) and  protein on a duplicate gel were 
electrophoretically transferred to nitrocellulose and probed with anti-His tag mouse monoclonal IgG 
antibody and a secondary goat anti-mouse IgG-HRPC antibody (B). Molecular weight marker (Mw); E. 
coli BL21(DE3) untransformed cell lysate (lane 1); cell culture pellet (lane 2); cell lysate supernatant 
(lane 3); rPfLDH unbound fraction (lane 4); 20 mM imidazole wash sample (lane 5); fractions eluted with 
250 mM imidazole (lanes 6-8). The SDS-PAGE gel was stained with Coomassie brilliant blue R-250. 
rPfLDH was not expressed by the host cell alone (Figure 2.3A). Some rPfLDH remained 
in the unbound fraction (lane 2 and 3). Two major bands at 75 and 36 kDa were eluted from 
the Ni2+-NTA affinity matrix (lane 6 to 8). 
The western blot of the same gel  (Figure 2.3A) was probed with mouse anti-His tag 
IgG (Figure 2.3B). No protein was detected in the untransformed E. coli BL21 (DE3)  (lane 1). 
Various bands were detected in lanes 2 and 3, below the 36 and 75 kDa marker. Some rPfLDH 
at 36 kDa was detected in the unbound fractions (lane 4 and 5) and the eluted fractions picked 
up various bands, with the major band being 36 kDa (lane 6 to 8). The various bands detected 
in different lanes were suspected to be degraded and truncated rPfLDH. 
2.3.4. Expression and purification of recombinant PfGAPDH  
PfGAPDH was recombinantly expressed as a His-tag fusion protein with the gene 
cloned within a pET-15(b) plasmid in an E.coli BL21 (DE3) bacterial host. The recombinant 
protein was affinity purified using a Ni2+-chelate chromatography matrix. An SDS-PAGE gel 
and western blot were used to track the expression and purification of rPfGAPDH (Figures 
2.4A and B). 
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(A)                                                                           (B) 
 
Figure 2.4: Recombinant expression and Ni2+-chelate affinity purification of PfGAPDH analysed 
by SDS-PAGE and western blotting. rPfGAPDH was expressed in E.coli BL21(DE3) cells as a His6-
tag fusion protein and was purified using Ni2+-chelate affinity chromatography. Each step of the 
purification was analysed on a 12.5% reducing SDS-PAGE gel (A) and proteins on a duplicate gel were 
electrophoretically transferred to nitrocellulose and probed with anti-His tag mouse monoclonal IgG 
antibody and a secondary goat anti-mouse IgG-HRPC antibody (B). Molecular weight marker (Mw); E. 
coli BL21(DE3) untransformed cell lysate (lane 1); cell culture pellet (lane 2); cell lysate supernatant 
(lane 3); rPfGAPDH unbound fraction (lane 4); 20 mM imidazole wash sample (lane 5); eluents 1-3 with 
250 mM imidazole (lanes 6-8). The SDS-PAGE gel was stained with Coomassie brilliant blue R-250. 
rPfGAPDH was not expressed by the E. coli BL21 (DE3) host cell alone (Figure 2.4A). 
The fractions eluted of the affinity matrix (lanes 6 to 8) had a major band at 39 kDa, and a few 
protein bands above and below the 39 kDa band.  
The western blot (Figure 2.4B) from the gel (Figure 2.4A) was probed with mouse 
monoclonal anti-His tag IgG. No protein was detected in the untransformed lane, indicating no 
host E. coli BL21 (DE3) lysate. Only His-tag proteins were detected, indicating the bands in 
lane 7 could be aggregates or multimers of rPfGAPDH. 
2.3.5. Isolation of chicken polyclonal anti-rPfHRP-2 IgY 
Eggs from chickens that were previously immunised with rPfHRP-2 were collected on a 
weekly basis and stored at 4°C. Using the method described by Polson et al., (1985). Isolated 
IgY was affinity purified for anti-rPfHRP-2 IgY using anti-rPfHRP-2 affinity matrix (Figure 2.5A 
and B).  
 
 
 
 
 
 
35 
(A)                                                                    (B) 
 
Figure 2.5: Purification of anti-rPfHRP-2 IgY using PEG 6000 analysed by SDS-PAGE and affinity 
purified using an rPfHRP-2 Aminolink® affinity matrix. A 12.5% reducing SDS-PAGE gels showing 
each step in IgY purification. The lanes were loaded as follows: molecular weight marker (Mw); whole 
egg yolk sample (lane 1); filtrate (lane 2); second supernatant (lane 3); third supernatant (lane 4); final 
pure isolated IgY (lane 5) (A). Measure of affinity purification of anti-rPfHRP-2 IgY. Crude IgY was pooled 
and affinity purified using a recombinant rPfHRP-2 AminoLink® matrix (•) represents the initial eluents 
and (•) unbound fraction passed over the recombinant rPfHRP-2 AminoLink® matrix for a second time 
(B). 
Each step in the purification shows proteins being removed (lane 1 to 5), two major 
bands remain- the heavy chain (HC; 65 kDa) and the light chain (LC; 25 kDa; Figure 2.5A). 
The bands above the HC are thought to be partially reduced IgY at 90 kDa (Heavy chain + 
light chain) and the highest band above the 116 kDa marker is unreduced IgY.  
Following isolation of chicken IgY containing rPfHRP-2 IgY from chicken egg yolk, the 
unbound fraction was passed over an rPfHRP-2-Aminiolink® affinity resin. The anti-rPfHRP-2 
IgY was affinity purified and the eluents were tracked at an absorbance of 280 nm (Figure 
2.5B). 
2.3.6. Detection of rPfHRP-2 using anti-rPfHRP-2 IgY 
The affinity purified antibody was used in an ELSIA to find the limit of detection of 
rPfHRP-2 (Figure 2.6), which was 15 ng.  
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Figure 2.6: Measuring the limit of detection of rPfHRP-2 using anti-rPfHRP-2 IgY. Varying amounts 
of rPfHRP-2 (150 to 1.5 ng) were coated onto Nunc® 96 well plates and incubated overnight at 4°C. 75 
ng of anti-rPfHRP-2 IgY served the primary antibody and rabbit anti chicken HRPC secondary antibody 
was used. Error bars indicate the S.D of triplicate results. 
2.3.7. Differential scanning fluorometry: Optimising a DSF assay using carbonic 
anhydrase  
Carbonic anhydrase was used as a control protein to optimise conditions for the DSF 
assay. The protein was shown by Wright et al., (2017) to be a suitable candidate for thermal 
melt curve analysis. Carbonic anhydrase shows very little initial fluorescence and fluorescence 
increases as the protein denatures. The fluorescence curves fitted with a sigmoidal curve are 
not shown as it is difficult to interpret the Tm from those curves. A first derivative (dF/dT) was 
employed as the peak of the curve corresponds to the predicted Tm (Niesen et al., 2007). AMT 
buffers ranging from pH 4 to 9 were tested with carbonic anhydrase (Figure 2.7). 
 
Figure 2.7: DSF first derivative of fluorescence data for carbonic anhydrase at different pH 
values. Carbonic anhydrase was added to AMT buffers ranging from pH 4 to 9. SYPRO Orange was 
added and the raw fluorescence data were measured from 25°C to 95°C and the first derivative was 
calculated and presented. 
When carbonic anhydrase was in alkaline AMT buffers (Figure 2.7), the protein had a 
higher Tm. The highest Tm for carbonic anhydrase was at pH 9 (67.85°C) and the lowest at pH 
4 (40.25°C). Calculation of the first derivative data from fluorescence raw data was done using 
Rotor-Gene-6000 software. 
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 Each curve appeared ideal by starting off with a low dF/dT and there were no major 
changes in the thermal melt profile. This was significant as its implied AMT buffers were 
suitable with carbonic anhydrase at a pH of 4 to 9 while keeping the ionic strength constant.  
2.3.8. Measurement of carbonic anhydrase Tm in the presence of Zn2+ 
Carbonic anhydrase has been shown to bind Zn2+ at an allosteric site (Sanyal and 
Maren, 1981). Therefore, the Tm of carbonic anhydrase was determined in the presence of  
Zn2+ with an AMT buffer (pH 9.0) to test if there would be a shift in Tm (Figure 2.8).  
 
Figure 2.8: DSF first derivative of fluorescence data for carbonic anhydrase in the presence of 
Zn2+. Carbonic anhydrase was added to AMT buffer at pH 9 and was incubated with Zn2+ (1 mM). 
SYPRO Orange was then added and raw fluorescence was measured from 25 to 95°C and the first 
derivative was calculated and presented. 
A peak shift from 67.85°C (apo carbonic anhydrase) to 60.75°C (Zn2+- carbonic 
anhydrase) was observed (Figure 2.8). This implies carbonic anhydrase was destabilised. Zn2+ 
did not interfere with SYPRO Orange in the control experiment. 
2.3.9. Thermodenaturation of rPfHRP-2  
The stability of rPfHRP-2, rPfLDH and rPfGAPDH and chicken IgY antibodies raised 
against rPfHRP-2, rPfLDH and antigen-antibody interactions were all analysed by looking at 
their thermodenaturation profiles using our optimised DSF assay. The first P. falciparum 
diagnostic protein analysed was rPfHRP-2 (Figure 2.9). 
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(A)                                          (B)                                             (C)  
 
Figure 2.9: DSF First derivative of fluorescence data for rPfHRP-2 at different pH values. rPfHRP-
2 in AMT buffer at pH 4 (A), pH 7 (B) and pH 9 (C). SYPRO Orange was added and the raw fluorescence 
data was measured from 25 to 95°C and the first derivative was calculated and presented. Each panel 
represents triplicate results.  
The dF/dT curves (Figure 2.9A to C) could not be used to obtain a Tm value from, as 
there was no transition (peaks) observed at any of the 3 pH values (4,7 and 9) with SYPRO 
Orange.  
2.3.10. DSF analysis of thermodenaturation of anti-rPfHRP-2 IgY  
The thermodenaturation analysis chicken anti-rPfHRP-2 IgY at pH values of 4,7 and 9 
and the DSF dF/dT curves of raw fluorescence data was plotted (Figure 2.10). 
(A)                                         (B)                                                (C)  
 
Figure 2.10:DSF first derivative of fluorescence data for anti-rPfHRP-2 IgY at different pH values. 
Anti-rPfHRP-2 IgY in AMT buffer at pH 4 (A), pH 7 (B) and pH 9 (C). SYPRO Orange was added and 
the raw fluorescence data was measured from 25 to 95°C and the first derivative was calculated and 
presented. Each panel represents triplicate results.  
The analysis of anti rPfHRP-2 IgY antibodies showed lower Tm observed at pH 4 (Tm 
56.98°C) indicating it was least stable, while anti-rPfHRP-2 IgY was most stable at pH 9 (Tm 
75.08°C; Figure 2.10).  A pH of 4 resulted in a 2-fold higher fluorescence peak amplitude 
compared to pH 7 and 9. The amplitude of the peak, however, is based on arbitrary relative 
fluorescence units (RFU) and does not play a role in determining Tm of a protein. 
39 
2.3.11. DSF analysis of thermodenaturation of rPfHRP-2 interacting with anti-rPfHRP-2 
IgY 
Since the Tm for rPfHRP-2 could not be determined (Figure 2.9), rPfHRP-2 binding to 
anti-rPfHRP-2 IgY was evaluated with DSF (Figure 2.11). 
(A)                                         (B)                                            (C) 
 
Figure 2.11: DSF first derivative of fluorescence data for anti-rPfHRP-2 IgY interacting with 
rPfHRP-2 at different pH values. Anti-rPfHRP-2 IgY in AMT buffer at pH 4 (A), pH 7 (B) and pH 9 (C) 
were incubated with rPfHRP-2 in a 4:1 ratio. SYPRO Orange was added and the raw fluorescence data 
was measured from 25 to 95°C of which the first derivative was calculated and presented. Each panel 
represents triplicate results.  
When rPfHRP-2 is in the presence of anti-rPfHRP-2 IgY, DSF dF/dT curves are 
obtained at all three pH values (4, 7 and 9). At pH 4, there is evidence of a more stable species 
being formed, as there is a Tm shift from 59.75°C (anti-rPfHRP-2 IgY; Figure 10A)  to 71.1°C 
(Figure 11A). The 11.35°C difference in Tm is an indication that anti-rPfHRP-2 IgY bound to 
rPfHRP-2 forming a more stable complex. At pH 7 and 9 (Figures 2.11B and C) there was no 
significant Tm shifts compared to anti-rPfHRP-2 IgY alone (Figure 2.10B and 7). At pH 7, the 
complex had a Tm 0.07°C lower than anti- rPfHRP-2 alone while at pH 9 the complex had a 
Tm of 0.47°C higher than the anti- rPfHRP-2 IgY molecule.  
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2.3.12. DSF analysis of thermodenaturation of rPfLDH and anti-rPfLDH IgY 
The second P. falciparum diagnostic protein analysed for its thermal stability was 
rPfLDH using DSF dF/dT curves to obtain a Tm at different pH values (4 to 9; Figure 2.12). 
 
Figure 2.12: DSF first derivative of fluorescence data for rPfLDH at different pH values. rPfLDH in 
AMT buffer from pH 4 to 9. SYPRO Orange was added and the raw fluorescence data was measured 
from 25 to 95°C of which the first derivative was calculated and presented.  
rPfLDH at different pH values were shown to have different Tm’s (Figure 2.12). A Tm for 
rPfLDH at pH 4 could not be determined from the dF/dT profile. At pH 5, rPfLDH was least 
stable with a Tm of 37.92, while at pH values of 6, 7 and 8 had similar Tm’s at 44.58°C, 45.75°C 
and 45.59°C respectively and pH 9 had a Tm of 42.42°C. The Tm values indicate rPfLDH is 
most stable at pH’s 6 to 8. The amplitude of the peaks for rPfLDH was in general higher when 
rPfLDH was less stable (pH 5 and 9). 
2.3.13. DSF thermodenaturation of anti-rPfLDH IgY 
Following the determination of Tm for rPfLDH, DSF analysis for the thermodenaturation 
of anti-rPfLDH IgY against the whole rPfLDH protein was analysed (Figure 2.13). 
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Figure 2.13: DSF first derivative of fluorescence data for anti-rPfLDH IgY at different pH values. 
Anti-rPfLDH IgY (against rPfLDH) in AMT buffers at pH of 4 7 and pH 9. SYPRO Orange was added 
and the raw fluorescence data was measured from 25 to 95°C of which first derivative was calculated 
and presented.  
Analysis of anti-rPfLDH-IgY antibodies was found to have a high noise to signal ratio 
(Figure 2.13). At a pH of  4, a Tm for the anti-rPfLDH IgY could not be determined by the dF/dT 
melt profile as there was an absence of a single transition, while the Tm at pH of 7 and 9 was 
72.05°C and 73.45°C respectively. The peak at pH 9, seemed to have two minor peaks 
present, while the peak at pH 7 had a higher amplitude.  
2.3.14. DSF analysis of the thermodenaturation of anti-rPfLDH IgY + rPfLDH 
Next rPfLDH and anti-rPfLDH IgY were evaluated in the same sample using DSF 
(Figure 2.14). 
(A)                                                 (B)                                                 (C)  
 
Figure 2.14: DSF first derivative of fluorescence data for anti-rPfLDH IgY in the presence of 
rPfLDH. Anti-rPfLDH IgY in AMT buffer at pH 4, pH 7, pH 9 was incubated with rPfLDH in a 2:1 ratio 
(A); Anti-rPfLDH IgY in AMT buffer at pH 4, pH 7, pH 9 was incubated with rPfLDH in a 3:1 ratio (B); 
Anti-rPfLDH IgY in AMT buffer at pH 4, pH 7, pH 9 was incubated with rPfLDH in a 4:1 ratio (C). Each 
panel represents the interaction at 4°C. SYPRO Orange was added and the raw fluorescence data was 
measured from 25 to 90°C and the first derivative was calculated and presented.  
A single peak (transition) was present at pH 4 with a Tm of 66.75°C (Figure 2.14A). This 
is an indication of a stabilised  complex anti-rPfLDH IgY due to rPfLDH binding.  
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A similar result was observed for anti-rPfHRP-2 IgY where it was stabilised by rPfHRP-
2 being bound at pH 4 (Figure 2.11A). For the sample with anti-rPfLDH IgY and rPfLDH Two 
peaks (transitions) were present with a Tm’s of 45.45°C and 71.75°C for peaks 1 and 2 at pH 
7 and 43.75°C and 71.75°C for peaks 1 and 2 at pH 9. At pH of 9 the rPfLDH peak was 1.33°C 
higher Tm. 
Similar trends in Tm were observed in Figure 2.14B and 2.14C, which was a single peak 
at a pH of 4 (the stabilised IgY), at pH 7 and 9 there were two peaks which was rPfLDH with 
the lower Tm and anti-rPfLDH IgY with the higher Tm. There was also the predicted increase in 
the amplitude of the second peak due to the presence of a higher anti-rPfLDH IgY 
concentration. Due to the large volume of Tm data obtained, all values were summarised in 
Table 2.1. With the addition of rPfLDH and anti-rPfLDH IgY in a 1:1 ratio and the rPfLDH and 
anti-rPfLDH IgY been incubated together at 37°C.  
2.3.15. DSF analysis of thermodenaturation of anti-rPfLDH IgY 
A third peak (Figure 14B and 14C) with a low amplitude was observed and  is thought 
to be a stabilised anti-rPfLDH IgY complex. To more clearly visualise the third peak and get 
the Tm, the DSF assay was repeated with the incubation of anti-rPfLDH IgY with rPfLDH done 
at 37°C (Figure 15A and B).  
(A)                                                                                  (B) 
 
Figure 2.15: DSF first derivative of fluorescence data for anti-rPfLDH IgY interacting with rPfLDH 
at pH 9. Anti-rPfLDH IgY  in AMT buffer at pH 9 was incubated with rPfLDH (3:1 ratio) (A); Anti-rPfLDH 
IgY in AMT buffer at pH 9 was incubated with rPfLDH (in a 4:1 ratio) (B). SYPRO Orange was added 
and the raw fluorescence data was measured from 25 to 95°C of which the first derivative was calculated 
and presented.  
The Tm’s of the three peaks (Figure 2.15A) were 44.65°C, 71.65°C and 81.85°C and  
44.65°C, 71.75°C, and 80.35°C (Figure 2.15B). The third peak was more prominent when 4 
µg of anti-rPfLDH IgY was present, however the Tm was 1.5°C lower. Interestingly, the first 
peak (rPfLDH) had a 2°C higher Tm compared to rPfLDH at pH 9, signifying rPfLDH in the 
presence of anti-rPfLDH IgY was stabilised.  
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Table 2.1: Thermal melt temperature (Tm) results from DSF analysis of anti-rPfLDH IgY interacting 
with rPfLDH at different ratios.  
 
The first column refers to the ratios of protein used. The second column indicates the temperature at 
which anti-rPfLDH IgY was incubated with rPfLDH. The third column refers to the pH at which the 
experiment was performed. The last 3 columns are the Tm of each peak, with the dashes indicating a 
Tm could not be determined. 
The ratio of 
anti-rPfLDH to 
rPfLDH 
Incubation 
temperature 
(°C) 
pH Melt temperature (°C) 
   Peak 1 Peak 2 Peak 3 
1:1 4°C 
4 - 65.75 - 
7 45.45 71.75 - 
9 43.75 71.75 - 
      
2:1 4°C 
4 - 65.75 - 
7 45.65 72.05 - 
9 43.95 71.65 80.75 
      
3:1 4°C 
4 - 65.85 - 
7 45.85 71.75 - 
9 44.45 71.95 80.35 
      
4:1 4°C 
4 - 66.65 - 
7 46.05 71.75 - 
9 44.45 71.85 80.35 
      
1:1 37°C 
4 - 66.05 - 
7 45.55 71.45 - 
9 43.95 71.65 - 
      
2:1 37°C 
4 - 65.85 - 
7 45.75 72.25  
9 44.15 72.15 80.25 
      
3:1 37°C 
4 - 66.35 - 
7 45.85 71.75 - 
9 44.65 71.65 81.85 
      
4:1 37°C 
4 - 66.35 - 
7 45.95 71.95 - 
9 44.65 71.75 80.35 
 
44 
 
In summary, the results of Table 2.1 showed that when anti-rPfLDH IgY was incubated 
with rPfLDH at 4°C and 37°C, the change in temperature had no significant change in the 
species formed or significant change in the stabilising effect, since Tm were similar.  
2.3.16. A comparison of common epitope anti-rPfLDH IgY with rPfLDH and rPyLDH  
Following the thermodenaturation DSF dF/dT curves of rPfLDH with anti-rPfLDH IgY, 
DSF analysis was done on anti-rPfLDH IgY that was raised against a common malaria LDH 
epitope (APGKSDKEWNRDDL). The aim was to compare two variables. Firstly, is a rPfLDH 
complex with anti-rPfLDH IgY raised against the whole protein is more stable than a rPfLDH-
anti-rPfLDH IgY raised against the common epitope? The second experiment compared the 
Tm of the anti-rPfLDH IgY (common epitope) and rPfLDH to a complex of anti-rPfLDH IgY 
(common epitope) and rPyLDH. The DSF thermodenaturation analysis of the common epitope 
ant-rPfLDH IgY antibodies is shown in  Figure 2.16. 
(A)                                      (B)                                          (C) 
 
Figure 2.16: DSF first derivative of fluorescence data for anti-rPfLDH IgY at different pH values. 
Anti-rPfLDH IgY in AMT buffer at pH 4 (A), pH 7 (B) and pH 9 (C). SYPRO Orange was added and the 
raw fluorescence data was measured from 25 to 95°C and the first derivative was calculated and 
presented. Each panel represents triplicate results.  
The Tm for anti-rPfLDH IgY obtained from DSF analysis (Figure 2.16A to C), showed 
that the IgY was least stable at pH 4 as was the case for all IgY molecules analysed thus far. 
The Tm at pH 4 was 54.32°C, there was a presence of the formation of a second peak around 
68°C, however, the peak was minor and not distinct (Figure 2.16A). At pH 7 the Tm was 
72.65°C, the quality of the curve was good as there was little signal below the x-axis (Figure 
2.16B). This indicates that the IgY molecules are likely in a stable conformation. At a pH value 
of 9 there is the presence of two peaks, the first and second with Tm of 64.15°C and 71.08°C 
(Figure 2.16C). Two peaks generally indicate the presence of different domains of the IgY 
molecule.  
2.3.17. Comparison of both rPfLDH molecules using DSF 
Anti-rPfLDH IgY raised against the entire protein (Figure 2.13) had a different dF/dT 
profile to that of anti-rPfLDH IgY raised against the common malaria LDH epitope (Figure 2.16).  
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At pH 4 (Figure 2.13A) the dF/dT curve for anti-rPfLDH IgY (against the protein) had 
no transition therefore a Tm could not be interpreted from the dF/dT curve.  
The second major difference between the both anti-rPfLDH IgY molecules was 
observed at pH 9 where the anti-rPfLDH IgY (against LDH) was most stable with a Tm of 
73.45°C while in Figure 2.16C anti-rPfLDH IgY (common epitope) dF/dT curve showed the 
presence of two peaks with Tm values of 64.15°C and 71.08°C. At pH 7 both molecules had 
similar Tm values 72.05°C (anti-rPfLDH IgY whole protein) and 72.65°C (anti-rPfLDH IgY 
common epitope).  
2.3.18. Analysis of rPyLDH 
DSF analysis of the thermodenaturation of rPyLDH (Figure 2.17). 
(A)                                           (B)                                             (C)  
 
Figure 2.17: DSF First derivative of fluorescence data for rPyLDH at different pH values. rPyLDH 
in AMT buffer at pH 4 (A), pH 7 B(B) and pH 9 (C). SYPRO Orange was added and the raw fluorescence 
data was measured from 25 to 95°C and the first derivative was calculated and presented. Each panel 
represents triplicate results.  
All thermodenaturation dF/dT curves for rPyLDH were not able to provide a clear Tm of 
the protein at different pH values 4, 7 and 9. At pH 4, rPyLDH was completely denatured as 
there is no transition observed, therefore a Tm could not be determined (Figure 2.17A). At pH 
values of 7 and 9 the curves had ambiguous transitions, which were not  smooth or distinct. 
The peaks were broad with various kinks; however, an estimation was made using the highest 
dF/dT values. At pH 7 there were two peaks with Tm of 46.65°C and 57.12°C (Figure 2.17B). 
Following the same criteria at pH 9 which was used at pH 7, the Tm was 50.52°C and 55.68 for 
both peaks (Figure 2.17C).  
The quality of dF/dT curves for rPfLDH (Figure 2.12) was better than rPyLDH dF/dT 
curves, as single peaks were observed, at which distinct Tm could be obtained. Both proteins 
were most stable at pH 7 (Table 2.2). The state of the poor rPyLDH may be a result of the 
enzyme not being folded in its most stable conformation following IMAC purification of the 
protein from an E. coli cell lysate. 
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2.3.19. Interaction of anti-rPfLDH IgY (common epitope) with rPyLDH 
The interaction of rPfLDH and rPyLDH with anti-rPfLDH IgY (common epitope) was 
analysed using DSF. The analysis was conducted with rPfLDH and rPyLDH in a 1:1 and a 1:4 
ratio with anti-rPfLDH IgY. The results for the antigen: antibody (1:4) ratio are presented 
(Figure 2.18). 
 
 
 
Figure 2.18: DSF first derivative of fluorescence data anti-rPfLDH-IgY interacting with rPfLDH 
and rPyLDH. rPfLDH  in AMT buffers at pH 4 (A), at pH 7 (B), at pH 9 (C) and rPyLDH in AMT buffers 
at pH 4 (D), at pH 7 (E) and at pH 9 (F), were incubated with anti-rPfLDH-IgY in a (1:4 ratio) for two 
hours at 37°C. SYPRO Orange was added and the raw fluorescence data was measured from 25 to 
95°C of which the first derivative was calculated and presented. Each panel represents triplicate results.  
Incubation of rPfLDH and rPyLDH with anti-rPfLDH IgY (common epitope) dF/dT 
curves were analysed at pH values of 4,7 and 9 (Figure 2.18). rPfLDH at pH 4 indicated two 
transitions (peaks) with similar Tm at 50°C and around 54.05°C (Figure 2.18A). The 50°C 
transition is thought to be a stabilised rPfLDH-anti-rPfLDH IgY (complex, with rPfLDH in 
excess), while the 54.05°C Tm  transition is the anti-rPfLDH IgY and showed no increase in Tm 
compared to anti-rPfLDH IgY alone in Figure 2.16. At pH 7 two transitions were observed, the 
first was rPfLDH and the second rPfLDH bound to anti-rPfLDH IgY, both transitions Tm was 
0.47°C higher than the original molecules (Figure 2.18B). At pH 9, two peaks were present, 
the first was rPfLDH with a 0.96°C higher Tm than rPfLDH alone and the second peak which 
had a Tm of 71.75°C, 0.67°C higher then anti-rPfLDH IgY (common epitope; Figure 2.18C).  
For rPyLDH with anti-rPfLDH IgY (Figure 2.18D-F) different dF/dT profiles were 
compared to rPfLDH interaction with anti-rPfLDH IgY (Figure 2.18A-C).   
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At pH 4 (Figure 2.18D), a single main peak was present with a kink; the kink had a Tm1 
of 50.52°C and the main peak had a Tm2 of 55.68°C. It is believed that Tm1 was a stabilised 
rPyLDH and Tm2 was the anti-rPfLDH IgY.  
The second transition showed to have a Tm of 70.58 which is believed to be anti-rPfLDH 
IgY-rPyLDH. The anti-rPfLDH IgY (common epitope), showed only a single transition at pH 7 
with a Tm 71.98°C which had a similar Tm to that of the anti-rPfLDH IgY alone (Tm 72.65°C). At 
pH 9, there was no significant shifts in Tm for any of the transitions for anti-rPfLDH IgY in the 
presence or absence of rPyLDH, both transitions Tm were similar (Table 2.2). 
Table 2.2: Thermal melt temperature (Tm) results from DSF analysis of anti-rPfLDH IgY (common 
epitope) interacting with rPfLDH and rPyLDH at different ratios.  
 
The first column refers to the pH of the AMT buffers used. The second column indicates the ratios of 
antibody and antigen used. The third column indicates the Tm of the protein. The dashes indicating a 
Tm could not be determined. 
 
2.3.20. rPfLDH incubated with anti-RSA IgY 
To show the higher Tm seen when rPfLDH incubated with anti-rPfLDH IgY at pH 4 was 
due to the interaction of the antigen and antibody, rPfLDH was incubated with anti-rabbit serum 
albumin (RSA) IgY at pH 4 (Figure 2.19). 
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Figure 2.19: DSF first derivative of fluorescence data for rPfLDH, anti-RSA IgY and a combination 
of both at different pH values. rPfLDH, anti-RSA IgY and rPfLDH + anti-RSA IgY were diluted into 
AMT buffer at pH 4. SYPRO Orange was added and the raw fluorescence data was measured from 25 
to 90°C and the first derivative was calculated and presented. Each panel represents triplicate results.  
Only anti-RSA IgY was shown to have a transition, which resulted in a Tm of 58.25°C. 
rPfLDH showed no transitions as was seen in Figure 2.12 while the combination of rPfLDH 
and anti-RSA did not have a transition peak. It is thought that this is due to the rPfLDH's (in 
the mixture) high initial fluorescence preventing anti-RSA IgY transition being seen. Therefore, 
the results for rPfLDH and rPfHRP-2 shown to increase the Tm of their respective IgY 
antibodies at pH 4, is likely due to protein-protein interactions between both antigens’ specific 
antibodies interacting with the respective antigens. The resulting antigen-antibody complex 
was more stable than the antibody alone (Figure 2.11, 2.14 and 2.18). 
Table 2.3: Summary of Tm values for chicken IgY raised against different antigens analysed at 
pH values 4, 7 and 9. 
  
  Tm (°C)   
pH 4 7 9 
Naïve IgY 59.75 74.25 74.85 
Anti-rPfHRP-2 
IgY 56.98 73.75 75.08 
Anti-rPfLDH IgY N.D  72.05 73.45 
Anti-rPfLDH IgY 54.32  72.65  64.15 
(raised a 
common malaria 
epitope) 68 - 71.08 
Anti-RSA IgY 58.25 70.65 71.25 
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The Tm summarised in Table 2.3, show that each IgY antibody varies, indicating that 
the Fab portion plays an important role in determining the Tm of the entire molecule. The Tm 
showed that naïve IgY antibodies had the highest Tm values except for rPfHRP-2 at pH 9.  
2.3.21. Comparing the Tm of naïve chicken IgY to glycine-HCl buffer treated naïve 
chicken IgY 
To show the affinity purified chicken IgY lower Tm is not a result of the affinity purification 
step requiring the use of a pH 2.8 glycine-HCl buffer and more is likely due to the variety of 
antibodies present in the naïve IgY pool. Naïve IgY was incubated in pH 2.8 glycine-HCl buffer 
for 10 minutes (Since chicken IgY is affinity purified with this buffer) and neutralised with 1 M 
Tris-HCl. This was compared to naïve IgY which was diluted into Tris-glycine buffer. The 
results are presented in Table 2.4. 
Table 2.4: Comparing Tm of naïve IgY to glycine-HCl treated naïve IgY 
        Average S.D 
     Tm (°C)     
Naïve IgY  74.42 74.58 74.58 74.53 0.092 
Naïve IgY 
glycine-HCL 
buffer 
treated 
74.41 74.25 74.25 74.3 0.092 
 
The Tm values for both sets of naïve IgY  were very close with little variance. This 
showed that chicken IgY can withstand elution with glycine-HCl at low pH without the 
conditions affecting the molecule, to any great extent. 
2.3.22. DSF thermodenaturation of rPfGAPDH  
The third P. falciparum protein analysed by DSF was rPfGAPDH. Analysis was 
conducted on the rPfGAPDH at different pH values (Figure 2.20). 
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Figure 2.20: DSF first derivative of fluorescence data for rPfGAPDH at different pH values. 
rPfGAPDH in AMT buffers from pH 4 to 9. SYPRO Orange was added and the raw fluorescence data 
was measured from 25 to 95°C of which the first derivative was calculated and presented. 
Evaluation of rPfGAPDH in AMT buffers at different pH values had different Tm and 
different dF/dT profiles (Figure 2.20). At pH 4 and 5, a single peak  for rPfGAPDH was present 
with a Tm of 43.95°C and 49.55°C respectively. rPfGAPDH at pH 6, 7 and 8 had two peaks 
present with Tm’s at pH 6 of 49.75°C and 54.25°C; pH 7 was 50.05°C and 53.65°C; pH 8 was 
50.25°C and 54.25°C.  
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2.3.23. Analysis of Tm of anti-malarial drug with rPfGAPDH 
Of the four anti-malarial drugs analysed with rPfGAPDH, chloroquine and quinine were 
found to destabilise rPfGAPDH shown by the decrease in the Tm (Figure 2.21A and D). Apo-
rPfGAPDH had a Tm of 54.75°C while rPfGAPDH in the presence of chloroquine and quinine 
had Tm’s of 47.75°C and 49.75°C respectively. Pyrimethamine interfered with the fluorescence 
signal and had a fluoresce curve with SYPRO Orange, while amodiaquine quenched all 
fluorescence (Figure 2.21B and C).  
 
Figure 2.21: DSF first derivative of fluorescence data for rPfGAPDH with anti-malaria drugs. 
rPfGAPDH was incubated with chloroquine (A), Pyrimethamine (B), Amodiaquine (C), Quinine (D). At 
pH 6 in AMT buffer. SYPRO Orange was added and the raw fluorescence data was measured from 25 
to 95°C of which the first derivative was calculated and presented. 
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Triplicate experiments were conducted on chloroquine and quinine to verify the results 
(Figure 2.20). 
(A)                                                                                       (B) 
 
Figure 2.22: DSF first derivative of fluorescence data for rPfGAPDH interacting with anti-malaria 
drugs. rPfGAPDH was incubated with (A) chloroquine, (B) quinine. At pH 6 in AMT buffer. SYPRO 
Orange was added and the raw fluorescence data was measured from 25 to 95°C of which the first 
derivative was calculated and presented. 
Chloroquine and quinine were repeated in triplicates and the data obtained matched 
the data before (Figure 2.21 A and D). An observation was made with increased amplitude in 
the samples containing the drug. The shift in Tm for chloroquine was 7.7°C and for quinine was 
5.2°C (Figure 2.22). The result suggests that both drugs bound to and destabilised rPfGAPDH. 
2.3.24. Anti-malarial drug interaction with rPfLDH 
Following the changes in Tm of rPfGAPDH with chloroquine and quinine both drugs 
were tested with rPfLDH (Figure 2.23). 
 
Figure 2.23: DSF first derivative of fluorescence data for rPfLDH interacting with anti-malaria 
drugs. rPfLDH was incubated with (A) chloroquine (B) quinine. At pH 6 in AMT buffer. SYPRO Orange 
was added and the raw fluorescence data was measured from 25 to 95°C of which the first derivative 
was calculated and presented. 
Quine and chloroquine were shown to increase the Tm of rPfLDH by 3.6°C and 3.43°C 
respectively. Chloroquine was shown to decrease the amplitude of the dF/dT signal (Figure 
2.23). 
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To test if the anti-malarial drugs interfered with the assay, each of the drugs were 
analysed in the absence of protein (Figure 2.24). Only pyrimethamine was shown to have a 
signal indicating the drug fluoresces, as there was no protein to provide hydrophobic residues 
for SYPRO Orange to add fluorescence.   
 
Figure 2.24: DSF first derivative of fluorescence data for anti-malaria drugs. Different Antimalarials 
were diluted in AMT buffer (pH 6). SYPRO Orange was added and the raw fluorescence data was 
measured from 25 to 95°C of which the first derivative was calculated and presented. 
To show the Tm shifts caused by chloroquine and quinine interacting with rPfLDH 
(Figure 2.23) were due to both drugs specifically interacting with rPfLDH, quine was incubated 
with carbonic anhydrase as a control protein (Figure 2.25) and DSF analysis was carried out. 
 
Figure 2.25: DSF first derivative of fluorescence data for carbonic anhydrase interacting with 
quinine. Carbonic anhydrase was incubated in the presence and absence of quinine at pH 6 in AMT 
buffer. SYPRO Orange was added and the raw fluorescence data was measured from 25 to 95°C of 
which the first derivative was calculated and presented. 
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1 mM quinine (Figure 2.25) did not interact with the carbonic anhydrase and the Tm 
shifts seen with rPfGAPDH and rPfLDH were due to quinine binding to the proteins. 
2.3.25. Molecular docking chloroquine and quinine with PfGAPDH and PfLDH 
illustrating how the drugs bind to the protein 
A monomer of PfGAPDH in a ribbon conformation is illustrated (Figure 2.26A) with quinine  
represented as a space fill model (Figure 2.26A and B). Quinine is binding to the cofactor 
binding site of PfGAPDH where NADPH would usually bind.  
(A)                                                                                             (B) 
 
 
 
 
 
 
 
(C) 
(C) 
 
 
Figure 2.26: Docking of quinine to PfGAPDH.  PfGAPDH (ribbon structure) with quinine (space fill 
structure) docked in the co-factor binding site (A). A close view of quinine bound to the co-factor binding 
site of PfGAPDH (B). 2D view showing the amino acids in the co-factor binding site interacting with 
quinine (C). 
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The amino acids serine and isoleucine within  the co-factor binding site interacting with 
quinine is shown in Figure 2.26C.  
A monomer of PfGAPDH in a ribbon conformation is illustrated (Figure 2.27A) with 
chloroquine represented as a space fill model. Chloroquine is binding to the cofactor binding 
site of PfGAPDH where NADPH would usually bind (Figure 2.27A and B). The specific amino 
acids threonine, aspartate and phenylalanine  within  the co-factor binding site interacting with 
quinine is shown in Figure 2.27C.  
(A)                                                                                       (B) 
 
 
 
 
 
 
 
  (C) 
(C) 
 
Figure 2.27: Docking of chloroquine to PfGAPDH. PfGAPDH (ribbon structure) with chloroquine 
(space fill model) docked in the co-factor binding site (A). A close view of chloroquine bound to the co-
factor binding site of PfGAPDH (B). 2D view showing the amino acids in the co-factor binding site 
interacting with chloroquine (C).  
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A monomer of PfLDH in a ribbon conformation is illustrated (Figure 2.28A) with 
chloroquine represented as a space fill model. Chloroquine is binding to the cofactor binding 
site of PfLDH where NADPH would usually bind (Figure 2.28A and B). The amino acids 
glutamate and the amino group in the ring of chloroquine interact with phenylalanine and two 
water molecules within  the co-factor binding site interact with quinine (Figure 2.28C). 
 
(A)                                                                                       (B) 
 
 
 
 
 
 
 
 
    (C) 
 
 
Figure 2.28: Docking of chloroquine to PfLDH. PfLDH (ribbon structure) with chloroquine (space fill 
model) docked in the co-factor binding site (A). A close view of quinine binding to the co-factor binding 
site of rPfLDH (B). 2D view showing the amino acids in the co-factor binding site interact with chloroquine 
(C).  
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A monomer of PfLDH in a ribbon conformation is illustrated (Figure 2.29A) with quinine 
represented as a space fill model. Quinine is binding to the cofactor binding site of PfLDH 
where NADPH would usually bind (Figure 2.29A). The specific amino acids glutamate and 
lysine within  the co-factor binding site interacting with quinine is shown in Figure 2.29B. 
(A)                                                                        (B) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.29: Docking of quinine to PfLDH. PfLDH (ribbon structure) with the quinine docked in the 
co-factor binding site(A). 2D view showing the amino acids in the co-factor binding site interacting with 
quinine (B).  
Chloroquine and quinine were both shown to interact with rPfLDH and rPfGAPDH 
experimentally with DSF and in silico using docking studies. However, it is still unclear as to 
why rPfGAPDH was destabilised while rPfLDH was stabilised by both drugs. Glutamate (122) 
was found to be important for the binding of chloroquine and quinine. 
2.4. Discussion  
2.4.1. Recombinant expression and purification of PfHRP-2 
Conditions for the recombinant expression of PfHRP-2 (Figure 2.1 and 2.2) were 
optimised previously. rPfHRP-2 was purified using Ni2+-chelate affinity chromatography and 
eluted using 500 mM imidazole (Figure 2.1A and Figure 2.2A), which were two-fold higher than 
the concentration used to elute rPfLDH and rPfGAPDH (Figure 2.3 and Figure 2.4).  
The need for the higher concentration of imidazole is due to the rPfHRP-2 consisting 
of 34% histidine which has a high affinity for the Ni2+-NTA resin (Sulkowski, 1985; Bauer et al., 
2017). rPfHRP-2 was purified as a doublet at 54 kDa. The reported molecular weight of PfHRP-
2 is 30 kDa (Choi et al., 1999; Ndonwi et al., 2011).  
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The reason for the change in mobility of rPfHRP-2 in the SDS-PAGE gel is unknown, 
however it could be due to its unique structure and high concentration of histidine residues, 
(Baker et al., 2010). Other histidine rich proteins have been reported to migrate at higher 
molecular weights in SDS-PAGE gels than the predicted size (Shelake et al., 2017), possibly, 
the proteins are in a more open conformation and therefore migrate slower through the 
acrylamide (Shelake et al., 2017).  
2.4.2.  Stress on E. coli due to the expression of rPfHRP-2 
A plasmid induces stress on the E. coli host when the recombinant protein is 
overexpressed, resulting in a metabolic burden for the host cell (Hoffmann and Rinas, 2004). 
Understanding the full extent of the metabolic burden is complex and depends on the 
characteristics of each recombinant protein. rPfHRP-2 is rich in His and Ala residues (Choi et 
al., 1999), therefore, the E. coli host will be depleted of both amino acids the most when 
expressing rPfHRP-2. Depletion of His and Ser residues results in  the deactivation  of some 
pathways and the activation of alternate pathways for the cells to survive (Chang et al., 2002; 
Cashel and Kalbacher, 1970). Several proteins were expressed by the E. coli cells expressing 
rPfHRP-2 (Figure 2.2, lane 6-8) that were not expressed by cells expressing rPfLDH and 
rPfGAPDH (Figure 2.3 and 2.4) that bound to the Ni2+-NTA resin. The presence of these 
proteins is an indication of a stress response induced by the expression of rPfHRP-2.  
Chang et al., (2002) looked at the stress response on E. coli when expressing a toxic 
recombinant protein (glucose-lactose diauxide ) as well as the effect of oxidative stress from 
H2O2 on E. coli. The results showed that alternate pathways had to be upregulated for the 
bacterial cells to survive, including the His-operon, therefore proteins with high histidine 
content were expressed. The expression of proteins with higher than usual histidine contents 
was also reported by Robichon et al., (2011). In their study, they reported 17 proteins with a 
high histidine content. Of the proteins15 bound strongly to IMAC resins and required above 55 
mM imidazole to elute the proteins.  
Similar results were observed for the recombinant expression of PfHRP-2 (Figure 2.1A 
lane 6 and Figure 2.2A lanes 6-8). The proteins (Figure 2.3 and 2.4) were eluted of the Ni2+-
NTA matrix with 250 mM imidazole which is generally used to elute a His-tag recombinant 
protein. Interestingly in Figure2.2B lanes 6 to 8, 18 proteins eluted with 250 mM 
imidazole(Figure 2.2B lane 6-8). The contaminating proteins reduced the binding capacity of 
the Ni2+-NTA resin therefore a 2ml resin was used.   
2.4.3. rPfLDH and rPfGAPDH expression and purification 
When rPfLDH was expressed, protein of 36 kDa and 75 kDa (Figure 2.3A and B) were 
obtained. The size of native rPfLDH is 34.7 kDa, while the predicated size of a His6-tag rPfLDH 
is around 35.7 kDa (1 kDa for the His6-tag; Berwal et al., (2008).  
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The 75 kDa band detected was a dimer of rPfLDH. The purified rPfGAPDH (Figure 
2.4A and B) ran at an estimated size of 39 kDa on an SDS-PAGE gel which is similar to 
the 36.6 kDa found in studies by Satchell et al., (2005) and Daubenberger et al., (2003).  
2.4.4. Expression conditions for all three proteins  
E. coli BL21 (DE3) cells were used as the host strain for recombinant protein 
expression due to its advantages, such as the cell number doubling in 20 min which results in 
cell culture densities around 1 x 1010 cell per litre of cell culture in a short period of time. The 
hdsb mutation which prevents the plasmid being lost and it is lysogenised, which is a 
requirement for the pET-15(b) and pKK223-3 plasmid vectors (Chart et al., 2000; Rosano and 
Ceccarelli, 2014; Daegelen et al., 2009).   
All three proteins were expressed in TB, which is a nutrient rich autoinduction broth 
containing lactose. The lactose is important to facilitate recombinant protein expression by 
binding to the LacI repressor on the lac (pET-15) or tac operator (pKK223-3). This allows T7 
RNA polymerase to be transcribed and expressed as the recombinant protein. A disadvantage 
of using lactose was that it was used up by the cell unlike its structural analogue, IPTG, that is 
not degraded  (Sørensen and Mortensen, 2005). One of the weaknesses of the expression 
was that ampicillin could not be supplemented into the culture every 3 hours as the cell culture 
was grown overnight. Therefore, in future, cultures grown overnight can be supplemented  with 
carbenicillin in conjunction with ampicillin. Carbenicillin is not hydrolysed as ampicillin is and 
will maintain selective pressure throughout the 16-hour growth period (Busso et al., 2008). 
2.4.5. Chicken IgY purification  
Chicken IgY antibodies were chosen (Figure 2.5) because of their superior stability and 
the non-invasive methods used to isolate them from chicken eggs (Larsson et al., 1991; 
Schade et al., 1996). The anti-rPfHP-2 IgY LOD  for rPfHRP-2 was 15 ng (Figure 2.6). 
2.4.6. DSF analysis  
Identifying the correct buffer is essential for DSF (Crowther et al., 2010). AMT buffers 
were used to determine thermal stability of proteins using DSF because of the pH range and 
having a constant ionic strength across pH 4 to 9 (Ellis and Morrison, 1982). The highest Tm 
for carbonic anhydrase obtained using AMT buffer was at pH 9 (Figure 2.7 and Figure 2.8) and 
corresponded to its optimal pH (Sanyal and Maren, 1981).  
2.4.7. Using SYPRO Orange as the fluorophore 
SYPRO Orange was the fluorophore used for DSF assays (Chapter 2 and 3) because 
it offers high fluorescence with a low dielectric constant when present in a hydrophobic 
environment.  
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The excitation  wavelength is 490 nm (460 nm – 510 nm), where few small molecules 
interfere with SYPRO Orange (Hawe et al., 2008; Niesen et al., 2007; Steinberg et al., 1996). 
1-Anilino-8-naphthalene sulfonate is an alternative fluorophore that is twice as sensitive as 
SYPRO Orange, but the excitation wavelength is 350 nm, which may interfere in screening 
ligands (Niesen et al., 2007). 
2.4.8. Why dF/dT was used to calculate Tm  
The dF/dT curves were used to determine Tm of proteins (He et al., 2010; Menzen and 
Friess, 2013; Crowther et al., 2010; Uniewciz et al., 2010) because of its simplicity and good 
agreement with Tm obtained by other methods. However, Tm from dF/dT curves are sometimes 
higher than the actual Tm of the protein (He et al., 2010). Alternatively, Tm can be determined 
by finding the point of inflection on the Boltzmann function fluorescence curves (Nieasen et al., 
2007) or by finding the second derivative (Goldberg et al., 2011). If a user would prefer finding 
the point of inflection, Niesen et al., (2012) has created a Microsoft® spreadsheet to aid with 
the calculations. 
2.4.9. DSF analysis of rPfHRP-2 and anti-rPfHRP-2 IgY interaction 
A Tm for rPfHRP-2 could not be determined, possibly due to the high concentration of 
Ala residues that may have bound SYPRO Orange, therefore, causing a high initial 
fluorescence and no transition to determine a Tm (Figure 2.9). Markwalter et al., (2018) 
suggested PfHRP-2 is stable at 80°C. Thiol based fluorophores like BODIPY FL L-cystine 
(BFC) (Hofmann et al., 2016) and N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl] 
maleimide (CPM) (Alexandrov et al., 2008; Vedadi et al., 2010) can be used as an alternative 
to SYPRO Orange to determine the Tm of rPfHRP-2 using DSF. Since CPM and BFC bind to 
cysteine residues, which are present on PfHRP-2, cysteine residues are generally embedded 
within a protein and are exposed upon protein denaturation. Both thiol probes (BFC and CPM) 
have been used to determine the Tm  of proteins when SYPRO Orange was not suitable and 
under the right conditions BFC is more sensitive. Thiol based probes are pH sensitive and 
need to be used with caution (Hofmann et al., 2016).  
rPfLDH and rPyLDH share 93% identity, but their dF/dT curves were different (Figure 
2.12 and Figure 2.17), except at pH 4 where both proteins were denatured indicating LDH is 
sensitive to denaturation in an acidic pH  environment. rPfLDH produced ideal dF/dT curves 
while rPyLDH dF/dT curves had high background.  
This could have been due to suboptimal purification conditions that resulted in rPyLDH 
being partially denatured, therefore hydrophobic patches could be exposed, resulting in the 
high background fluorescence (Reinhard et al., 2013).  
rPfGAPDH was less sensitive to acidic pH denaturation compared to the LDH 
molecules and had dF/dT peaks from pH 4 to 9 (Figure 2.20). The presence of a kink and a 
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major peak in the dF/dT curves is thought to be a tetramer and a monomer of rPfGAPDH 
melting as the rPfGAPDH expressed were shown to exist as both (Krause et al., 2017). DSF 
analysis on rPfGAPDH had a Tm of 49.9°C, in an optimal HEPES buffer described by Crowther 
et al., (2010).  Their Tm corresponds to the minor Tm (Figure 2.20) at pH 6-8, while the second 
Tm was ± 55°C. The HEPES buffer (Crowther et al., 2010) was tested with rPfGAPDH and two 
Tm were obtained at 50 and 55°C respectively (Data not shown). 
2.4.10. DSF analysis of the different IgY molecules 
Different chicken IgY Tm varied slightly (Table 2.3) with naïve pool IgY having a ±2°C 
higher Tm than all affinity purified IgY (Figures 2.10; 2.13 and 2.16), except for anti-rPfHRP-2 
IgY at pH 9. Chicken IgY incubated in glycine-HCl buffer (Table 2.4)  showed no change in Tm 
compared to the naïve chicken IgY i, indicating affinity purifying IgY with glycine-HCl buffer for 
10 min does not affect the stability of the molecule. Based on the varying Tm values, majority 
of the dF/dT peak must depend on the Fab domain as it has the variable region and constant 
regions CH1-4 are identical across all chicken IgY (Zhao et al., 2000). Anti-rPfLDH IgY (raised 
against a common epitope) was the only IgY molecule to show two transitions Tm’s at 54.32°C 
and 68°C. It is suspected that the second Tm  (68°C) corresponds to the Fab portion since the 
first Tm (54.32°C) is in a similar range as the other IgY molecules reported in Table 2.3 and 
only the Tm of the variable region should vary.  
2.4.11. DSF analysis of protein-protein interactions 
DSF was used to show protein-protein interactions of rPfHRP-2 and rPfLDH with their 
respective IgY antibodies (Figures 2.11 and 2.14). Both antigens at pH 4 did not show a 
transition, but when incubated with their respective IgY antibodies a significant increased Tm 
was seen only at pH 4. This indicated the antigens bound to and stabilised their respective 
antibodies. rPfLDH incubated with anti-RSA IgY (Figure 2.19) served as a control and showed 
that this was not a non-specific interaction and antigen-antibody interactions can be visualised 
using DSF. At pH 7 and 9 there was no significant increase in Tm because at 72°C the antigen 
dissociates from the Fab domain the IgY molecule denatures (Markwalter et al., 2018).  
However, in Figure 2.14 rPfLDH-anti-rPfLDH IgY at pH 9 the third transition observed 
with a Tm above 80°C is thought to be rPfLDH bound to the Fab domain of the anti-rPfLDH 
IgY. This could be a thermally more stable polyclonal anti-rPfLDH IgY isotype present. 
 
2.4.12. DSF analysis of anti-rPfLDH IgY common epitope interacting with rPfLDH and 
rPyLDH  
rPfLDH interacting with anti-rPfLDH IgY (Figure 2.14) was more stable than rPfLDH 
interacting with anti-rPfLDH IgY (against a common epitope; Figure 2.18A). This is likely  due 
to the more peptides recognised and therefore will allow for more interactions with anti rPfLDH 
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IgY (against whole protein) and better stability (Lipman et al., 2005). Anti-rPfLDH IgY (against 
a common epitope) produced two peaks at pH 4, both are thought to be antigen-antibody 
complexes, with the first being the antigen in excess and the second peak the antibody is in 
excess. The Tm for rPyLDH was difficult to interpret due to its poor transition peak and the Tm 
was estimated from the highest point on the peak. Potentially, the purification conditions were 
not optimal for rPyLDH purification therefore poor transition peaks were present.  
DSF analysis of anti-rPfLDH IgY (common epitope) interacting with rPfLDH was 
different compared rPyLDH and the Tm were different (Table 2.2). A common transition peak 
with a Tm of 54.08°C was present this was common with anti-rPfLDH IgY alone and rPfLDH 
with anti-rPfLDH IgY indicating that must be CH2-4 and part of the Fab fragment as it is common. 
2.4.13. Why the study could not predict the number of binding sites for the protein-
protein interactions 
Layton and Hellinga, (2011) used DSF to show the complexity for determining protein-
protein interactions. A two-protein system with a lower melting partner (LMP) and a higher 
melting partner (HMP) and both having a single binding site results in 8 states. With polyclonal 
antibodies the number of binding sites is unknown and therefore it is impossible to predict the 
number of possible states. The minimum antibodies bound per protein would be 1, however 
an antibody raised against a single peptide will only recognise that peptide. This could possibly 
explain why the rPfLDH-anti-rPfLDH IgY (against the protein) complex was more stable than 
the rPfLDH-anti-rPfLDH IgY (against a common epitope).  
2.4.14. Anti-malaria drug interaction with rPfLDH and rPfGAPDH 
Binding of chloroquine and quinine to both rPfGAPDH and rPfLDH was shown 
experimentally using DSF and in silico using Maestro and bound to the co-factor binding site 
as reported by Read et al., (1999). The in silico method may provide some insight into which 
amino acids play a role in binding, therefore those interactions can be used to develop new 
drugs against malaria (Figure 2.26 – 2.29). 
 Furthermore, by inhibiting both rPfGAPDH and rPfLDH, the glycolytic pathways are 
removed from the malaria parasite and it will not be able to survive as the glycolytic pathway 
is responsible for providing most of the energy for the parasite (Mehta et al., 2005).  
2.4.15. Conclusion 
rPfHRP-2, rPfLDH and rPfGAPDH were all recombinantly expressed and affinity 
purified using Ni2+-NTA affinity chromatography and tested using DSF. Interestingly rPfGAPDH 
had a higher Tm compared to rPfLDH, indicating it is more stable. DSF was confirmed to be a 
reliable technique for measuring protein-protein interactions. Furthermore, DSF confirmed 
chloroquine and quinine bound to rPfLDH and rPfGAPDH. The in silico data suggested a 
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potential mechanism as to how the drugs cure malaria by inhibition of the glycolytic pathway 
of the parasite. 
 
 
64 
3. CHAPTER 3: Comparing the thermodynamic stability of 
polyclonal chicken IgY, mammalian IgG and optimising a 
conjugation method for chicken IgY 
3.1. Antibodies   
Antibodies are glycoproteins expressed by B-lymphocytes when the B cells are 
stimulated by the binding of foreign antigens. Antibodies are expressed by all mammals, fish, 
amphibians, reptiles and birds (Marchalonis et al., 2006; Sun et al., 2008). Mammals have five 
classes of antibodies namely: IgA, IgM, IgE, IgD and IgG compared to IgA, IgM and IgY found 
in chickens (Sun et al., 2008) and IgH, IgM, IgD and IgM found in crocodiles (Han et al., 2016). 
Historically it was believed that IgY resembled IgG due to their similar function and 
concentrations in serum. However, due to large structural differences between the two meant 
this was not the case. Analysis of the DNA sequences of antibodies show that chicken IgY is 
closer to that of mammalian IgE than mammalian IgG (Warr et al., 1995). 
A comparison of a chicken IgY and a rabbit IgG molecule is shown in Figure 3.1. 
Chicken IgY is a 167.250 KDa heterodimer, made up of two light chains (LC; variable region 
light chain (VL) + constant region light chain (CL); 18.660 kDa each) and two heavy chains (HC; 
CH1-4 + VH; 65.105 KDa each; Sun et al., 2001). The light chains of both IgY and IgG have a 
single variable (VL) and a constant (CL) region, whilst the heavy chain of IgY has four constant 
(CH1 -CH4) regions and one variable (VH) region. The IgG molecule differs from that of IgY in 
the HC domain, in that there are only three constant regions (CH1-3) and a single variable region 
(Schade et al., 2005). A hinge region is present in IgG but is less developed in IgY (Shimizu et 
al., 1992). The general structure of IgY is depicted as a “Y” shape molecule. The arms consist 
of the antigen binding fragment (Fab; 45.359 kDa) regions which are responsible for 
recognition of an epitope on an antigen. The base of the “Y” is the Fc portion which is 
glycosylated by two carbohydrate side chains on CH2 and CH3 for IgY whereas IgG has a single 
glycosylated site on the CH2 domain (Schade et al., 2005).  
IgY and IgG antibodies are both used in immunochemistry with the latter being more 
popular. The advantages of IgY over IgG were recognised in 1996 by European center for the 
validation of alternate methods (ECVAM; Schalde et al., 1996). At the workshop they 
suggested the potential for using chicken IgY antibodies to replace mammalian IgG molecules 
for research purposes as IgY can be obtained using non-invasive techniques (Schade et al., 
1996;  Schade and Hilmak, 1996; Polson et al., 1985).  
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Figure 3.1: A cartoon comparison of a heavy and light chain fragment rabbit IgG been compared 
to chicken IgY heavy and light chain fragment. The CH are the constant heavy chain domains, the 
VH and the VL are variable heavy chains and heavy light chains.  (Figure adapted Shimizu  et al., 1992). 
Chicken IgY antibodies have been reported to have superior stability to IgG molecules 
because of its two glycosylation sites (Shimizu et al., 1992). To date there is no ΔµG DSF data 
comparing chicken IgY antibodies to mammalian polyclonal IgG molecules. Stability studies 
conducted by He et al., (2010); Li et al., (2011); and Menzen and Friess, (2013) found the melt 
temperature (Tm) of monoclonal IgG antibodies.  
Typical methods to measure protein stability are the determination of Gibbs unfolding 
energy by DSC (Garbett and Chaires, 2012), isothermal calorimetry (ITC; Svilenov et al., 
2018), hydrogen-deuterium exchange mass spectroscopy (HDX-MS; Larsericsdotter et al., 
2004), thermal denaturation and more recently DSF (Wright et al., 2017). The determination 
and the comparison of the Gibbs unfolding energy of different antibodies allows for the 
selection of the most stable class of antibody for use as immunochemical reagents.  
Conjugating methods for antibodies to HRPC 
Conjugated antibodies are used in immunochemical techniques, such as 
histochemistry and western blotting (Avrameas et al.,1978). A conjugated antibody is an 
enzyme which has been crosslinked and bound to the antibody. The most commonly used 
enzymes are horseradish peroxidase (HRPC) and alkaline phosphatase (AP).  
Conjugation occurs at the Fc domain of the antibody and will not interfere with antigen 
binding.  
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Binding of a conjugated antibody to an antigen is visualised by the enzyme catalysed 
reaction with a suitable substrate. Recognition of the antigen by the antibody can be both 
quantitative or qualitative. Thus robust, sensitive and high affinity antibodies are required 
(Koivunen and Krogsrud., 2005; Rosner et al., 1991).   
The conjugating of enzymes to antibodies involves a small organic molecule, activating 
reactive groups on the enzyme. This allows the activated enzyme to couple to a second protein 
(antibody) by various mechanisms depending on the small organic molecule used (Avrameas 
et al., 1978). These include cyanuric chloride (Avrameas et al., 1978), p,p'-Difiuoro-rn,m'-
dinitrophenyl sulfoite (FNPS) (Modesto and Pesce, 1973; Nakane and Pierce, 1966), N, N’-o-
phenylenedimaleimide (Kato et al., 1976), Tetra-azofized o-diunisidine (Gregory and Williams, 
1967), toluene diisocyanate (Modesto and Pesce, 1973) and m-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS) (Peeters et al., 1989). 
In the current study the stability and ΔμG of polyclonal chicken IgY, rabbit and mouse 
polyclonal IgG as well as crocodile IgY and IgM were determined using DSF. Glutaraldehyde 
(Avrameas 1969), sodium periodate (Nakane and Kawaoi, 1974) and (MBS) coupling reagents 
were tested for the conjugation of horseradish peroxidase to chicken IgY. 
3.2. Materials and methods: 
3.2.1. Materials and equipment  
All common reagents, buffers, salts and SDS-PAGE reagents were purchased from 
Sigma and Merck. Protein molecular weight marker, containing: 116 kDa β-galactosidase; 66.2 
kDa bovine serum albumin; 45 kDa ovalbumin; 35 kDa lactate dehydrogenase; 25 kDa REase 
Bsp981; 18.4 kDa β-lactoglobulin and 14.4 kDa lysozyme (Vilinius, Lithuania). Bovine serum 
albumin (BSA) was purchased from Roche (Mannheim, Germany). Maxi Sorp™ 96-well ELISA 
plates were from Nunc products (Roskilde, Denmark). PCR-X clear tubes (Star labs; 
Germany). SYPRO Orange (Sigma). HRPC (VI, 150 U/mg) were purchased from Sigma 
AvantiTM J-26 XPI and AllegraTM X-22R centrifuges from Beckman Coulter 
(California, USA); UV-1800 Shimadzu spectrophotometer from Shimadzu corporation (Kyoto, 
Japan); pH meter from HANNA instruments;  Corbett Research PCR Rotorgene 6000 and 
VersaMax™ ELISA plate reader was purchased from Molecular Devices Corporation 
(California, USA). 
3.2.2. Thermal melt assay, sample preparation  
Chicken IgY antibodies were isolated from chicken egg yolk  by PEG precipitation 
(Polson et al., 1985). Purified crocodile IgY and IgM were isolated, purified and available 
inhouse.  
Mouse and rabbit IgG antibodies were kindly donated by Professor THT Coetzer.  
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All antibodies were diluted in dH2O to a final concentration of 0.5 mg/ml. Antibodies at 
2.5 µg, were added to 7.5 µl constant ionic strength AMT (Ellis and Morrison, 1982) buffer (200 
mM MES, 200 mM Na-acetate, 400 mM Tris-HCl), at various pH values and  the reaction 
volume made up to 20 µl with dH2O. Before reading, SYPRO Orange (at a 10x final 
concentration) was added.  
The DSF reactions were carried out in a Rotor Gene-6000 machine, at a temperature 
range of 25°C to 95°C. The Rotor-Gene-6000  software captured the data, plotted the Boltzan 
sigmoidal curve and was used to calculate the dF/dT data. All data was processed using 
Microsoft excel (365) Niesen et al., (2012). 
3.2.3. Thermodynamic properties of proteins using DSF 
The melt curves of chicken IgY, mouse IgG, rabbit IgG and crocodile IgY and IgM 
polyclonal antibodies were analysed (Section 3.2.1). The sigmoidal curve of fluorescence 
against temperature allows for the determination of the antibodies change in Gibbs unfolding 
energy (ΔµG; Eqn 1-5), entropy (ΔµS), melting temperature (Tm) and enthalpy (ΔµH) was 
calculated by the following equations:  
Equation 1:  Fmax = (FTm -Fmin) + FTm  
Fmax is maximum fluorescence; FTm is the melting temperature; Fmin is the minimum 
fluorescence  
Equation 2:     Pf = 1 – ((F – Fmin)/ (Fmax – Fmin)) 
Pf is the ratio of folded protein; F is fluorescence at any time point  
Equation 3: Pµ = 1 - Pf  
  Pµ is the ratio of unfolded protein  
Equation 4: Kµ = (Pµ/Pf) 
  Kµ is the ratio of unfolded protein to folded protein 
Equation 5: ΔµG = -RTln(Kµ) 
ΔµG is the unfolded Gibbs energy; R is the noble gas constant -8.314 J.K-1.mol-1;                                         
T is temperature in Kelvin; Ln is the natural log of the unfolded protein ratio. 
Equations 1 to 5 were used and a linear plot of ΔµG against T(K) to obtain a linear fit 
line, allowed for the determination of ΔµG at any temperature. Using equations 6 and 7 
unfolding entropy (ΔµS) and unfolding enthalpy (ΔµH) was calculated. 
Equation 6:  ΔµS = ΔµG/(Tm-T) 
Equation 7: ΔµH = TmΔµS  
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3.2.4. Glutaraldehyde conjugation of chicken IgY to HRPC 
Glutaraldehyde conjugation was performed as previously described (Boorsma and 
Kalsbeek, 1975). Briefly, 10 mg of HRPC was dissolved in 200 µl of phosphate buffer (100 
mM, pH 6.8) containing 1.25% glutaraldehyde, resulting in a final concentration of 150 U/mg 
HRPC. After 18 h at RT the solution was filtered through a Sephadex G-25 column (bed volume 
(Vo) = 73 ml). Which had been equilibrated with phosphate buffer (100 mM NaH2PO4, pH 6.5), 
and the brown coloured fractions were collected, pooled and concentrated to 1 ml using 
Amicon filtration (MWCO 10 kDa). Chicken anti-rabbit albumin (RSA) IgY (5 mg) and 100 µl 
carbonate-bicarbonate buffer (1 M; pH 9.5) was added to HRPC fractions. After 24 h at 4°C, 
100 µl of lysine (0.2 M) was added to deactivate any remaining glutaraldehyde for 2 h at 4°C.  
The sample was dialysed twice for 2 h and once overnight in PBS (137 mM NaCl; 3 
mM KCl; 7 mM Na2HPO4; 1.5 mM KH2PO4; pH 7.2) to remove lysine. Excess HRPC was 
removed by passing the dialysed solution over a rabbit albumin Aminolink™ affinity matrix. The 
chicken anti-rabbit albumin IgY conjugated to HRPC was eluted with 900 µl Glycine-HCl (100 
mM, pH 2.8) and neutralised with 100 µl phosphate buffer (1 M, pH 8.5).  
3.2.5. Periodate conjugation of chicken IgY to HRPC  
Sodium periodate 200 µl (0.1 M) was added to 5 mg HRPC (150 U/mg) and dissolved. 
The solution turned from brown to greenish-brown and was mixed end over end for 20 min in 
the dark at RT. Sodium periodate was removed by dialysis against sodium acetate buffer (0.1 
M sodium acetate; 0.22% (v/v) acetic acid; pH 4.4) twice for 2 hours and once overnight. To 
raise the pH to 9.5, 40 µl carbonate buffer (0.2 M; pH 9.5) was added. To this solution, 5 mg 
chicken anti-rabbit albumin IgY (5 mg) was added and the IgY-HRPC mixture was mixed over 
2 hours at RT.  All HRPC not coupled was reduced by the addition of 100 µl NaBH3 (4 mg/ml) 
and the solution was left to stand for 2 hours at 4°C. 
The solution was then dialysed against borate buffer (0.1 M; pH 7.4) twice for 2 hours 
and once overnight. Lastly, an equal volume borate buffer (0.1 M, 60% (v/v) glycerol) was 
added and the sample stored at 4°C.  
3.2.6. MBS conjugation of chicken IgY to HRPC 
Chicken anti-RSA IgY (3.2 mg) was dialysed overnight against reduction buffer (100 mM 
Tris-HCl, 1 mM EDTA; pH 8.0) at 4°C and reduced with 10 mM DTT for 90 min at 37°C. DTT 
was removed using a G-1 column (10 ml) equilibrated, washed and eluted with phosphate 
buffer (100 mM NaH2PO4 100 mM; pH 7.0). DTT was removed and the reduced samples were 
determined using Elman’s reagent.  
Four mg of HRPC (150 U/mg) was dissolved in 500 µl PBS was mixed with 500 µl of 1.2 
mg of MBS (MBS dissolved in dimethyl formamide 200 µl + 300 µl PBS) incubated for 60 min 
at RT.  
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Unbound MBS was separated from HRPC using a G-25 gel filtration column (73 ml) 
equilibrated with phosphate buffer (100 mM NaH2PO4; pH 7.0). Eluted fractions with an 
absorbance at 280 nm A280 above 0.3 were pooled. 
Reduced IgY and MBS-HRPC fractions were pooled and gently stirred for 3 h at RT, 
before been concentrated using centricon concentration (MWCO 10 kDA). Unbound HRPC 
was removed by passing the conjugated IgY-MBS-HRPC over a rabbit albumin AminolinkTM 
affinity matrix. Specific IgY antibodies were eluted with 900 µl Glycine-HCl buffer (100 mM; pH 
2.8) and neutralised using 100 µl Phosphate buffer (1 M; pH 8.5).  
3.2.7. The ELISA for detection of conjugated anti-RSA IgY 
Varying concentrations of RSA were coated onto Nunc® 96 well plates overnight at 
4°C. After washing with PBS (3 x 350 µl per well) and PBS-Tween 20 (0.1% v/v) (3 x 350 µl 
per well), wells were blocked with 200 µl 5% (w/v) milk-PBS for 2 h at 37 °C. Chicken anti-RSA 
IgY conjugated to HRPC (100 ng), was diluted in PBS (pH 7.0) was added and incubated for 
2 hours at 37°C. The substrate tetramethylbenzidine (TMB) (284 µM TMB; 1.92 mM H2O2 in 
0.15 M citrate-phosphate buffer pH 5.0), was added to each well, after 1 h at RT absorbance 
was measured at 652 nm using the VersamaxTM microplate reader . 
3.3. Results  
The thermal stability of chicken IgY, mouse IgG, rabbit IgG, crocodile IgY and IgM was 
analysed at different pH values (4-9) in AMT buffers. The dF/dT curves of the Boltzmann non-
linear fit function were analysed and plotted.  
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3.3.1. Tm of chicken IgY 
 
Figure 3.2: DSF first derivative data of fluorescence data for naïve polyclonal chicken IgY at 
different pH values. Chicken IgY thermodenaturation was analysed as a dF/dT function against 
temperature in AMT buffers at different pH values (4-9). SYPRO Orange was added and fluorescence 
data was measured from 25 to 90°C. 
The thermodenaturation of naïve polyclonal chicken IgY was analysed at different pH 
values and produced a single dF/dT transition peak (Figure 3.2). From this peak the Tm could 
be determined at each pH value tested.  
The Tm increased from pH 4 (59.45°C) to pH 9 (74.75°C), with a 1°C difference in Tm 
between pH 7 and 9.The antibody is most stable (higher Tm) in a pH 7 to 9 environment. A 
single transition peak suggests that all the domains comprising the chicken IgY molecule 
melted at  the same Tm.  
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3.3.2. Tm of polyclonal mouse IgG 
 
Figure 3.3: DSF first derivative of fluorescence data for polyclonal mouse IgG at different pH 
values. Mouse IgG thermodenaturation was analysed as a dF/dT function against temperature in AMT 
buffers at different pH values (4-9). SYPRO Orange was added and fluorescence data was measured 
from 25 to 90°C. 
Mouse IgG was measured by DSF and the dF/dT curves had two transition peaks in acidic 
AMT buffers (Figure 3.3). At an alkaline pH a single transition peak was observed. The mouse 
IgG antibody was least stable at a pH value of 4, with the lowest Tm1 of 48.25°C and second 
peak Tm2 of 75.25°C. The Tm peaks increased with increasing pH up to pH 6. At pH 7, 8 and 
9 the dF/dT curve was judged to have a single peak corresponding to a single transition with 
Tm values of 73.38, 76.68 and 76.08°C. 
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3.3.3. Tm analysis of polyclonal rabbit IgG 
 
Figure 3.4: DSF first derivative of fluorescence data for pooled polyclonal rabbit IgG at different 
pH values. Rabbit IgG thermodenaturation was analysed as a dF/dT function against temperature in 
AMT buffers at different pH values (4-9). SYPRO Orange was added and fluorescence data was 
measured from 25 to 90°C. 
The change in Tm with different pH values observed for chicken IgY (Figure 3.2) and 
mouse IgG (Figure 3.3) antibodies was similar for rabbit IgG (Figure 3.4) which had higher Tm 
values at neutral to alkaline pH values. Three transitions were observed with Tm values of 
50.25, 54.58 and 75.75°C at pH 4, indicating three separate domains melted at different 
temperatures. At pH 5, two transition peaks were observed with Tm1 at 63.08°C and Tm2 at 
80.08°C. At alkaline pH values rabbit IgG melted as a single transition and based on Tm values 
rabbit IgG was most stable at pH 9 with a Tm 76.92°C. A proteins stability using DSF is judged 
by the Tm of the domain with the lowest Tm. The DSF dF/dT results from the mouse IgG and 
rabbit IgG molecules unfolding in a similar fashion and different to that of naïve chicken IgY, 
which did not show multiple transitions at any pH tested.  
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3.3.4. Tm analysis of polyclonal crocodile IgM 
 
 
Figure 3.5: DSF first derivative of fluorescence data for crocodile IgM at different pH values. 
Crocodile IgM thermodenaturation was analysed as a dF/dT function against temperature in AMT buffers 
at different pH values (4-9). SYPRO Orange was added and fluorescence data was measured from 25 
to 90°C. 
The Tm of crocodile IgM increased with increasing pH and had the highest Tm at pH 8  
(62.58°C), although the Tm at pH at 7 and 9 were very similar at 61.52 and 61.75°C respectively 
(Figure 3.5). At each pH value tested, a single transition was observed suggesting the entire 
molecule destabilised and unfolded at the same temperature.  
 
 
 
 
 
 
 
 
 
 
74 
3.3.5. Tm analysis of crocodile IgY 
 
Figure 3.6: DSF first derivative of fluorescence data for crocodile IgY at different pH values. 
Crocodile IgY thermodenaturation was analysed as a dF/dT function against temperature in AMT buffers 
at different pH values (4-9). SYPRO orange was added and fluorescence data was measured from 25 
to 95°C. 
The dF/dT curves for crocodile IgY (Figure 3.6) differed from chicken IgY (Figure 3.2) 
as there were two transitions present at each pH value for crocodile IgY compared to the single 
transition with chicken IgY. Crocodile IgY was least stable at pH 4 with the first transition Tm1 
41.92° and the second transition at Tm2 58.08°C. Increasing pH resulted in the molecule 
becoming more stable, which is seen by an increase in Tm. The two transitions are an indication 
that crocodile IgY has two domains that have different thermal stabilities or unfolding takes 
place in two phases. pH also effects the microenvironment around the IgY molecule as 
increasing pH results in both transition peaks moving closer together.  
The two transition peaks for crocodile IgY were closest at pH 8, while the Tm at pH 7 
was 12°C lower than that of pH 8 (54.08°C compared to 66.25°C). The increased amplitude of 
the dF/dT peaks at pH 6 to 9 is due the unfolding of the crocodile IgY molecule at a lower range 
of temperatures as compared to acidic conditions. 
A Tm summary of all five antibodies is presented in Table 3.1. 
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Table 3.1: Summary of Tm of different polyclonal antibodies. 
    Tm(°C) 
pH   4 5 6 7 8 9 
Chicken IgY Tm1 59.45 67.25 71.25 73.75 74.05 74.75 
Mouse IgG Tm1 48.25 57.92 64.75 73.38 76.58 76.08 
 Tm2 75.25 78.25 80.08    
Rabbit IgG Tm1 50.25 63.08 69.58 74.08 76.25 76.92 
 Tm2 54.58 80.08     
 Tm3 72.75      
Crocodile IgM Tm1 N.D 50.08 58.92 61.52 62.58 61.75 
Crocodile IgY Tm2 41.92 42.92 51.58 54.08 66.25 66.42 
  Tm3 58.05 57.75 64.58 72.75 72.25 72.25 
 
A summary of the Tm’s  determined by DSF at pH 4 to 9 of chicken IgY, mouse IgG, rabbit IgG, 
crocodile IgM and IgY  is reported in Table 3.1.  
3.3.6.   Thermodynamic analysis of carbonic anhydrase 
After dF/dT thermal melt analysis, the data was used to determine the Gibbs free 
unfolding energy (ΔµG), entropy of unfolding (ΔµS) and enthalpy of unfolding (ΔµH). As 
described by Wright et al., (2017). Carbonic anhydrase was used as a control and the data as 
it was used by Wright et al., (2017). 
Table 3.2: Comparison of the thermodynamic parameters obtained for carbonic anhydrase to 
Wright et al., 2017. 
  
Wright et al., 
2017 
Current 
experiment  %Error 
Tm 62.8 59.5 5 
ΔµG Kj.mol-1 60.4 56.7 6 
ΔµH Kj/mol-1 536 552 3 
ΔµS KJ.mol-
1.K-1 1.6 1.66 4 
 
The results obtained in Table 3.2 are similar to that determined by Wright et al., (2017). 
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3.3.7. Fluorescence curves of different antibodies 
A good transition is seen from a steady constant fluorescence to a visible sharp 
increase. Good transitions were observed for all antibodies except for crocodile IgM (Panel D). 
Using the Wright et al., (2017) method, the thermodenaturation DSF fluorescence curves were 
analysed (Figure 3.7). A sample calculation for chicken IgY is reported in Table 3.3 and the 
appendix.  
 
Figure 3.7: Thermodenaturation fluorescence curves of different naïve polyclonal antibodies.  
Thermodenaturation of polyclonal chicken IgY (A); polyclonal mouse IgG (B); polyclonal rabbit IgG (C) 
;polyclonal crocodile IgM (D); polyclonal crocodile IgY (E) was measured using DSF in AMT buffer pH 
7.0. SYPRO Orange was used to monitor the transitions causing the RFU measured at different 
temperatures. Each panel shows triplicate results. 
3.3.8. Thermodynamic calculations for the stability of antibodies 
Using equation 2 (section 3.2.2) and applying it to the data from Figure 3.7, the partial 
folded (Pf) protein concentration was calculated. Thereafter, equation 3 was used to find the 
ratio of unfolded protein (Pµ). Together, the folded and unfolded protein concentration was 
used in  equation 4 to calculate the unfolded protein equilibrium (Kµ). These results for chicken 
IgY are reported in the appendix. A sample calculation of chicken IgY is presented below in 
Table 3.3. 
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Table 3.3: Chicken IgY data calculated from equations 1-5. 
Fmin 
Chicken IgY 
Fluorescence 
data 
F- F 
min 
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
Pf = 1-(F-
Fmin)/Fmax-
Fmin) 
Pu Pf 
Ku= 
(pu/pf) 
T in 
(K) 
ΔGµ 
(F-
Fmin)/Fmax-
Fmin) 
9.37 9.401 0.031 19.5 0.002 0.998 0.002 0.998 0.002 335.2 17995.27 
9.37 9.421 0.051 19.5 0.003 0.997 0.003 0.997 0.003 335.5 16595.49 
9.37 9.438 0.068 19.5 0.003 0.997 0.003 0.997 0.003 335.8 15806.05 
9.37 9.438 0.068 19.5 0.003 0.997 0.003 0.997 0.004 336.1 15800.2 
9.37 9.447 0.077 19.5 0.004 0.996 0.004 0.996 0.004 336.4 15464.12 
9.37 9.483 0.113 19.5 0.006 0.994 0.006 0.994 0.006 336.7 14407.64 
9.37 9.54 0.17 19.5 0.009 0.991 0.009 0.991 0.009 337 13268.15 
9.37 9.559 0.189 19.5 0.01 0.99 0.01 0.99 0.01 337.3 12983.31 
9.37 9.588 0.218 19.5 0.011 0.989 0.011 0.989 0.011 337.6 12584.07 
9.37 9.62 0.25 19.5 0.013 0.987 0.013 0.987 0.013 337.9 12205.67 
9.37 9.69 0.32 19.5 0.016 0.984 0.016 0.984 0.017 338.2 11506.96 
9.37 9.747 0.377 19.5 0.019 0.981 0.019 0.981 0.02 338.5 11048.33 
9.37 9.815 0.445 19.5 0.023 0.977 0.023 0.977 0.023 338.8 10581.7 
9.37 9.879 0.509 19.5 0.026 0.974 0.026 0.974 0.027 339.1 10205.95 
9.37 9.956 0.586 19.5 0.03 0.97 0.03 0.97 0.031 339.4 9804.579 
9.37 10.054 0.684 19.5 0.035 0.965 0.035 0.965 0.036 339.7 9362.345 
9.37 10.165 0.795 19.5 0.041 0.959 0.041 0.959 0.042 340 8930.28 
9.37 10.271 0.901 19.5 0.046 0.954 0.046 0.954 0.048 340.3 8564.89 
9.37 10.389 1.019 19.5 0.052 0.948 0.052 0.948 0.055 340.6 8205.982 
9.37 10.541 1.171 19.5 0.06 0.94 0.06 0.94 0.064 340.9 7795.888 
9.37 10.721 1.351 19.5 0.069 0.931 0.069 0.931 0.074 341.2 7369.269 
9.37 10.912 1.542 19.5 0.079 0.921 0.079 0.921 0.086 341.5 6970.612 
9.37 11.133 1.763 19.5 0.09 0.91 0.09 0.91 0.099 341.8 6561.053 
9.37 11.38 2.01 19.5 0.103 0.897 0.103 0.897 0.115 342.1 6154.677 
9.37 11.629 2.259 19.5 0.116 0.884 0.116 0.884 0.131 342.4 5786.902 
9.37 11.94 2.57 19.5 0.132 0.868 0.132 0.868 0.152 342.7 5371.514 
9.37 12.276 2.906 19.5 0.149 0.851 0.149 0.851 0.175 343 4968.969 
9.37 12.664 3.294 19.5 0.169 0.831 0.169 0.831 0.203 343.3 4547.671 
9.37 13.056 3.686 19.5 0.189 0.811 0.189 0.811 0.233 343.6 4161.127 
9.37 13.477 4.107 19.5 0.211 0.789 0.211 0.789 0.267 343.9 3778.317 
9.37 13.975 4.605 19.5 0.236 0.764 0.236 0.764 0.309 344.2 3359.365 
9.37 14.487 5.117 19.5 0.262 0.738 0.262 0.738 0.356 344.5 2960.62 
9.37 15.074 5.704 19.5 0.293 0.707 0.293 0.707 0.413 344.8 2532.082 
9.37 15.65 6.28 19.5 0.322 0.678 0.322 0.678 0.475 345.1 2136.039 
9.37 16.286 6.916 19.5 0.355 0.645 0.355 0.645 0.55 345.4 1719.297 
9.37 16.939 7.569 19.5 0.388 0.612 0.388 0.612 0.634 345.7 1308.417 
9.37 17.647 8.277 19.5 0.424 0.576 0.424 0.576 0.738 346 875.788 
9.37 18.361 8.991 19.5 0.461 0.539 0.461 0.539 0.856 346.3 449.35 
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These values (Table 3.3) were then substituted into equation 5 to calculate the Gibbs 
unfolding energy at different temperatures from the data for chicken IgY (Figure 3.8).  
 
Figure 3.8: Fitting of DSF data to equation 5. DSF data (ΔµG) for polyclonal chicken IgY and R2 
values were calculated using excel. 
Due to the large volume of data for each of the antibodies tested, equations of the 
remaining graphs for each antibody and the replicates whose R2 is greater than 0.9 is reported 
(Table 3.4).  
Table 3.4: Summary of linear equations for data fitted into equation 5 for the different antibodies. 
  ΔµG equation in the 
form y = mx + c 
R2 - value 
Chicken IgY y= -1470x + 509178 0.992 
 y = -1481x + 513137 0.993 
 y = -1495,2x + 518068 0.997 
Mouse IgG y = -1103,2x + 381932 0.998 
 y = -1208,3x + 417 474 0.995 
 y = -1185,4x + 410205 0.996 
Rabbit IgG  y = -1149x + 398391 0.998 
 y = -1121,6x + 388814 0.998 
 y = -1106,7x + 383708 0.994 
Croc IgM  y = -2066,9x + 690612 0.994 
 y = -2081,7x + 695631 0.996 
 y = -2101x + 702903 0.995 
Croc IgY  y = -2038,6x + 689227 0.999 
 y = -2019,3x + 682899 0.999 
 y = -2037,9x + 389104 0.999 
Croc IgY y = -1494,4x + 512846 0.994 
 y = -1503,1x + 515663 0.984 
  y = -1537,1x + 527452 0.992 
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The linear equations in Table 3.4 can be used to calculate the ΔµG energy for each 
antibody at any temperature. In this study, at 25°C (295K) the calculation of the ΔµG using 
linear equations was deemed accurate as all the R2 values were above 0.99 except for a single 
replicate reading with crocodile IgY in the second transition. However, since the value was still 
above 0.9, it was included in the study. Using  equation 6 and equation 7, the ΔµH and ΔµS 
were calculated and reported in Table 3.5.   
Table 3.5: Thermal stability and thermodynamic data for antibodies. 
     1 2  3  Average S.D 
 Chicken 
IgY 
ΔµG (KJ.mol.-1) 71.12 71.71 71.60 71.48 0.32 
ΔµS (KJ.mol-
1.K-1 
1.46 1.47 1.47 1.47 0.01 
ΔµH (KJ.mol.-1) 506.00 510.00 509.00 508.33 2,08 
Tm (°C) 73.75  73.55  73.95  73.75  0.2 
       
Mouse 
IgG 
ΔµG (KJ.mol.-1) 53.13 52.40 56.96 54.16 2.45 
ΔµS (KJ.mol.-1 
K-1) 
1.09 1.18 1.17 1.15 0.05 
ΔµH (KJ.mol.-1) 378.30 391.11 405.00 391.47 13.35 
Tm (°C)  73.75  73.15 73.25  73.38  0.32 
       
Rabbit 
IgG 
ΔµG (KJ.mol.-1) 55.99 54.58 53.91 54.83 1.06 
ΔµS (KJ.mol.-1) 1.15 1.12 1.11 1.12 0.02 
ΔµH(KJ.mol.-1) 398.10 388.00 383.20 389.77 7.61 
Tm (°C)  73.15  73.75 73.45  73.45  0.3 
       
Croc IgM 
ΔµG (KJ.mol.-1) 74.68 75.28 75.96 75.31 0.64 
ΔµS (KJ.mol.-
1K-1) 
2.06 2.09 2.10 2.08 0.02 
ΔµH (KJ.mol.-1) 688.60 698.60 701.00 696.07 6.58 
Tm (°C)  61.25 61.35  61.15  61.25  0.1 
       
Crocodile 
IgY 1 
ΔµG (KJ.mol.-1) 81.72 81.15 81.81 81.56 0.36 
ΔµS (KJ.mol.-
1K-1) 
2.18 2.16 2.18 2.17 0.01 
ΔµH (KJ.mol.-
1.K-1) 
731.00 726.00 732.00 729.67 3.21 
Tm (°C) 65.25  65.15  65.45  62,30  0.15 
       
Crocodile 
IgY 2 
ΔµG (KJ.mol.-1) 67.51 67.74 69.40 68.22 1.03 
ΔµS (KJ.mol.-
1.K-1) 
1.42 1.43 1.46 1.44 0.02 
ΔµH (KJ.mol.-1) 491.00 492.00 504.00 495.67 7.23 
Tm (°C)  71.25 71.45  71.45  71.38  0.12 
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The fluorescence curves produced (Figure 3.7) were at pH 7. Only the crocodile IgY 
antibody had two transitions (Panel E) at pH 7. 
Chicken IgY, mouse IgG and rabbit IgG had a similar Tm at pH 7 of 73.75, 73.38 and 
73.45°C respectively (Table 3.5). Crocodile IgM had the lowest Tm of 61.25°C, whilst crocodile 
IgY second transition Tm (71.38°C) is similar to that of chicken IgY (Table 3.5). A higher ΔµG 
is an indication of a more stable antibody. Based on the results in Table 3.5 Crocodile IgY 
transition 1  had the highest ΔµG (81.56 KJ. Mol-1) followed by crocodile IgM (75.31 KJ.mol-1), 
chicken IgY (71.48 KJ.mol-1), crocodile IgY transition 2 (68.27 KJ.mMol-1) while mouse IgG and 
rabbit IgG had similar ΔµG (54.16 and 54.83 KJ.mol-1). Alfano et al., (2017) stated that the two 
most common methods used to determine protein stability is Tm and ΔµG. Since only DSF was 
used, the proteins stability was judged based on the combined Tm and ΔµG. Therefore, the 
order of stability of the antibodies from most stable to least stable was chicken IgY, crocodile 
IgY, crocodile IgM, rabbit IgG and mouse IgG.  
3.3.9. Stability of chicken IgY stored at 4°C from 1990 
To investigate if chicken IgY is more stable than both the mouse and rabbit IgG, DSF 
analysis of chicken IgY which had been stored at 4°C since 1990 was performed (Figure 3.9). 
 
Figure 3.9: DSF first derivative of the fluorescence data for chicken IgY-1990 at different pH 
values. Chicken IgY-1990 in AMT buffer from pH 4 to 9. SYPRO Orange was added and the raw 
fluorescence data was measured from 25 to 95°C of which the first derivative was calculated. 
Similar to the chicken IgY (Figure 3.2), chicken IgY-1990 had an increasing Tm with 
increasing pH and only a single transition. This indicates the chicken IgY is remarkably stable. 
The difference in both the chicken IgY molecules was the chicken IgY-1990 had a 2.17°C lower 
Tm (at pH 7) compared to the freshly isolated chicken IgY. 
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3.3.10. Comparing the conjugating efficiency of three cross linking reagents 
The conjugating efficiency of HRPC to the chicken anti-RSA IgY using glutaraldehyde, 
sodium periodate and MBS was measured using a direct ELISA (Figure 3.10). 
 
Figure 3.10: Comparison of glutaraldehyde, sodium periodate and MBS conjugation of HRPC to 
chicken anti-RSA IgY. Microplates were coated with RSA (0.1 – 10 µg) and detected with chicken anti-
rabbit RSA IgY-HRPC conjugates, coupled with either glutaraldehyde, sodium periodate or MBS. TMB 
was used for detection and was measured at 652 nm. Error bars indicate S.D of triplicate results. 
Detection of RSA by chicken anti-RSA IgY-HRPC conjugate confirmed that all three 
conjugating reagents resulted in successful conjugation of  chicken anti-RSA IgY to HRPC. 
The conjugates detected RSA, detected between 0.1 to 10 µg (Figure 3.10).  
RSA at 1 to 10 µg was detected by the Na-periodate IgY-HRPC, which was similar to 
the MBS conjugate. At 0.1 µg RSA, the Na-periodate detected it with a higher absorbance, 
while the glutaraldehyde IgY-HRPC conjugate had a higher absorbance for 0.1 – 10 µg RSA. 
All three conjugates had no non-specific binding and the results indicate the glutaraldehyde 
method was the most efficient method used to couple chicken IgY to HRPC.  
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3.3.11. Finding the LOD of glutaraldehyde coupled IgY  
The LOD of the glutaraldehyde conjugate was determined (Figure 3.11). 
 
Figure 3.11: Glutaraldehyde coupled anti-RSA-IgY-HRPC detecting RSA in an ELISA. Microplates 
were coated with RSA (20 – 100 ng) and detected with glutaraldehyde coupled chicken anti-RSA IgY-
HRPC conjugate (100 ng). TMB was as the substrate and was measured at 652 nm. Error bars indicate 
S.D of triplicate results. 
When diagnosing a disease in the field using an ELISA, an O.D cut off is around 0.2 
(Voller et al., 1980). Using the same cut off on our conjugates to define their LOD (Figure 3.10).  
Glutaraldehyde coupled IgY-HRPC detected 20 ng of RSA with an absorbance above 0.2 
(Figure 3.11). This was 5 times less RSA, than the RSA concentration detected by anti-RSA 
IgY, coupled by the sodium periodate method and  50 times less RSA compared to the anti-
RSA IgY coupled by the MBS method (comparing Figure 3.10 to Figure 3.11).  
3.3.12. Analysis of MBS conjugation 
MBS conjugation required the reduction of IgY with DTT to expose internal cysteines 
for their sulfhydryl groups, resulting in the reduction.  This meant light and heavy chains were 
separated, which was confirmed by SDS-PAGE (Figure 3.12).  
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Figure 3.12: Analysis of anti-RSA IgY following DTT reduction and size exclusion 
chromatography on an SDS-PAGE. A 12.5% SDS-PAGE gel run in the absence of β-mercaptoetahnol 
showing chicken anti-rabbit RSA IgY fractions were run through a Sephadex G-25 matrix to remove 
DTT. Lanes 1 -9 are the 9 fractions that were the eluted collected fractions. Arrows 1-5 indicate the 
different species of IgY eluted from gel filtration chromatography after DTT reduction. 
Two bands lie above the 116 kDa (arrow 1 and 2). The highest band (arrow 1) is thought 
to be non-reduced IgY, the second band (arrow 2) above 130 kDa could be two heavy chains 
(HC). The third band (arrow 3) below 116 kDa marker (90 kDa) may be the  HC and Light chain 
(LC) joined. The remaining two bands could be the HC (65 kDa) and LC (25 kDa) (Figure 3.12). 
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3.3.13. MBS conjugation mechanism 
 
 
 
Figure 3.13: Proposed mechanism of HRPC conjugation to IgY the molecule using MBS. IgY is 
represented by “Y” shape molecule. LC and HC represent the heavy and light chains. 
The image (Figure 3.13) shows the possible method for  MBS conjugation of a chicken 
IgY molecule to HRPC. The IgY molecule is reduced with DTT into two HC and LC fragments 
with two exposed cysteine residues. The MBS molecule as a linker between the cysteine 
residues and the HRPC.  
3.3.14. Conjugation of redox treated chicken anti-RSA IgY 
Since glutaraldehyde conjugation was the most efficient at conjugating HRPC to IgY, it 
was used in conjunction with both oxidised and reduced IgY to couple a chicken IgY to HRPC. 
The efficiency of the co method was analysed using an ELISA (Figure 3.14). 
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(A)                                                                    (B) 
 
Figure 3.14: Redox-glutaraldehyde coupled anti-RSA IgY-HRPC detecting RSA in an ELISA. 
Microplates were coated with RSA (10 – 0.001 µg), detected with glutaraldehyde coupled to the reduced 
chicken anti-RSA IgY-HRPC conjugate (A) and the reduced chicken anti-RSA IgY that was oxidised (B). 
Colorimetric substrate TMB was used for detection and measured at 652 nm. Error bars indicate S.D of 
triplicate results. 
ELISA results on Figure 3.14A confirm that RSA could be detected with reduced anti-
RSA IgY-HRPC conjugate, while Figure 3.14B showed no detection of RSA when anti-RSA-
IgY was oxidised after reduction with H2O2. Reducing IgY did not increase the limit of detection 
of the  glutaraldehyde conjugated anti-RSA IgY-HRPC. 
3.3.15. Analysis of different HRPC samples with different limits of activity 
The  HRPC used in the assay was of low activity (150 U/mg). A 1000 U/mg HRPC and 
150 U/mg HRPC were run on SDS-PAGE gel to evaluate the structure of the enzyme in the 
samples (Figure 3.15). The 150 U/mg HRPC, had additional proteins at different sizes 
compared to the 44 kDa HRPC molecule in the samples (Figure 3.15 lanes 1 and 2) which 
were not present in the 1000 U/mg activity HRPC (Figure 3.15 lanes 3 and 4). This meant the 
150 U/mg HRPC present is in lower concentrations than anticipated.  
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Figure 3.15: 150 U/mg and 1000 U/mg HRPC run on an SDS-PAGE gel. Two samples of HRPC (17 
6U/mg and 1000 U/mg) were analysed on a 12.5% non-reducing SDS-PAGE gel. Lane 1 and 2 HRPC 
(150 U/mg). Lane 3 and 4 had HRPC (1000 U/mg). The gel was stained with Coomassie brilliant blue 
R-250. 
3.4. Discussion 
Using DSF a proteins stability is judged on its Tm value (Niesen et al., 2007). By using 
the ΔµG the conformational stability of a protein was  measured (Freire et al., 2013; Wright et 
al., 2017). Based on the thermodynamically most stable antibody (polyclonal chicken IgY) 
different conjugation techniques were tested.  
3.4.1. Using ΔµG as a measure of proteins stability 
Wright et al., (2017) showed HRPC type I had a Tm of 64.1°C and a ΔµG of 24.6 KJ.mol-
1 while  carbonic anhydrase isozyme (II) from bovine erythrocytes has Tm 62.8°C and a ΔµG 
of 60.4 KJ.mol-1. Both proteins had similar Tm but a ΔµG difference of 35.8 KJ.mol-1 indicating 
carbonic anhydrase was more stable than HRPC. The ΔµG of a protein represents the  
conformational stability, while Tm is based on when half the protein has unfolded (Freire et al., 
2013; Niesen et al., 2007). Therefore, ΔµG may be a more accurate measure of protein 
stability.  
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3.4.2. Analysis of mouse and rabbit IgG molecules 
DSF analysis of polyclonal IgG antibodies from mice and rabbits showed two peaks at 
acidic pH values while a single peak was observed at neutral and alkaline pH (Figures 3.3 and 
3.4).  The first peak is likely the CH2 domain while the second peak is the simultaneous 
thermodenaturation of the CH3 and Fab domains of the molecules melting, this was shown with 
mouse monoclonal IgG using DSC (Ionescu et al., 2008; Garber and Demarest, 2007) and 
DSF (He et al., 2010). The CH2 domain is glycosylated making it more sensitive to the acidity 
of the buffer compared to the CH3 and Fab fragment, therefore two peaks appear. At alkaline 
pH the entire molecule melts simultaneously (Wen et al., 2008; He et al., 2010). Similar results 
with mouse monoclonal IgG antibodies were observed in previous studies (Menzen and Friess, 
(2013); Svilenov et al., (2018); Garber and Demarest, (2007), Ionescu et al., (2008).  
3.4.3. Comparison of polyclonal chicken IgY vs polyclonal mouse and rabbit IgG 
Based only on the Tm (dF/dT curve), the chicken IgY antibodies were more stable than 
both IgG molecules in acidic AMT buffers (pH 4 to 6). A proteins stability is dependent on the 
stability of the weakest domain (He et al., 2010) .  
Chicken IgY has two glycosylation sites and the additional glycosylation site has been 
reported to aid in the stabilisation of IgY (Spillner et al., 2012). Alsenaidy et al., (2014) showed 
that the absence of carbohydrates in mouse monoclonal IgG resulted in reduced thermal 
stability of the antibodies.  
The absence of two transitions (peaks) for chicken IgY is probably due to the less 
developed hinge region. This was seen before when murine IgG1 which had a single transition 
while IgG2a had two, at pH 6.0 and was attributed to a less developed hinge region (Ionescu 
et al., 2008;  Vermeer et al., 1998).  
3.4.4. Analysis of crocodile IgM and IgY 
Crocodile IgM (Figure 3.5) appeared to be more sensitive to pH denaturation compared 
to the other antibodies analysed as there was no transition at pH 4, indicating IgM was 
completely denatured. The IgM molecule is typically greater than 900 kDa and lacks a hinge 
region (Plomp et al., 2016), this could explain why a single transition was observed at all pH 
values. The results were surprising since IgM is made up of five 180 kDa monomers which are 
thought to be similar to IgY. It was expected that the Tm would be higher than 62°C or there 
would be multiple transitions.  
Crocodile IgY (Figure 3.6) was different to that of chicken IgY as at each pH value there 
were two peaks. This could potentially be because the CH2 + CH3 domains and the CH4 + Fab 
domains melted at different temperatures. Since the CH2 + CH3 domains are glycosylated.  
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3.4.5. Comparing the ΔµG of the antibodies 
ΔµG for all five antibodies (Wright et al., 2017) is shown in Table 3.5. ΔµG of chicken 
IgY was compared to rabbit IgG and mouse IgG, at pH 7 and all three molecules had a Tm of 
around 73°C. However, the ΔµG calculation showed that chicken IgY was 17 KJ.mol-1 more 
stable than both IgG molecules.  
A higher ΔµH is expected for more stable molecules as it is based on the ΔµG and ΔµS 
of the system. Comparing the ΔµS, a value close to one is ideal, the ΔµG for both IgG 
molecules were lower than that of chicken IgY but the IgY ΔµS was marginally above 1 
indicating 1 state.  
Comparison of crocodile IgM and IgY were somewhat ambiguous and had to be 
considered. The Tm was for croc IgM was the lowest at 61.25°C, however the ΔµG was higher 
than chicken IgY and both IgG molecules which would be an indication that it was more stable 
but since the ΔµS was 2, it meant there were two states of disorder in the molecule.  
An ΔµS 2 could be due to the pentameric structure of IgM. The crocodile IgY molecules 
was the only antibody that was shown to have two transitions. The transitions of the 
carbohydrate moiety of CH3 and CH4 and  CH2 and Fab melting at different temperatures 
(Ionescu et al., 2008; Garber et al., 2007). Interestingly the ΔµS was above 2 for the first 
transition indicating it may not be the most stable. The second transition however was 
remarkably similar to the chicken IgY with all four thermodynamic parameters.  
Based on the results polyclonal chicken IgY antibodies appeared to be the most stable. 
A 1990 sample IgY (28 years) stored at 4°C was analysed by DSF analysis showed the 
antibodies had a similar dF/dT profile and similar Tm (Figure 3.9) to freshly isolated chicken 
IgY indicating they were in their native conformation.  
3.4.6. Using DSF to calculate ΔµG  
DSF is not often used to compare the thermodynamic stability of proteins, while DSC 
remains the gold standard (Garbett and Chaires, 2012). To our knowledge this is the first-time 
polyclonal  antibodies were compared with ΔµG rather than Tm alone. In previous studies when 
monoclonal antibodies were compared, acidic buffers were used due to monoclonal antibodies 
degrading in alkaline pH buffers (Manning  et al., 2011). This was not observed for chicken IgY 
antibodies (stored at pH 7.4), as we show the molecule still had dF/dT peaks after 28 years 
(Figure 3.9).  
He et al., (2010) showed that no transitions were missed with DSF compared to DSC 
with monoclonal antibodies and the SYPRO Orange fluorescence dye did not interfere with the 
assay.  
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Several studies have looked at the correlation between DSF and DSC for antibodies 
and shown that both methods have a linear correlation when estimating Tm. DSF usually 
overestimates Tm as compared to DSC (Menzen and Friess, 2013; He et al., 2010).  
3.4.7. Comparison of the three cross linking reagents used to conjugate anti-RSA-IgY 
to HRPC  
A two-step conjugation method coupled anti-RSA-IgY to HRPC using glutaraldehyde, 
Na-periodate and (Figure 3.10). Two-step conjugating methods show less non-specific 
binding, offer better conjugation quality and efficiency compared to single step conjugating 
(Beyzavi et al., 1987). Of the three methods the glutaraldehyde method was the most efficient 
followed by Na-periodate, reduced glutaraldehyde method and then MBS.  
3.4.8. Na-periodate, Glutaraldehyde and MBS conjugating mechanism explained 
Several previous studies have reported Na-periodate conjugation to be more efficient 
than glutaraldehyde (Tijssen and Kurstak, 1984; Beyzavi et al., 1987). However, those reports 
used IgG molecules. To explain why glutaraldehyde conjugation was fivefold better, than Na-
periodate conjugation, the mechanisms of the methods were evaluated.  
Na-periodate oxidises the carbohydrate glycans on HRPC to form reactive aldehydes.  
Once this mixture is added to the anti-RSA-IgY, Schiff bases form with the amino groups 
present on the antibody.  A low concentration of Na-periodate results in poor conjugating 
efficiency of HRPC to IgY and too high concentration results in carboxyl groups forming rather 
than aldehyde groups (on IgY), which are less reactive in the covalent Schiff base formation. 
Further optimisation steps would need to be done to decide as to what led to the poor 
conjugating efficiency.  
Migneault et al., (2004) indicated that up to 13 different forms of glutaraldehyde and 
about 8 different reactions could take place during conjugation. Depending on pH, temperature 
and ionic strength. The conditions used in this study seemed to favour HRPC conjugating to 
IgY.  
The third conjugating reagent tested was MBS which is a bifunctional coupling reagent. 
MBS is popular in the conjugation of peptides to carrier proteins (Peeters et el., 1989) and is 
used for the conjugation of IgG to Urease. MBS coupling uses the benzoyl motif to benzoylate 
and the free amino acid groups on the antibody. N-hydroxysuccinimide ester acts as a linker 
between IgG and Urease. Urease sulfhydryl group undergoes thiolation with the malemide 
motif.  
HRPC does not have surface cysteines to provide sulfhydryl groups. Since IgY was 
reduced, only fractions that have the Fab and an available sulfhydryl group would react with 
the MBS. Therefore, the IgY molecules was reduced with DTT to expose cysteine residues.  
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The HRPC was incubated with MBS to benzoylate the free amino groups, thereafter 
the fragments of reduced IgY would couple to HRPC by malemide motif. The proposed 
mechanism and conjugate are shown in Figure 3.13.   
3.4.9. Glutaraldehyde redox coupled anti-RSA IgY 
Results in Figure 3.14 compared glutaraldehyde conjugated to anti-RSA-IgY reduced 
with DTT. The rationale to test if using 90 kDA (HC + LC) fragment of the IgY molecule it may 
be more sensitive in detecting RSA due to less steric hinderance. The LOD of the conjugated 
fragment detected 100 ng and not a more sensitive conjugate.  
This is likely due to a low concentration of  90 kDA (HC + LC) IgY coupled HRPC. 
Interestingly the coupling method was more efficient than MBS and less efficient compared to 
Na-periodate. 
3.4.10. Strategy to the improve sensitivity of ELISA’s 
All three methods anti-RSA-IgY-HRPC conjugates were separated from unbound 
HRPC by passing the mixture over an RSA Aminolink® resin. The short fall is unconjugated 
anti-RSA-IgY would elute with the conjugated IgY. The two could be separated by size 
exclusion chromatography using a S-200 resin. 
The HRPC used had 150 U/mg, many protocols suggest using the 1000 U/mg enzyme 
and above (Migneault et al., 2004). Since lower activity and quality HRPC was used, the 
sensitivity was expected to be lower. The 150 U/mg HRPC sample (Figure 3.15) was impure, 
therefore, the HRPC concentration should be measured using the extinction coefficient EmM = 
100 at 403 nm, as this measures the heme of HRPC. A disadvantage of HRPC conjugates are 
they are less stable compared to urease and AP conjugates and some samples may have 
intrinsic peroxidase like activity which will result in false detection. The advantageous of HRPC 
are wide range of sensitive colorimetric and luminescence substrates, whereas urease does 
not have luminescence substrates, its relatively low cost as compared to urease and AP and 
if storage conditions are ideal it the conjugate will retain high activity.  
3.4.11. Conclusion 
DSF analysis of the different antibodies tested showed that polyclonal IgY was the most 
stable of all the antibodies analysed based on thermodynamic parameters. It would be 
interesting to measure the half-life of IgY. A second antibody that would be interesting to look 
at is mammalian IgE to compare to the chicken IgY. These two structures have been reported 
to be closer related than IgY to IgG (Warr et al., 1995). Na-periodate, MBS and glutaraldehyde 
were all used to couple HRPC to polyclonal chicken anti-RSA-chicken IgY. The glutaraldehyde 
method detected the lowest concentration of RSA (20 ng) in an ELISA indicating 
glutaraldehyde crosslinking was most efficient.  
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The result can be used as preliminary data for introducing IgY-HRPC conjugates into 
immunoassays by using higher activity HRPC. However, care should be taken if amino acids 
like lysine are on the site of IgY that recognises an epitope. This will not be involved in epitope 
recognition and potentially offer an alternative.  
The study should also be broadened to compare the coupling procedure to IgG antibodies 
as well as testing the conjugation efficiency of different enzymes like AP or Urease. 
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4. CHAPTER 4: Detecting recombinant P. falciparum Histidine Rich 
Protein-2 a malaria diagnostic target with two copper-based 
assays 
4.1. Introduction 
CM has no diagnostic method 
The most lethal form of malaria, in humans is caused by a P. falciparum infection. The 
disease can be cured if it is detected and treated early, therefore early detection is important. 
Current rapid diagnostic tests have several problems for example its sensitivity and specificity 
(Landier et al., 2016). An uncomplicated malaria infection can progress to cerebral malaria 
(CM), which is the most lethal form of malaria. To date there is no rapid diagnostic test for CM, 
though several studies have suggested high concentrations of PfHRP-2 may play a role in an 
uncomplicated malaria infection progressing to a CM malaria infection. (Seyedel et al., 2012; 
Rubach et al., 2012; Park et al., 2017; Fox et al., 2013). Therefore, detecting high 
concentrations of PfHRP-2 may be a marker for diagnosing the potential for a P. falciparum 
malaria infection to progress to CM (Dvorin, 2017).  
PfHRP-2 binds metal ions 
Plasmodium falciparum histidine rich protein-2 (PfHRP-2) is a unique protein 
expressed and secreted by P. falciparum infections only. The PfHRP-2 amino acid sequence 
is primarily made up of His, Ala and Asp (87%) amino acid residues hence the name (Howard 
et al., 1986). PfHRP-2 has been shown to have a high affinity for metal cations (Bauer et al., 
2017). The metal cations bind to the imidazole motif of histidine residues via coordination 
bonds, where either the delta or epsilon nitrogen provides both electrons for the metal cation 
to bind (Park et al., 2014). The most stable conformation is a single metal cation binding 
between two imidazole residues. These residues are in abundance in PfHRP-2, as the protein 
has 51 His-His-Ala repeats (Ndonwi et al., 2011). The repeats have a high affinity for metal 
ions. Bauer et al., (2017)  showed that PfHRP-2 has the highest binding affinity for Cu ions 
compared to other metal ions.  
HRPC-Cu+ as a detection assay 
Xianyu et al., (2013)  developed an ultrasensitive colorimetric assay to measure the 
concentration of Cu2+ in water samples. This was achieved by adding Na-ascorbate and 
horseradish peroxidase (HRPC) to water samples. If  Cu2+ was present it would be reduced 
(by Na-ascorbate) to Cu+, which is a potent inhibitor of HRPC activity. Therefore, HRPC would 
be inhibited to catalyse the oxidation of tetramethyl benzidine (TMB).  
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Shi et al., (2016) used this relationship to develop a Cu+-HRPC system to detect 
alkaline phosphatase (ALP) and pyrophosphate based on the molecules binding affinity for Cu. 
Fenton chemistry 
Cu2+ and Fe3+ are two metal ions that have shown to possess peroxidase like activity 
via the Fenton chemistry mechanism (Xu et al., 2015; Wu et al., 2014). Shan et al., (2016) 
showed the peroxidase like activity of Cu2+ is significantly increased in the presence of chloride 
ions (Cl-). The mechanism was termed chloride accelerated Fenton chemistry. The sensitivity 
of these mechanisms has allowed Fe3+ and Cu2+ to be used in detection assays, such as 
detection of free cysteine residues with Fe3+ in urine (Wu et al., 2014).  
The Cu2+-TMB-H2O2 system has been used for the detection of: Cu2+ in water samples 
(Shan et al., 2016); Uric acid (Lu et al., 2017); dopamine (Wang et al., 2017) and the  specific 
detection of L-histidine in urine samples (Xu et al., 2015). For the detection of L-histidine, uric 
acid and dopamine TMB oxidation was suppressed indicating the molecules were present. The 
advantage of using peroxidase like activity of metal ions to detect molecules are the assays 
are sensitive, cost effective and relatively simple to perform.   
In this chapter, rPfHRP-2 was used in two competition assays for the binding of Cu 
ions. The first assay was based on the presence of rPfHRP-2 binding to Cu+ and preventing 
Cu+ inhibiting HRPC (Cu+-HRPC-TMB assay). The second assay relied on Fenton chemistry 
and the presence of rPfHRP-2 would bind Cu2+ and prevent oxidation of TMB.  
4.2. Materials and Methods: 
4.2.1. Materials and equipment 
All common reagents, buffers, salts, metal ion salts, TMB, HRPC (VI, 150 U/mg and 
1000 U/mg) were purchased from Sigma. H2O2 and Bovine serum albumin (BSA; fraction 4) 
was purchased from Roche (Mannheim, Germany). Maxi Sorp™ 96-well ELISA plates were 
from Nunc products (Roskilde, Denmark). Saliva used was that of the authors of this study.  
UV-1800 Shimadzu spectrophotometer from Shimadzu corporation (Kyoto, Japan); pH 
meter from HANNA instruments.  VersaMax™ ELISA plate reader was purchased from 
Molecular Devices Corporation (California, USA). 
4.2.2. Optimising HRPC concentration for the Cu+-HRPC-TMB assay 
HRPC stocks (150 U/mg and 1000 U/mg both at 3 mg/ml) were prepared in Tris-HCl-
MeOH buffer (Chapter 5; (50 mM Tris-HCl, pH 8.0; 20% MeOH; 50 mM CaCl2)) and stored at 
4°C in the dark. The HRPC stocks were diluted to different concentrations to determine the 
enzymes optimal concentration for the respective assays. 
 Stocks of TMB (7.1 mM) were prepared in DMSO and stored at -20°C. TMB stocks 
were thawed at RT and made up in 150 mM citrate-phosphate buffer with 1.96 mM H2O2. 
94 
  A final concentration of 284 µM TMB and 0.784 µM H2O2 was used in the assays. TMB 
was added for 15 min before it was measured at O.D 652 nm using UV/Vis spectroscopy.  
4.2.3. Testing Cu+ and different metal ions inhibitory effect on HRPC activity 
HRPC (150 U/mg; 1 ng), was incubated with 125 µM of both CuCl2•2H2O and Na-
ascorbate. The Cu+ was incubated with HRPC (30 min at RT). Thereafter TMB was added as 
described previously (Section 4.2.2). HRPC (1000 U/mg; 0.180 ng) was incubated with both 
12.5 µM CuCl2·2H2O and Na-ascorbate. Cu+ was incubated with HRPC (30 min at 37°C). 
Thereafter, TMB was added as described (Section 4.2.2). The inhibition of CoCl2·7H2O, 
NiCl2·6H2O, FeCl3·6H2O, CdCl2·2H2O, and ZnCl2·7H2O all at 12.5 µM were tested on HRPC in 
the same manner as Cu+.  
4.2.4. Enzyme assay to measure HRPC activity in the presence of Cu+  
HRPC 100 ng  (150 U/mg) was incubated with Cu+ (1 to 15 mM; 30 min at RT). TMB 
concentrations of 100, 500 and 1000  µM were added and the O.D652  was taken every 60 
seconds. Lineweaver-Burk plots were plotted as sugested by Keyhani et al., (2003., 2005). 
Extinction coefficient of ε652 nm 3.9 x 104 M-1. Cm-1 was used for TMB.  
4.2.5. HRPC competition assay with imidazole  
HRPC (concentrations described in section 4.2) was incubated with Cu+ (125 µM or 
12.5 µM) and imidazole concentrations ranging from 0 to 500 µM or 0 to 250 µM (30 min at 
37°C). TMB was added as described (Section 4.2.2.). 
4.2.6. Cu+-HRPC-TMB for the detection of rPfHRP-2 in aqueous solution 
rPfHRP-2 was dialysed extensively against HEPES buffer (20 mM pH 7.4; 2 x 2 h and 
16 h) in 100-fold volume of 20 mM HEPES buffer  (4°C). The dialysed rPfHRP-2 (17 to 170 
ng) was incubated with 12.5 µM Cu+ for 10 min. HRPC (1000 U/mg, 180 pg) was added. The 
solution was incubated  (30 min at 37°C) and TMB was added for detection as described 
(Section 4.2.2.). 
4.2.7. Cu+-HRPC-TMB assay for the detection of rPfHRP-2 in saliva samples 
A saliva sample from a healthy individual was taken and centrifuged  (12 500 x g;  2 
min). The clear supernatant was then removed and spiked with dialysed rPfHRP-2 (50% v/v). 
The samples were then tested for the presence of rPfHRP-2 as described (section 4.2.5). 
4.2.8. Cu+-HRPC-TMB assay  for the detection of rPfHRP-2 captured with anti-rPfHRP-
2 IgY 
Polyclonal chicken anti-rPfHRP-2 IgY antibodies (100 ng and 1 µg) were used to coat 
Nunc Maxi Sorp™ 96-well ELISA plates overnight at 4°C.  
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BSA (0.05%) solution was used to block the plate for an hour  (37°C). rPfHRP-2 was 
added at varying concentrations (4.2 ng to 4.2 µg). The rPfHRP-2 was allowed to bind to the 
antibodies on the plate (2 h; 37°C). After each step, plates were washed with PBS.  
Thereafter, a 12.5 µM Cu+ solution was added and incubated (30 min; 37°C), after 
which HRPC (180 pg) was added and incubated (30 min). Finally, TMB was added as 
described (Section 4.2.2). 
4.2.9. Cu+-HRPC-TMB assay with captured rPfHRP-2 
rPfHRP-2 (5 ng to 5 µg) was coated onto Nunc Maxi Sorp™ 96-well ELISA plates 
overnight (4°C). Wells were blocked with 0.05% (w/v) BSA (1 h; 37 °C). A 12.5 µM Cu+ solution 
was added and incubated (30 min; 37°C). HRPC (180 pg) was added to incubate with the 
solution for a further 30 minutes. Finally, TMB was added (4.2.2). The other proteins tested in 
the assay were rabbit serum albumin (RSA), bovine serum albumin (BSA) and polyclonal 
chicken anti-rPfHRP-2 IgY as described previously. 
4.2.10. The oxidation of TMB with RCl- generated from NaCl and H2O2 
Reactive chloride species (RCl-) were used to oxidise TMB via Fenton chemistry. RCl- 
were generated using NaCl (100 mM) and H2O2 (750 mM). The chromogen was TMB (0.5 
mM). The reaction was catalysed using various concentrations of Cu2+ and Fe3+ in MES buffer 
(2 mM). To determine the peroxidase-like activity of different transition metals, the method was 
performed in a similar manner as before where, Co2+, Ni2+ and Zn2+ (5 µM) were used instead 
of either Cu2+ or Fe3+. 
4.2.11. Inhibition of Cu2+ oxidation of TMB by chelation of Cu2+ with imidazole 
To test if imidazole inhibited the reaction, 1 µM Cu+ or 5 µM Fe3+ ions was incubated 
(10 min; RT) with increasing concentrations of imidazole. A range of 0 – 500 µM imidazole for 
Cu2+ and 0 - 50 µM for Fe3+ in MES buffer (2 mM) was used. After 10 min a solution of H2O2 
(750 mM) and NaCl (100 mM) was added, allowing for the creation of RCl-. Finally, TMB (0.5 
M; DMSO) was added and the absorbance was measured at 652 nm. 
4.2.12.   Detection of rPfHRP-2 using the Cu2+-RCl--TMB assay  
Polyclonal chicken anti-rPfHRP-2 IgY antibodies (100 ng and 1 µg) were used to coat 
Nunc Maxi Sorp™ 96-well ELISA plates overnight at 4°C. BSA (0.05% (w/v)) solution was used 
to block the plate for an hour  (37°C).  rPfHRP-2 was added at varying concentrations (4.2 ng 
to 4.2 µg). The rPfHRP-2 was allowed to bind to the antibodies on the plate (2 h; 37°C). A 
solution of 1 µM Cu2+ was incubated with the plate (30 min; 37°C). Afterwards a RCl--TMB 
solution (100 mM NaCl, 750 mM MES pH 6.0 buffer and TMB (0.5 M) in DMSO) was added 
and the oxidation of TMB was measured at 652 nm. 
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4.3. Results 
4.3.1. Optimising 150 U/mg HRPC concentrations 
In order to develop a basic assay for the detection of copper (Cu), optimal 
concentrations of HRPC, Cu and Na-ascorbate were established. The concentration of H2O2 
and TMB were kept constant. HRPC catalyses the oxidation of TMB in the presence of H2O2 
and the oxidised TMB (TMB-diamine) absorbance can be measured at 652 nm. The 
absorbance values will be referred to as HRPC activity. The optimal concentration of HRPC 
(150 U/mg) was determined (Figure 4.1). 
 
Figure 4.1: HRPC activity was measured at different concentrations. Concentrations of HRPC (0.5 
to 5 ng) was used to oxidize TMB in the presence of H2O2 over a 15-minute time period Error bars 
indicate S.D of triplicate results. 
Increasing concentrations of HRPC resulted in higher absorbance values due to the 
oxidation of TMB (Figure 4.1). Up to 2 ng of HRPC there was a two-fold increase in absorbance 
values with a two-fold increase in enzyme concentration. HRPC concentrations above 2 ng 
resulted in complete oxidation of TMB. 5 ng of HRPC oxidised TMB more rapidly, resulting in 
the TMB- diamine to precipitate, therefore the absorbance of the oxidised TMB with 5 ng HRPC 
was lower than 2ng of HRPC. HRPC at a concentration of 1 ng was the optimal concentration. 
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4.3.2. Inhibition of HRPC with Cu+ 
Cu2+ was reduced to Cu+ in the presence of Na-ascorbate and the Cu+ was used to inhibit 
HRPC activity. The HRPC activity was measured with the addition and oxidation of TMB 
(Figure 4.2). 
 
Figure 4.2: HRPC activity in the presence of increasing concentrations of Cu+. Varying (0-500 µM) 
concentrations of Cu2+ were reduced to Cu+ in the presence of (0-500 µM) sodium ascorbate in 1:1 ratio. 
The  Cu+ was incubated with HRPC at 37°C after which TMB was added and O.D652 was measured (15 
min). Error bars indicate S.D of triplicate results. 
HRPC activity was inhibited with Cu+ in a dose dependent manner (Figure 4.2). HRPC 
activity was almost completely inhibited with 500 µM Cu+. The optimal inhibitory concentration 
of Cu+ chosen was 125 µM because any additives changing the activation or inhibition could 
be evaluated by a change in absorbance.  
4.3.3. Evaluating incubation times and incubation temperatures for optimal HRPC 
activity 
The time period for which Cu+ was incubated with HRPC (Figure 4.2) was adapted from 
the study by Xianyu et al., (2013). Therefore, the optimal incubation time for Cu+ with HRPC 
for this study had to be optimised (Figure 4.3A) as well as the optimal incubation temperatures 
at which HRPC is most active at (Figure 4.3B).  
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(A)                                                                (B)  
  
Figure 4.3: HRPC activity at different times and temperatures in the presence and absence of 
Cu+. HRPC activity in the presence and absence of Cu+ measured every 15 min (A). The effect 4°C (•), 
RT (•) and 37°C (•) on HRPC activity (B). Error bars on both figures represent S.D of triplicate results of 
two experiments. 
Over the 75 min incubation period, HRPC activity decreased in both the absence and 
presence of Cu+ (Figure 4.3A). The optimal incubation time was 30 min as 23% HRPC activity 
was lost in the absence of Cu+, while 76% HRPC activity was lost when Cu+ was present. 
HRPC had similar activity at all three temperatures but was highest at 37°C therefore, 37°C 
was used (Figure 4.3B).  
4.3.4. Enzyme Kinetics  
 
Figure 4.4: Lineweaver-Burk plot of HRPC showing mixed inhibition in the presence of Cu+.  1 to 
15 mM Cu+ was used to inhibit HRPC activity in the presence of H2O2 and TMB. 
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The Lineweaver-Burk plot (Figure 4.4) illustrates a mixed inhibition when Cu+ binds to 
HRPC. Cu+ concentrations of 1 and 5 mM resulted in non-competitive inhibition, while 10 and 
15 mM Cu+ showed uncompetitive inhibition.  
The result suggests Cu+ ions bind to allosteric sites and not the active site. Therefore, 
the HRPC Cu+ interaction could be reversed. (The assay was done in triplicates with similar 
trend, only one set of data is shown). 
4.3.5. Optimising 1000 U/mg HRPC activity and inhibition of HRPC with Cu+ 
The assay was defined as the Cu+-HRPC-TMB assay. Thus far low activity HRPC (150 
U/mg) was used, to economically ensure Cu+ significantly inhibited HRPC. To have a good 
chance at detecting low concentrations of PfHRP-2, minimal Cu+ would need to be used. 
Therefore, the  Cu+-HRPC-TMB assay was optimised once again using a higher activity HRPC 
(1000 U/m; Figure 4.5) rather than the 150 U/mg HRPC used in Figures 4.1 – 4.4. 
 
Figure 4.5: HRPC activity was determined by measuring the oxidation of TMB. Amount of HRPC 
(1000 U/mg) (0.09 ng– 0.36 ng) was used to oxidize TMB in the presence of H2O2 for 15 min. Error bars 
indicate S.D of triplicate results of the experiment done 3 times. 
Increasing amounts of HRPC (0.09 ng to 0.36 ng; Figure 4.5) resulted in an increased 
rate of TMB oxidation. The concentration of HRPC chosen was 0.18 ng, which was fivefold 
less than the chosen concentration  HRPC (150 U/mg).  
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4.3.6. Inhibition of HRPC (1000 U/mg) using Cu+ 
The minimum concentration of Cu+ required to inhibit HRPC (1000 U/mg) was 
determined  (Figure 4A and 4B).  
(A)                                                                  (B)  
 
Figure 4.6: HRPC activity in the presence of increasing concentrations of Cu+ at RT and 37°C. 0-
25 µM Cu2+ was reduced to Cu+ in the presence of 0-25 µM sodium ascorbate in 1:1 ratio. Cu+ was 
incubated with HRPC at RT (A) and 37°C (B) and TMB was added. O.D readings was measured (15 
min) at 652 nm. Error bars indicate S.D of triplicate results of the two experiments.   
Increasing Cu+ concentrations (Figure 4.6) inhibited HRPC activity in a dose dependent 
manner. HRPC activity inhibited by Cu+ at RT (Figure 4.6A) had more variance compared to 
HRPC-Cu+ at 37°C (Figure 4.6B). A Cu+ concentration of 12.5 µM  at 37°C resulted in a 71% 
inhibition of HRPC activity and was therefore chosen as the inhibitory concentration to be used 
in the assay.  At RT 12.5 and 25 µM Cu2+ (Figure 4.6A) was a more potent inhibitor of HRPC 
compared to Cu+ at 12.5 and 25 µM. At 37°C 12.5 and 25 µM Na-ascorbate completely 
prevented TMB oxidation (Figure 4.6B). The conclusion for the different inhibitory effects at RT 
and 37°C is thought to be due to the different conformation changes HRPC undergoes at 
different temperatures (Azevedo et al., 2001). In Figure 4.6B, Na-ascorbate may have reduced 
the TMB- back to TMB at a faster rate than observed in Figure 4.6A.  
4.3.7. The effect of metal ions on HRPC activity 
Different transition metal ions have been reported to inhibit HRPC activity. These 
transition metal ions inhibitory effect on HRPC activity was tested to determine if Cu+ was the 
most potent inhibitor. The metal ions were incubated with HRPC and the enzymes activity was 
measured using TMB (Figure 4.7).  
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Figure 4.7: The effect of various metals on the activity of HRPC. The effect of copper (Cu+ and 
Cu2+), zinc (Zn2+), nickel (Ni2+) cobalt (Co2+), cadmium (Cd2+) and iron (Fe3+) on HRPC activity. All metal 
ions were used at 12.5 µM. TMB was added and O.D652 was measured (15 min). Error bars indicate S.D 
of triplicate results of three experiments. P<0.05.  
Both Cu2+ and Cu+ showed significant inhibition (47% and 64%), with Cu+ being the 
most potent metal ion inhibitor. All other metal ions tested, had a minimal influence on HRPC 
activity (0 and 3%) except for Fe3+ which inhibited enzyme activity by 8.93%. Co2+ marginally 
increased enzyme activity (1.7%).  
4.3.8. Effectiveness of imidazole binding Cu+ 
The aim of the Cu+-HRPC-TMB assay was to be used as a malaria biosensor based 
on the detection of rPfHRP-2. The imidazole motif on the histidine residue binds Cu+ and 
removes the Cu+ from solution allowing HRPC to maintain activity. A preliminary experiment 
was performed, using imidazole, to test if it would bind Cu+ and to test if imidazole interferes 
with HRPC activity (Figure 4.8A and 4.8B).  
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(A)                                                                    (B) 
 
Figure 4.8: The effect of imidazole and Cu+ on HRPC activity in the presence of imidazole. A range 
(0 µM – 250 µM imidazole was incubated with HRPC and 12.5 µM Cu+ (A). HRPC was incubated with 
imidazole (0 – 200 µM) in the absence of Cu+ (B). After incubation, TMB was added and O.D652 was 
measured (15 min). Error bars indicate S.D of triplicate results. 
Increasing concentration of imidazole bound and removed Cu+ from solution, allowing 
HRPC to retain activity (Figure 4.8A). The linear increase in absorbance at 652 nm showed 
HRPC retained more activity in the presence of higher concentrations of imidazole because 
more Cu+ was bound and removed. The result also indicates imidazole has a higher binding 
affinity for Cu+ compared to HRPC. The enzyme was incubated with imidazole in the absence 
of Cu+ (Figure 4.8B) and imidazole does not influence enzyme activity. The result (Figure 4.8A) 
was due to the removal of Cu+.  
4.3.9. Testing if the Cu+-HRPC-TMB biosensor assay could detect rPfHRP-2 in 
aqueous solution 
Imidazole was shown to prevent HRPC inhibition by Cu+ (Figure 4.8A). rPfHRP-2 
(recombinantly expressed and  purified in Chapter 2) was tested in the Cu+-HRPC-TMB assay 
(Figure 4.9). 
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(A)                                                                       (B) 
   
Figure 4.9: Detection of rPfHRP-2 in aqueous solution using the Cu+-HRPC-TMB assay. Varying 
amounts of rPfHRP-2 (34 – 170 ng) were added to bind the Cu+ (12.5 µM) (A). Thereafter, 180 pg of 
HRPC was added. TMB was added and O.D652 was measured (15 min). Linear range of rPfHRP-2 
detected from (B). Error bars indicate S.D of triplicate results.  
The samples containing rPfHRP-2 (dialysed in HEPES buffer) allowed for HRPC to 
have higher activity compared to the Cu+ inhibited HRPC (Figure 4.9A). An  increasing 
absorbance was found with increasing concentrations of rPfHRP-2. This indicated that high 
concentrations of rPfHRP-2 bound to and removed Cu+ ions. However, rPfHRP-2 
concentrations of 102 ng and above were significant. To determine which rPfHRP-2 amounts 
detected were significant, the absorbance of HRPC inhibited by Cu+ was compared to  the 
absorbance of the samples containing rPfHRP-2. The O.D of Cu+- HRPC activity in the 
presence of rPfHRP-2 was shown to have a linear relationship (Figure 4.9B). The linear result 
meant an unknown rPfHRP-2 concentration can be calculated. The absorbance in Figure 4.9B 
was measured at 370 nm, whic is a less commonly used wavelength at which oxidised TMB 
can be read spectrophotometrically. A wavelength of 370 nm was used since the absorbance 
readings at 370 nm are higher than absorbance readings at 652 nm.  
4.3.10. Detecting rPfHRP-2 in saliva 
rPfHRP-2 is found in several body fluids including saliva. This is an attractive material 
to base a diagnostic on, as it in non-invasive. The Cu+-HRPC-TMB assay was used to test for 
rPfHRP-2 in saliva samples spiked with the protein (Figure 4.10).  
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Figure 4.10: Using the Cu+-HRPC-TMB assay for the detection of rPfHRP-2 and BSA spiked into 
a saliva. Varying concentrations of rPfHRP-2 (34 to 68 ng) were spiked into uninfected saliva samples 
for detection. HRPC, HRPC-saliva, HRPC-Cu(i) and HRPC-BSA served as controls. TMB was added 
and O.D652 was measured (15 min). Error bars indicate S.D of triplicate results. 
HRPC-Saliva had a 10.9% higher activity than HRPC alone. HRPC-Cu(i) was the 
control (Figure 4.10). The BSA spiked saliva samples were included to show a change in 
absorbance was due to rPfHRP-2 and not a protein added to a saliva sample. The presence 
of saliva prevented the inhibition seen with Cu+. rPfHRP-2 activated HRPC in a dose 
dependent manner, resulting in higher concentrations of rPfHRP-2 having higher absorbance 
readings. The mechanism involved is not understood. With the several proteins already 
present in saliva it is likely the increased activity of TMB oxidation is related to rPfHRP-2.  
4.3.11. Detection of rPfHRP-2 in an ELISA based format 
Before a blood sample was tested for PfHRP-2, a general ELISA based format was 
developed (Figure 4.11). The assay entailed using anti-rPfHRP-2 IgY to capture rPfHRP-2 and 
the Cu+-HRPC-TMB assay could be used for detection of rPfHRP-2. 
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Figure 4.11: Using the Cu+-HRPC-TMB assay to detect rPfHRP-2 in an ELISA. Anti-rPfHRP-2 IgY 
(A) 1 µg/ml (B) 10 µg/ml was used to capture rPfHRP-2. The Cu+-HRPC-TMB assay was added for 
detection and TMB was added and O.D652 was measured (15 min). Error bars indicate S.D of triplicate 
results. 
When the Cu+-HRPC-TMB assay was applied to an ELISA based format, rPfHRP-2 
was not detected (Figure 4.11A and 4.11B). Cu+ inhibited HRPC, however,  when rPfHRP-2 
was present (4.2 µg to 0.042 µg) it did not remove the Cu+.  
4.3.12. Detection of rPfHRP-2 coated directly onto microplates 
After rPfHRP-2 was not detected in the antibody capture ELISA (Figure 4.11) . rPfHRP-
2, anti-rPfHRP-2 IgY, BSA and RSA were coated onto a microplate (Figure 4.12A - D). rPfHRP-
2 (5 µg) was able to reduce the inhibition of HRPC activity by Cu+ by 48% (Figure 4.12A). 
However, HRPC-Cu+ in the presence of rPfHRP-2 of 500 ng to 5 ng had the same activity  
(Figure 4.12A). It was suspected that BSA which was used as a block agent, may have 
interfered with the assay  (Figure 12A- 12D). Similarly, for RSA, BSA and anti-rPfHRP-2 IgY 
(Figure 12B, 12C and 12D) the Cu+ inhibition was reduced at all protein concentrations (5 µg 
to 5 ng) but none gave the same effect as 5 µg rPfHRP-2.  
It is uncertain why rPfHRP-2 was only detected in aqueous solution (Figure 4.9 and 
4.10) and not detected in a capture ELISA (Figure 4.11) or when coated directly onto a 
microplate (Figure 4.12).  
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Figure 4.12: Using the Cu+-HRPC-TMB assay for the detection of rPfHRP-2 coated directly onto 
ELISA plates. 5 µg to 5 ng of rPfHRP-2 (A); anti-rPfHRP-2 IgY (B); RSA (C) and BSA (D) were coated 
onto Nunc® 96 well plates and incubated overnight (4°C). The Cu+-HRPC-TMB assay was used for 
detection and TMB was added and O.D370 was measured (15 min). Error bars indicate S.D of triplicates 
results. 
4.3.13. Chemiluminescence  
A Chemiluminescent assay was evaluated to determine if it would be more sensitive 
than the colorimetric Cu+-HRPC-TMB assays described so far. However, when using the same 
concentration of HRPC for chemiluminescence that was used for the  Cu+-HRPC-TMB assays 
there was no signal. Therefore, no further testing was carried out.  
4.3.14. Fenton catalysed reactions (Fe3+) 
Since the Cu+-HRPC-TMB assay did not detect rPfHR-2 in an ELISA a second assay 
was optimised based on the peroxidase like activity of Fe3+ and Cu2+ ions. For the assay to be 
suitable as a biosensor for PfHRP-2, low concentrations of metal ions are required. Wu et al., 
(2014) reported the peroxidase like activity of Fe3+ ions, however, to enhance the oxidation of 
TMB, Fe3+ was a catalyst used to generate reactive chloride species (RCl-) from H2O2 and 
NaCl. 
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Figure 4.13: Colorimetric assay of Fe3+ based on Fe3+-Fenton chemistry used to catalyse TMB 
oxidation. Fe3+ was used in the form of FeCl3 at 5 µM and 0.5 µM respectively in the presence of H2O2 
alone (•) H2O2 with NaCl (•). TMB was added and O.D652 was measured (15 min). Error bars represent 
S.D of triplicate results. 
RCl- species (generated by Fe3+, H2O2 and NaCl) was a significantly more potent 
oxidant of TMB compared to reactive oxygen species (ROS; generated by Fe3+ and H2O2) at 
5 µM and 0.5 µM of Fe3+ (Figure 4.13).  
4.3.15.  Optimizing conditions for the generation of RCl- 
For the generation of RCl- species and to attempt to improve the sensitivity of Fe3+ 
catalysed oxidation of TMB, H2O2 and NaCl concentrations were optimised. Both were 
evaluated at concentrations from 0.1 M to 1 M while Fe3+ was used at a fixed concentration of 
5 µM (Figure 4.14).  
Increasing H2O2 concentrations lead to an increased rate of TMB oxidation (Figure 
4.14A), saturation was reached at 500 mM H2O2. However, 750 mM was selected as the 
optimal concentration, as it was present in the centre of the linear saturation curve and was 
suggested by Shan et al., (2016).  
In Figure 4.14B increasing concentrations of Cl- ions resulted in increased catalysed 
oxidation of TMB up to  500 mM NaCl after which the absorbance decreased. This was due to 
aggregation of TMB within the 15-minute incubation period. Shortly after the incubation, both 
250 mM and 500 mM samples also began aggregating, therefore, 100 mM NaCl was chosen. 
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(A)                                                                (B) 
 
Figure 4.14: TMB oxidation catalysed by Fe3+-Fenton chemical reactions by either H2O2 or NaCl 
to find their optimal concentrations. Varying concentrations of H2O2 (0.1 M to 1 M) were looked at in 
the absence of NaCl to catalyse the oxidation of TMB (A). Varying concentrations of NaCl (0.1 M to 1 
M) were looked at in the absence of H2O2 (B). TMB was added and O.D652 was measured (15 min) Error 
bars represent S.D of triplicate results. 
4.3.16. Assessing peroxidase like activity of different metal cations 
The peroxidase like activity of different metal ions on TMB (Figure 4.15).  
 
Figure 4.15: Peroxidase like activity of metal cations measured by the oxidation of TMB. No metal 
(control), 5 µM of Fe3+, Cu2+, Co2+, Ni2+ and Zn2+ were all incubated with H2O2 (0.75 M) and NaCl (0.1 
M). TMB was added and its oxidation was measured at 652 nm. Error bars indicate S.D of triplicate 
results. 
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It was important to show that the catalysis of TMB oxidation was not due to the 
presence of a transition metal and was rather due to Cu2+ and Fe3+ forming ROS and RCl-, that 
caused oxidation of TMB. Cu2+ was the most potent catalyst for the oxidation of TMB followed 
by Fe3+ (Figure 4.15). The Co2+, Ni2+ and Zn2+ had very little peroxidase like activity. To our 
knowledge none of the metal ions used above have been reported to have peroxidase like 
activity or known to catalyse Fenton reactions.  
4.3.17. Imidazole binding Fe3+  
Fe3+ oxidation of TMB was referred to as the Fe3+-RCl- -TMB assay. PfHRP-2 has been 
shown to play a role in heme detoxification (Choi  et al., 1999). His residues on PfHRP-2 bind 
to heme via its Fe3+ centre as well as pi-pi interactions. Imidazole was used to see if it would 
bind Fe3+, which may suppress Fe3+-RCl- formation and inhibit TMB oxidation (Figure 4.16).                                           
 
Figure 4.16: The Fe3+-RCl-- TMB assay in the presence of imidazole. Varying imidazole (15 to 50 
µM) concentrations were incubated with Fe3+ for 10 minutes before the addition of H2O2, NaCl, TMB 
was added and O.D652 was measured (15 min). Error bars indicate S.D of triplicate results. 
Increasing concentrations of imidazole bound and removed Fe3+ ions form solution 
(Figure 4.16). Therefore, less Fe3+ ions remained to catalyse the formation of RCl- and TMB 
oxidation was decreased.  
Cu2+ like Fe3+ is also involved in Fenton chemistry (Figure 4.15) and Cu2+ was shown 
to be the most potent catalyst of TMB oxidation. Similarly, Shan et al., (2016) had reported 
Cu2+ catalyses the generation of RCl- that oxidise TMB. For the detection of rPfHRP-2, Cu2+ 
concentrations had to be optimised (Figure 4.17). 
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4.3.18. Cu2+ catalysed oxidation of TMB 
 
Figure 4.17: O.D of TMB oxidation catalysed by different concentrations of Cu2+. Various Cu2+ (1 
to 10 µM) concentrations were used in the presence of 100 mM NaCl and 750 mM H2O2. TMB was 
added and O.D652 was measured (15 min). Error bars indicate S.D of triplicate results of three 
experiments. 
The absorbance at 652 nm increased with increasing concentrations of Cu2+ (Figure 
4.17). The concentration of Cu2+ chosen was 1 µM, which was  5-fold less than that of Fe3+ (5 
µM) suggesting that Cu2+ was a better catalyst is oxidising TMB. The Cu2+ oxidation of TMB 
was defined as Cu2+-RCl-- TMB assay. 
 
Figure 4.18: The Cu2+ -RCl--TMB assay in the presence of imidazole. Varying imidazole (0 to 500 
µM) concentrations were incubated with Cu2+ for 10 minutes before a reaction mixture containing H2O2, 
NaCl, TMB was added and O.D652 was measured (15 min) was added. An optimal decline was followed 
at 652 nm. Error bars indicate S.D of triplicate results. 
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A decrease in absorbance was observed as imidazole concentration increased (0 to 
500 µM) due to Cu2+ being bound by (Figure 4.18). The imidazole range detected was 10-fold 
greater than that for Fe3+ in the presence of imidazole (Figure 4.16). The result is an indication 
that Cu2+ more efficiently complexes with imidazole compared to Fe3+.  
(A)                                                                (B) 
 
Figure 4.19: Using the Cu2+-RCl--TMB assay for the detection of rPfHRP-2 in an ELISA based 
format. Specific chicken polyclonal anti-rPfHRP-2 IgY at 100 ng (A) and1 µg (B) was used to capture 
rPfHRP-2. Thereafter the Cu-RCl--TMB assay was added for detection. Error bars indicate S.D of 
triplicate results. 
The next step was to see if rPfHRP-2 could be detected using an ELISA based format. 
rPfHRP-2 was captured with anti-rPfHRP-2 IgY (Figure 4.19). With all the concentrations of 
rPfHRP-2 (4.2µg to 0.042 µg) none suppressed the oxidation of TMB. The results were similar 
to that of the Cu+-HRPC-TMB assay (Figure 4.11).  
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4.4. Discussion 
A graphical representation  of both Cu assays developed for the detection of rPfHRP-
2 is illustrated in Figure 2.20.  
 
Figure 4.20: A graphical representation of two copper assays for the detection of rPfHRP-2. The 
first assay illustrates the presence of PfHRP-2 in a sample allows for HRPC to oxidise TMB (A). The 
second assay illustrates the presence of PfHRP-2 in a sample allows RCl- to oxidise TMB (B).   
The first assay (Figure 2.20A) shows Na-ascorbate reduces Cu2+ to Cu+ which inhibits 
HRPC activity. The presence of PfHRP-2 binds and removes Cu+, therefore allowing HRPC to 
remain active and oxidise TMB. The second assay (Figure 2.20B) shows Cu2+ catalyses the 
formation of RCl- from H2O2 and NaCl, the presence of PfHRP-2 in a sample binds and 
removes Cu2+, therefore preventing the oxidation of TMB. The absorbance value is dependent 
on the concentration of PfHRP-2 present in the sample.  
4.4.1. Optimal HRPC concentration 
Two HRPC molecules with 150 U/mg and 1000 U/mg of enzyme activity were 
evaluated. Initially the 150 U/mg HRPC was used to save cost (Figure 4.1-4.4). The optimal 
pH for HRPC activity is at a pH of 6-6.5 (Critchlow and Dunford, 1972) but pH 7.0 was used to 
allow deprotonation of the imidazole motif on rPfHRP-2 which has a pka of 7 (Perrin et al., 
1981). A  HRPC concentration 180 pg (Figure 4.5) was in the range used in a Cu+-HRPC-TMB 
assay for the detection of ALP (500 pg HRPC used) and pyrophosphate (Shi et al., 2016).  
4.4.2. Optimising CuCl2 and sodium ascorbate concentration 
The 1000 U/mg HRPC required 10 times less Cu+ (12.5 µM; Figure 4.6) to inhibit 
enzyme activity compared the  150 U/mg HRPC (125 µM; Figure 4.2).  
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CuCl2 and Na-ascorbate were used in a 1:1 stoichiometric ratio. Excess Na-ascorbate 
would reduce the TMB-diamaine (blue) back to TMB (colourless) which will be perceived as 
false HRPC inhibition  (Arnao et al., 1996; Figure 4.6). If Cu2+ were in excess, it could  bind to 
amino acid residues that Cu+ would bind to, such as Phe, Try and Tyr (Xianyu et al., 2013; 
Burdett and Sevov, 1995). This is predicted to decrease the inhibition of HRPC activity. To 
prevent Cu+ been oxidised to Cu2+ by environmental O2, Na-Ascorbate was added immediately 
before the assay began.  
4.4.3. Incubation time and temperature effect of Cu+ binding to HRPC 
Temperatures 4°C, RT and 37° had little effect on HRPC activity (Figure 4.3A). HRPC 
losing activity over 15 minutes when incubated at 37°C (Figure 4.3B) is probably due to the 
enzyme unfolding, therefore having a reduced activity. The Tm of HRPC is 64.1°C and the 
unfolding ΔuG is 24.6 KJ.mol-1 (Wright et al., 2017). The ΔµG of HRPC suggest the enzyme 
unfolds rapidly.  
4.4.4. Mixed inhibition of HRPC by Cu+ on HRPC 
Xianyu et al., (2013) reported Cu+ binds to amino acids residues on HRPC and not the 
active site. This was supported in Figure 4.4 where Cu+ was shown to be a mixed inhibitor of 
HRPC. There are currently no studies stating the number of Cu+ ions that bind to HRPC. 
Keyhani et al., 2003 and 2005 reported Cd2+ and Ni2+ had similar inhibitory effects on HRPC 
activity. Cu+, Ni2+ and Cd2+ inhibit HRPC by causing a conformational change in the structure 
of the enzyme, therefore making the active site less accessible to substrates by blocking the 
hydrophobic access channel (Zaton and Ochoa De Aspuru, 1995; Veitch and Smith, 2000). 
4.4.5. Effect of transitions metal ions on HRPC activity 
Co2+ (Mahmoudi et al., 2003; Han et al., 2008), Ni2+ (Keyhani et al., 2005), Zn2+ (Moyo, 
2014), Cd2+ (Keyhani et al., 2003) Fe3+, Cu2+ and Cu+ (Mahmoudi et al., 2003; Xianyu et al., 
2013) have all been reported to inhibit HRPC activity, where Cu+ is the most potent inhibitor 
(Figure 4.7). Xianyu et al., (2013) showed this using UV-spectroscopy, Density functional 
theory (DFT) calculations and inductively coupled plasma optical emission spectrometry (ICP-
OES). 
4.4.6. Imidazole binds and removes Cu+ allowing HRPC to maintain activity 
Imidazole has been shown to bind Cu+ atoms by Rannulu and Rodgers, (2005). They 
suggested 4 possible ligands resulting  between 1 to 4 imidazole molecules binding to a single 
Cu+ atom. The Gibbs energy for each Cu(imidazole)x complex (where x is 1-4) was determined, 
0.0 KJ.mol-1, 18.6 KJ.mol-1 and 48.3 KJ.mol-1 respectively. The stable ligand formed is 
Cu+(imidazole)2 and is likely the ligand in highest concentration in Figure 4.8A.  
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When Cu+ is chelated by imidazole, a lower concentration is free to inhibit HRPC 
therefore, HRPC will be more active. Experiments found Cu+ needed 30 minutes to bind to 
imidazole (Figure 4.8).  
4.4.7. Fenton reactions, Cu2+ and Fe3+ oxidation of TMB  
RCl- species have been described to be more potent catalyst of TMB compared to ROS 
(Shan et al., 2016). Cu is a catalyst for ROS formation and works by breaking down H2O2 into 
OH• and O2- (ROS), however if Cl- ions are present they scavenge OH• and form RCl- species 
(Bokare and Choi, 2014). Results from Figure 4.13 show RCl- species are more potent oxidants 
than ROS.   
RCl- species oxidises TMB either directly or the RCl- species dissociate into Cl- anions 
which can bind to Cu2+ forming a reactive intermediate [CuCl-]+. The reactive intermediate is 
reduced by H2O2 (H2O2 -> -OOH + H+) into a more stable CuCl intermediate which is more 
stable and allows for the decomposition of H2O2 into OH• radicals that also oxidise TMB. The 
cycle continues, and the CuCl intermediate provides the ions for RCl- formation. (Shan et al., 
2016; De Laat and Le, 2006). The absorbance was proportional to the increase in Cu2+ 
concentration (Figure 4.17). Shan et al., (2016) observed that if TMB is oxidised by OH•, the 
rate of the of oxidation is consistent.   
The first reported assay using Fe3+ ions peroxidase like activity was in 2014, when Wu 
et al., showed that Fe3+ can be used for the detection of cysteine residues. Th mechanism of 
Fe3+ RCl- to oxidised TMB (Figure 4.13) is  Fe3+ complexes with Cl- to form a reactive 
intermediate [FeCl-]2+. The reactive intermediate would allow for the accelerated 
decomposition of H2O2 into OH• radicals. The OH• radicals then react with Cl- to from RCl-, 
which attacks and oxidises TMB more effectively than that OH• alone.  
4.4.8. Optimising H2O2 and NaCl concentrations for Fenton reactions  
Metal ions catalyse break down H2O2 is to produce ROS, which oxidise TMB. The 
optimal concentration of H2O2 chosen was 750 mM  (Figure 4.14A) which was used by Shan 
et al., (2016). TMB was oxidised in the absence of H2O2 (Figure 4.14B). This meant the Cl- ions 
formed a reactive complex with Fe3+ and it is hypothesized to be [FeCl-]2+. A concentration of 
500 mM NaCl allowed for the highest oxidation of TMB, however 100 mM was selected as 
concentrations above 100 mM caused TMB to precipitate. Shan et al., 2016 used 250 mM, but 
their assay was for Cu2+ limit of detection instead of detecting molecules. Aggregation was 
noticed for their assay at  concentrations of NaCl above 250 mM. 
4.4.9. Assessing the peroxidase like activity of different metal ions  
Cu2+ showed the highest oxidation of TMB followed by Fe3+. Zn2+, Co2+ and Ni2+ had 
little significant peroxidase like activity (Figure 4.15).  
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Other reported metal ions reported with peroxidase like activity are Cr3+, Au3+ and Ag+ 
(Shan et al., 2016), but those metal ions work with direct TMB oxidation where as Cu2+ and 
Fe3+allow for oxidation of TMB via Fenton chemistry. Cu2+ works best because Cu2+ can easily 
be reduced and has a relatively low electron potential (0.16V).  
4.4.10. Imidazole binding Fe3+ and Cu2+  
Imidazole was used for two reasons. Firstly, imidazole is the moiety on histidine 
residues that is most likely to bind to and remove Fe3+ and Cu2+ thus preventing the oxidation 
of TMB. Alternatively, the experiment was to test if Cu2+ and Fe3+ bind imidazole rings and act 
as  probes to increase the oxidation of substrates, as was observed when Cu2+ was combined 
with alizarin for the detection of BSA (Wu et al., 2014). The oxidation of TMB by both metal 
ions was inhibited by imidazole (Figure 4.16 and 4.18), indicating Cu2+ and Fe3+ were not able 
to catalyse H2O2 decomposition, hence the mechanism was inhibited. The interaction of 
transition metals with the imidazole ring is very well characterized and reviewed by Sundberg 
and Martin, (1974). The results from Figures 4.16 and 4.18 were consistent to studies that 
detected free Cys and His residues (Wu et al., 2014; Xu et al., 2015; Zhou et al., 2014).  
4.4.11. Detection of rPfHRP-2: using the Cu+-HRPC-TMB    
For rPfHRP-2 the limit of detection was 102 ng in aqueous solution (HEPES buffer; 
Figure 4.8; 4.20), Mash and Chin, (2003) reported that a non-sulfonated HEPES molecule in 
HEPES buffer bound Cu. Controls (Figure 4.9 and Figure 4.10) show the HEPES buffer did 
not interfere with the assay in this study.  
The stoichiometric ratio of the potential binding sites on rPfHRP-2 and Cu+ were 
calculated, using a Mw of 30 kDa for rPfHRP-2 and  27 binding sites, 51 His-His-Ala repeats 
and His6-tag and if 1 Cu+ binds 2 histidine’s. If a maximum of 27 Cu+ atoms bound per molecule 
of rPfHRP-2, 5.53 x 1013 Cu+ can bind. If Cu+ bound in the same binding sites as hemozoin 
binds there would only be 21 sites (18 of the protein + 3 from His6-tag), therefore 4.3 x 1013 
Cu+ could bind. The optimal Cu+ concentration has 1.51 x 1015 (12.5 µM) atoms of Cu+ (Figure 
4.6). Therefore, if the maximum amount of theoretical Cu+ is removed (by binding to rPfHRP-
2), HRPC would not reach full activity as there would still be Cu+ in excess (2.44 nM)  that 
remains to inhibit HRPC.  
Since PfHRP-2 is found in saliva (Nantavisa, 2014; Fung et al., 2012), rPfHRP-2 was 
added to saliva samples and detected using the Cu+-HRPC-TMB assay (Figure 4.10). Samples 
with HRPC in the presence of rPfHRP-2 had higher activity compared to samples with BSA. 
BSA was selected as a control because it has been shown to bind Cu at the Asp-Thr-His N-
terminus end (Orlovskaia and Belitser, 1964 and Peters and Blumenstock, 1967).  
The mechanism behind the increased HRPC activity in the presence of rPfHRP-2 in 
saliva is not understood.  
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A potential explanation could be that the saliva favoured Cu+ atoms binding to the 
epsilon nitrogen rather than the delta nitrogen of the imidazole ring, resulting in Cu+ facilitating 
the decomposition of H2O2 (substrate for HRPC) producing OH• radicals which can oxidise 
TMB directly. Therefore, both OH• and HRPC would catalyse the oxidation of TMB and may 
explain the increased absorbance as the concentration of rPfHRP-2 increases (Figure 4.10). 
The concentrations of rPfHRP-2 (4.2 µg to 420 ng) captured by the ELISA was not able 
to remove enough Cu+ to allow HRPC to regain activity (Figures 4.11). The result was 
unexpected based on the stoichiometry 4.215 x 1016 to 4215 x 1017 (420 ng to 4.2 µg) binding 
sites were available to bind 1.51 x 1015 Cu+ atoms. The Cu2+-RCl-- TMB assay, the Cu2+ 
concentration was 1 µM which means 1.204 x 1014 atoms were present (Figure 4.19).  
4.4.12. Potential reasons as to why both copper binding assays did not work 
Both the Cu+-HRPC-TMB and Cu2+-RCl- - TMB assay were not able to detect rPfHRP-
2 that was captured using anti-rPfHRP-2 IgY. The reason why rPfHRP-2 was not detected 
could not be explained in the study. A reason could be that the polyclonal anti-rPfHRP-2 IgY 
used could have prevented Cu atoms binding to the His residues on rPfHRP-2 by causing 
steric hinderance, therefore the Cu+ remained in solution and inhibited HRPC. Alternatively, 
the hydrophobic interactions on the microtiter plate may have interfered and prevented Cu 
atoms binding to rPfHRP-2, Figure 4.12 showed that when rPfHRP-2 was coated directly to 
the microtiter plate the Cu+-HRPC-TMB assay was less sensitive compared to when rPfHRP-
2 was in aqueous solution.   
4.4.13. Choice of buffers for both copper assays  
For the Cu+-HRPC-TMB assay PBS was used, since the buffer was used successfully 
by Xianyu et al., (2013) with no interferences. Buffers for the Cu2+-RCl--TMB assay were a 
more complicated as the pH must be acidic or additives like acetonitrile need to be 
supplemented (Xu et al., 2015).  Therefore, MES buffer was used as recommended by Shan 
et al., (2016). Na-acetate buffer is an alternative to consider, it was used to detect dopamine 
and uric acid (Wang et al., 2017 and Lu et al., 2017). 
4.4.14. Conclusion 
Two copper binding assays were developed for the detection of rPfHRP-2 namely the 
Cu+-HRPC-TMB assay and the Cu2+-RCl--TMB assay. The Cu+-HRPC-TMB assay was shown 
when Cu+ is present, HRPC is inhibited, but when a molecule is present that binds Cu+ the 
inhibition on HRPC is reduced. rPfHRP-2 was detected in aqueous solution and when coated 
directly onto a microplate. 
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  The Cu2+-RCl-TMB assay was shown when imidazole was present, which binds Cu2+ 
the oxidation of TMB is reduced signifying the detection of a copper binding molecule. Both 
assays were not sensitive enough for the detection of rPfHRP-2 when captured using specific 
polyclonal anti-rPfHRP-2 IgY antibodies, therefore both assays cannot be used as a malaria 
diagnostic. Currently from the data does not suggest an exact reason for rPfHRP-2 not been 
detected in the ELISA assay. 
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5. CHAPTER 5: An aqueous-organic buffer to increase storage 
stability of horseradish peroxidase  
5.1. Introduction  
Enzymes are used as biocatalysts in many industries, such as the chemical, 
pharmaceutical, wastewater, biomedical industries, and is becoming more popular. Enzymes 
offer high catalytic efficiency while being regarded as biofriendly. Therefore, enzymes are the 
“green” solution (Li et al., 2017, Xianyu et al., 2013). Industrial processes often result in heat 
being generated as a by-product, which creates an unfavourable microenvironment around the 
enzyme catalyst, resulting in enzymes being degraded. Poor storage conditions for enzymes 
also result in a loss of enzyme activity (Schmidt et al., 2002; Sato et al., 1995). Therefore, 
techniques to stabilise enzymes are vital for use in the field of biotechnology and industry 
(Schmidt et al., 2002).  
Enzymes can be stabilised for storage with organic solvents, which has become a 
popular stabilising component in some enzyme buffers. Unlike water in aqueous environments, 
organic solvents reduce the enzyme’s flexibility, preventing the unfolding of the tertiary 
structure. The result is the catalytic efficiency of enzymes are often lost, and concentrations of 
organic solvents of 60-70% completely inactive enzymes (Stepenkova et al., 2013). 
Various strategies have been used to preserve enzyme structure and activity such as 
adsorption to mesoporous particles, covalent binding, cross-linking, entrapment (by 
adsorption), reversed micelle, chemical modification, protein engineering, propanol rinsed 
preparation, ionic liquid coating and additives. Unfortunately, each technique has different 
levels of success, depending on variables such as the morphology of the enzyme, and the 
process for which an enzyme must be stabilised (Stepenkova et al., 2013).  
HRPC is commonly conjugated to secondary antibodies for use in molecular biology 
and biotechnology. The enzyme is small (44 kDa), has high catalytic oxidation of chromogenic 
substrates and is relatively stable in high concentrations. However, when the enzymes are 
used, they are diluted several folds. The  diluted enzyme solution has low storage stability 
(Mozhaez, 1993; Eremin et al., 2002). To combat loss of stability, new dilutions must be 
prepared frequently to ensure reproducible results. The loss of activity is believed to be 
primarily due to HRPC unfolding when stored in dilute solutions. 
Several different approaches have been made to stabilize HRPC and HRPC-
conjugated antibodies for extended periods of time in solution: 
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(i) Immobilization: Silica beads are used as a support structure to covalently bind to 
HRPC. The HRPC was used in an aqueous-organic solvent medium containing 20% 
DMSO, which increased stability by 300% (Azevedo et al., 2001).  
(ii) Eremin et al., (2002) compared an aqueous-organic solvent mixture and a protein-
based stability mixture. The result showed the organic solvent worked better.  
(iii) Schutz et al., (1997) explored using the substrates luminol and TMB to stabilise HRPC 
in a 50 mM PBS buffer was explored. 
(iv) Chemical additives are some of the simplest and most cost-effective reagents added 
to organic solvents to stabilise HRPC. Ca2+ improved HRPC stability (Haschke and 
Friedhoff, 1978). 
The numerous patented reagents sold to stabilise enzymes signifies the importance of 
preserving enzyme stability. A buffer cocktail that could preserve the storage stability of HRPC 
would be advantageous to biochemical reactions using HRPC. This study reports a chemical 
buffer containing Tris-HCl, methanol and Ca2+ improved the storage stability of HRPC.  
5.2. Materials and Methods: 
5.2.1. Materials and equipment  
All buffers and salts were purchased from Sigma and Merck with no further purification 
required. HRPC (type VI 150 U/mg and 1000 U/mg; Sigma). Maxi Sorp™ 96-well ELISA plates 
were from Nunc products (Roskilde, Denmark),  UV-1800 Shimadzu spectrophotometer from 
Shimadzu corporation (Kyoto, Japan); pH meter from HANNA instruments.  VersaMax™ 
ELISA plate reader was purchased from Molecular Devices Corporation (California, USA). 
5.2.2. Preparation of buffers 
HRPC activity was evaluated at different pH values. Citrate phosphate buffer (150 mM) 
was used for pH values 5.0 and pH 6.0. phosphate buffered saline (PBS; 137 mM NaCl; 3 mM 
KCl; 7 mM Na2HPO4; 1.5 mM KH2PO4) at pH 7.4, PBS  (50 mM; 150 mM NaCl) at  pH 7.6. 
Tris-HCl (50 mM) at pH 8.0, carbonate buffer (100 mM) at pH 9.0 and Glycine buffer-Na (100 
mM) at pH 10.4. HRPC (150 Units) lyophilized powder was resuspended in dH2O at a 
concentration of 3 mg/ml).  
5.2.3. Measuring HRPC enzyme activity  
The optimal pH of HRPC was determined by using 0.5 ng HRPC to oxidise the 
chromogenic substrate tetramethyl benzidine (TMB) in the presence of H2O2. The assay was 
carried out in a 96  well microplate format, at room temperature (22-24°C). HRPC activity was 
determined by the oxidation of TMB (284 µM) to the TMB-diamine in the presence of H2O2 
(1.92 mM) and the absorbance at 652 nm was measured after 15 minutes.  
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5.2.4. Preparation of different concentration Tris-HCl buffers and Tris-HCl- organic 
solvent buffers 
Tris-HCl at pH 8.0 was prepared at concentrations of 10 mM, 50 mM, and 100 mM. 50 
mM Tris-HCl buffer was prepared with methanol or ethanol (10, 20, 30 and 40% (v/v)).  
5.2.5. Optimising Ca2+ concentrations with Tris-HCl-MeOH buffer 
As described in Section 5.2.3, an aqueous-solvent buffer was prepared with 10 and 
20% (v/v) methanol. Each preparation/buffer was supplemented with CaCl2·2H2O at a final 
concentration of either 10, 20, 50, 100, or 200 mM.  
The stabilising effects of the buffer on HRPC were measured after 0, 3 and 7 days, 
using the TMB substrate (described in Section 5.2.2.). The optimised buffer conditions were 
then used to stabilise HRPC over a longer period, and this was assessed weekly. 
5.2.6. Comparing HRPC activity in Tris-HCl to HRPC in Tris-HCl-MeOH buffer 
HRPC (1000 U/mg) was diluted to a final concentration of 0.5 ng in Tris-HCl (50 mM; 
pH 8.0) or Tris-HCl-MeOH (50 mM; 20% MeOH(v/v) with 50 mM  Ca2+). HRPC was stored at 
37°C and the activity of the enzyme was measured (described in section 5.2.4) at 1, 3, 5 and 
20 hours. 
5.3. Results: 
5.3.1. Comparing the stability of low concentration HRPC stored for a week 
HRPC activity was tested by measuring the absorbance (O.D) at 652 nm of oxidised 
TMB (Figure 5.1).  
 
Figure 5.1: Comparison of HPRC activity in Tris-HCl after one week. HRPC in 50 mM Tris-HCl 
activity was measured (week 0), and after been stored for a week at 4°C . TMB was added and O.D652 
was measured (15 min). Error bars S.D of triplicate results of an experiment repeated 3 times.  
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Tris-HCl is a commonly used biological buffer (Mohan, 2003), however the buffer was 
unsuitable for storage of dilute concentrations of HRPC, as the enzyme lost 93% of its activity 
in a week (Figure 5.1). 
5.3.2. Comparing HRPC activity in different buffers 
HRPC was incubated in different buffers and the enzyme activity was measured at 
different times (Figure 5.2). All the buffers tested have either been used in other HRPC stability 
studies or are common buffers.  
 
Figure 5.2: HRPC activity in different biological buffers at different pH values. HRPC was prepared 
in 150 mM citrate-phosphate buffer pH 5.0 and 6.0, 7 mM PBS pH 7.4, 50 mM PBS  pH 7.6, 50 mM 
Tris-HCl pH 8.0, 100 mM carbonate buffer pH 9.0, and 100 mM Glycine-NaOH pH 10.4. The activity of 
HRPC was determined by oxidation of TMB as determined from the measurement of absorbance after 
15 min, at 652 nm. Error bars indicate S.D of triplicate results of the experiment done twice. 
Citrate-phosphate buffer (pH 5.0, pH 6.0) showed the activity of HRPC was similar to 
that of PBS (7 mM; pH 7.4) and Tris-HCl. The activity of HRPC in PBS (50 mM; pH 7.6) was 
33.5% lower than PBS (7 mM, pH 7.4). HRPC prepared in carbonate (pH 9.0) and Glycine-
NaOH buffers (pH 10.4), had the lowest activity.  
Downstream experiments showed that PBS and citrate-phosphate buffer were not 
compatible with Ca2+ because both phosphate and citrate chelated the Ca2+ leading to 
precipitation Tris-HCl was selected as the buffer for HRPC storage.  
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5.3.3. Analysis of different concentration Tris-HCl buffer on HRPC activity 
 
Figure 5.3: HRPC activity at different concentrations of Tris-HCl. HRPC at 0.5, 1 and 1.5 ng were 
diluted in 10 mM, 50 mM and 100 mM Tris-HCl. The activity of HRPC was determined by oxidation of 
TMB measured after 15 min at 652 nm. Error bars indicate S.D of triplicate results. 
HRPC in different concentrations of Tris-HCl buffers had comparable activity (Figure 
5.3). As the concentration of HRPC increased, so did the enzyme activity. At each 
concentration, HRPC had the least activity in 100 mM Tris-HCl. Tris-HCl at 50 mM was 
selected for further assays.  
The buffer selected in Figure 5.3 was the same Tris-HCl buffer in which HRPC was 
stored in and lost most activity after a week (Figure 5.1). However, to improve the storage 
stability of low concentration solutions of HRPC over longer periods of time, two aqueous-
organic solvents buffer systems were analysed. 
5.3.4. Effect of ethanol and methanol of HRPC activity  
Various solvents have been tested to stabilize HRPC, such as tetrahydrofuran, 
dimethylformamide, dimethyl sulfoxide, acetonitrile and ethanol (Azevedo et al., 2001; Eremin 
et al., 2002). All solvents had different influence on HRPC activity. Ethanol was shown to have 
promise to stabilise HRPC (Eremin et al., 2002). There has been no reported use of MeOH in 
long-term storage buffers for HRPC. Therefore, the two organic solvents ethanol and methanol 
at different concentrations were tested (Figure 5.4).   
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Figure 5.4: Effect of different concentrations of aqueous-organic solvent buffers on HRPC 
activity. HRPC was dissolved 10 to 40% (v/v) of either ethanol or methanol ranging from 10 to 40% in 
50 mM Tris-HCl pH 8.0. Oxidation of TMB was measured after 15 minutes at 652 nm. Error bars indicate 
S.D of triplicate results. 
HRPC in Tris-HCl alone had the highest activity (Figure 5.4) indicating both EtOH and 
MeOH inhibited HRPC activity. When HRPC was tested with Tris-HCl-EtOH buffer, HRPC 
activity decreased with increasing concentrations of EtOH.  
 EtOH at 10% (v/v) had the least inhibition (4%) and EtOH 40% (v/v) the highest 
inhibitory effect (41%). HRPC in Tris-HCl-MeOH buffer showed MeOH 10 – 40% (v/v) inhibited 
HRPC activity by 17 and 22% respectively. 
5.3.5. HRPC activity in Tris-HCl-EtOH and Tris-HCl-MeOH supplemented with Ca2+ 
To attempt to improve the stability of HRPC, Ca2+ was added to the buffer because 
Ca2+ ions are sometimes lost and are important to maintain the active site of HRPC (Gajhede 
et al., 1997). 
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Figure 5.5: The effect of Ca2+ in Tris-HCl and Tris-HCl-MeOH on the activity of HRPC. Ca2+ (0 – 
200 mM) was added to different buffers to test their stabilising effect on dilute HRPC and HRPC activity 
was measured by the oxidation of TMB measured after 15 min at 652 nm. Error bars indicate S.D of 
triplicate results. 
The addition of Ca2+ increased the activity of HRPC at concentrations from 10 mM to 
50 mM in both Tris-HCl and Tris-HCl-MeOH buffers (Figure 5.5). HRPC in Tris-HCl alone (with 
Ca2+) had the highest activity and had the highest activity in the presence of  50 and 100 mM 
Ca2+.  
5.3.6. Comparing HRPC activity Tris-HCl with 10 or 20% MeOH supplemented with 
Ca2+ over a week 
It was unclear which MeOH concentration was better for stabilising HRPC. Therefore, 
both buffers were tested over a week (Figure 5.6).  
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(A ) 10% Methanol                                                (B)   20% Methanol  
 
Figure 5.6: Stabilising effects of Tris-HCl-MeOH supplemented with Ca2+ on HRPC activity over 
a week. HRPC was diluted and stored in (Tris HCl-(10% (v/v)) MeOH (A) and 20% Tris HCl-(20% (v/v)) 
MeOH (B). Both storage buffers were supplemented with CaCl2 ranging from 0 – 200 mM and stored at 
4°C. Samples were evaluated for HRPC activity by the oxidation of TMB at 0, 4 and 7 days at 652 nm. 
Error bars indicate S.D of triplicate results.   
Day 0 (Figure 5.6A and 5.6B) represents the initial HRPC activity. HRPC had the 
highest activity in the presence of 50 mM Ca2+. HRPC in Tris-HCl (10% (v/v)) MeOH buffer 
(Figure 5.6A) and 200 mM Ca2+ lead to a decrease in HRPC activity (86%). Interestingly after 
4 days of storage HRPC activity was marginally higher with10 – 50 mM Ca2+ compared to no 
Ca2+. HRPC stored in Tris-HCl-(20% (v/v)) MeOH buffer (Figure 5.6B) lost no activity over the 
7-day storage period, except when 200 mM Ca2+ was added. Therefore, the buffer chosen was 
a 50 mM Tris-HCl buffer supplemented with 20% MeOH and 50 mM Ca2+ as the stability buffer. 
5.3.7. Long-term stability of a dilute concentration of HRPC under different conditions 
HRPC (10 ng/ml) solutions were prepared in the Tris-HCl-MeOH buffer (50 mM Tris-
HCl; 20% MeOH and 50 mM Ca2+) buffer and stored at 4°C, 4°C in the dark, RT (22°C- 25°C) 
and at 37°C and enzyme activity was measured weekly (Figure 5.7). 
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Figure 5.7: A 14-week study of HRPC activity under different storage conditions. HRPC was stored 
at 4°C (•), 4°C in the dark (•), RT (•) and 37°C (•). The % Activity was the activity of HRPC at each week 
compared to the initial activity.  
The storage temperature was an important for HRPC stability as HRPC only had 8% activity 
after one week when stored at 37°C and at RT 11% activity after 4 weeks. HRPC at 4°C had 
43% and 72% when stored in the dark activity after the 14-weeks (Figure 5.7). This is a 
significant improvement in HRPC activity.  
HRPC in Tris-HCl-MeOH buffer (50 mM Tris-HCl; 20% MeOH and 50 mM Ca2+) had 
retained 44% activity after 6 months (Figure 5.8B).  
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(A)                (B) 
   
Figure 5.8: Comparison of HRPC in stability buffer after 6 months. 0.5 ng HRPC in stability buffer 
after 6 months is compared to HRPC in Tris-HCl (A). 0.5 ng HRPC in stability buffer storage was 
compared at week 0 to 6 months (B). P<0.001.  
5.3.8. Thermal stability of HRPC 
In industrial applications, the thermal stability of enzymes is of great importance, since 
elevated temperatures result in denaturation of enzymes resulting in lower activities. The Tris-
HCl-MeOH stability buffer was compared to Tris-HCl (50 mM) to see if there was any thermal 
stability allowed for (Figure 5.9). 
  
Figure 5.9: Comparison of HRPC activity in Tris-HCl and Tris-HCl-MeOH at 37°C. HRPC (0.5 ng) 
was stored at 37°C and the activity was compared in each buffer at 0, 3, 5 and 20 hours. Error bars 
indicate S.D of triplicate results of the experiment done twice. 
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Initially, the activity of HRPC in Tris-HCl was marginally higher than HRPC in the Tris-
HCl (20% MeOH; 50 mM Ca2+) buffer. After 3 and 5 hours HRPC in the Tris-HCl-MeOH buffer 
retained 100 and 94% activity, while in Tris-HCl HRPC had  76 and 64% activity. At 20 hours 
enzyme activity was much lower in both buffers. 
5.4. Discussion 
5.4.1. Selecting a buffer for storage of HRPC  
Several studies have reported using buffers for optimal storage of HRPC and HRPC 
conjugates (Mogharrab et al., 2007; Farzamfar et al., 2010; Lopes et al., 2015; Azvedo et al., 
2001; Schuetz et al., 1997). Some of the buffers used in Figure 5.2 are based on previous 
studies.  
The citrate ions from citrate phosphate buffer improve the conformation and enhance 
molecular interactions of HRPC therefore stabilising the enzyme (Eremin et al., 2002). PBS is 
one of the most commonly used biological buffers (Mohan, 2003) therefore, PBS (7 mM; pH 
7.4) was tested, and 50 mM PBS was used as a buffer by Schuetz et al., (1997) to store HRPC 
conjugates. High concentrations of phosphate ions reduce HRPC stability, possibly explaining 
how HRPC in 50 mM PBS had 44% lower activity than in 7 mM PBS (Haifeng et al., 2008, 
Asad et al., 2011). Tris-HCl (50 mM) was tested because it was used in a stability study of 
HRPC conjugates by Eremin et al., (2002). HRPC had the lowest activity at pH 9 and 10.4, 
which is likely due to the alkalinity of the buffers causing the Ca2+ ions to leach (Stepenkova et 
al., 2013). 
 HRPC was most active in citrate phosphate buffer (pH 6.0), PBS (7 mM; pH 7.4) and 
Tris-HCl (50 mM; pH 8.0). Tris-HCl was chosen as to our knowledge, there are no reports of 
reduced HRPC stability or the chelation of Ca2+ ions when in Tris-HCl buffer, while the citrate 
in citrate phosphate buffer and phosphate in PBS bind Ca2+ which was used to supplement the 
buffer causing a precipitate to form.  
5.4.2. The effect of organic solvents on HRPC activity and stability 
Organic solvents have been used to stabilise HRPC-conjugates (Farzamfar et al., 
2010; Lee et al., 2006; Eremin et al., 2002) because organic solvents reduce the flexibility and 
mobility of an enzyme by replacing the aqueous medium around it. Therefore, slowing down 
the unfolding and denaturation of the enzyme. Organic solvents often cause a conformational 
change of an enzyme’s 3D structure, which possibly explains the reduced HRPC activity in 
Figure 5.4. Organic solvent concentrations of above 60% (v/v) can denature HRPC 
(Stepenkova et al., 2013). Therefore, 40% (v/v) MeOH was the maximum concentration used 
in this study.  
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Eremin  et al., (2002) compared a Tris-HCl-EtOH buffer to a Tris-HCl-BSA buffer to 
stabilise HRPC. And found the organic solvent buffer was superior for storing HRPC. In the 
current study, buffers with protein additives were not analysed.  
MeOH has not been used to improve the storage stability of HRPC but has been shown 
to reduce enzyme activity by 2.3% (Sato et al., 1995). Streefkerk and Van der Ploeg, (1974) 
showed that MeOH had no effect on HRPC activity, when the enzyme was on polyacrylamide 
films. Contrary to their finding HRPC had approximately 22% reduced activity at 40% (v/v) 
MeOH in this study (Figure 5.4). This could be due to MeOH altering the conformation of HRPC 
resulting in the active site becoming accessible to substrates, while HRPC attached to a  
polyacrylamide film may have prevented the conformation change of the enzyme.  
5.4.3. Supplementing the Tris-HCl-MeOH buffer with Ca2+ ions 
Ca2+ ions are important for the stability of  HRPC and if the Ca2+ ions are depleted both 
the specific enzyme activity and thermal stability of HRPC decrease (Haschke and Friedhoff, 
1978). Howes et al. (2001) showed that the proximal Ca2+ atom is vital to stabilising HRPC 
because of its role in maintaining the structure of the heme pocket but is often lost which results 
in HRPC binding of substrates becoming less efficient (Howes et al., 2001).  
The increased HRPC activity observed when Ca2+ was added in Figure 5.5 and 5.6 
could be due to the Ca2+ ions replacing the Ca2+ ions lost at the proximal region of HRPC, 
therefore, making the heme pocket more accessible to substrates like H2O2. H2O2 can enter 
and oxidise Fe3+ in the protoporphyrin heme to Fe4+=O, more efficiently since the active site is 
maintained in the correct conformation by the Ca2+ ion. Even in the presence of 20% methanol 
which reduced HRPC activity (Figure 5.5), 10 mM to 100 mM Ca2+ allowed HRPC to have 
higher activity than HRPC in Tris-HCl alone.  
5.4.4.  Long-term stability of HRPC 
HRPC had highest activity when stored in the Tris-HCl-MeOH buffer stored at 4°C in 
the dark (Figure 5.7). However, the HRPC activity progressively decreased each week. 
Haifeng et al., (2008) showed the unfolding of HRPC follows the first order Lumry-Eyering 
model, indicating the reversible unfolding steps are followed by irreversible denaturation. 
Suggesting, once HRPC is denatured its activity cannot be regained. 
5.4.5.  Conclusion 
The Tris-HCl (50 mM; 20% (v/v) MeOH; 50 mM Ca2+) buffer was shown to significantly 
increase the storage stability of dilute HRPC (Figure 5.7 and 5.8). The dilute solutions of HRPC 
should not be stored for longer than 3 months in the buffer, where HRPC retained 72% of its 
activity. The thermal stability of 1000 U/mg HRPC was improved at 37°C for 20 h (Figure 5.9). 
A weakness of the study was Ca2+ ions were not tested independent of MeOH, therefore, there 
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is a degree of uncertainty as to whether Ca2+ activated HRPC only or aided in the storage 
stability of the enzyme.  
The (1000 U/mg) HRPC used in Chapter 4, was prepared in the Tris-HCl-MeOH 
stability buffer and was used over the course of a year for the various experiments, with little 
deviation in HRPC enzyme activity. 
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6. CHAPTER 6: General discussion  
6.1. Brief review  
Around half the world’s population is at risk of contracting a malaria infection. At the 
beginning of the 21st century (the year 2000) malaria related deaths were estimated to be 
around  839 000. The number of deaths has since then dropped to 435 000 in 2017 (WHO, 
2018; fact sheet November), However, in 2017 there were 219 million reported malaria 
infections. P. falciparum malaria infections are the most common and account for 99.7% 
malaria cases in the WHO Africa region, 62.8% in South-East Asia, 69% in the Mediterranean 
and 71.9% in the Western Pacific. In South America, P. vivax is the most common malaria 
infection (WHO, malaria fact sheet November 19.2018). 
 Mortality due to a malaria infection has decreased by around 50% since the year 2000. 
This is largely due to the increased use of insecticide-treated bed nets and more frequent 
diagnosis of suspected malaria infected patients (Sepúlveda et al., 2017). Early diagnosis of a 
malaria infection allows a patient to receive appropriate treatment and could save lives 
(Sepúlveda et al., 2017). The increased use of malaria rapid diagnostic tests (RDT’s) is due to 
the  Test and Treat policy by the WHO and his has increased sales of RDT’s from under 
200 000 (2005) (WHO, http:// www. WHO.int/malaria/test_treat_track/en/index.html) to 270 
million in 2015. RDT’s have become household diagnostic reagents in malaria endemic 
regions, however, due to RDT’s weaknesses the WHO recommends using an RDT in 
conjunction with a second diagnostic method such as light microscopy.  
 Weakness of RDT’s are they detect parasitaemia of 100 -200 parasites per µl of blood 
which is at least 5 times less sensitive than light microscopy of a Giemsa stained thick blood 
film, therefore some infections can be missed (Murray et al., 2008). A second issue is the high 
temperatures in some malaria endemic areas and the lack of cold chain storage facilities 
resulting in RDT’s losing performance. Gillet et al., (2011) reported 80% of RDT’s they had 
tested can withstand a maximum temperature of 30°C, whereas temperatures in storage 
facilities for RDT’s may exceed 40°C. A third problem is most RDT’s detect the PfHRP-
2 protein (Cheng et al., 2014). PfHRP-2 gene deletions have been reported in 10 countries, 
mainly in South America but more recently in Africa (Sepúlveda et al., 2017).  
A meta-analysis study by Sepúlveda et al., (2017) estimated PfHRP-2 gene deletion to 
be ~17%, with most being in the Peruvian Amazon basin. An uncomplicated P. falciparum 
malaria infection can progress into a CM infection Pal et al., (2016 and 2017) showed via in 
vitro and mouse in vivo models PfHRP-2 may participate in the development of CM. Since 
HRP-2 is not found in P. berghi malaria, rPfHRP-2 was injected into mice for in vivo analysis.  
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Studies have also shown high concentrations of PfHRP-2 could be an indicator for the 
development of CM (Park et al., 2017; Fox et al., 2013; Rubach et al., 2012; Seydel et al., 
2012). Currently there is no diagnostic test for a CM infection (Seydel et al., 2012).  
Even though the PfHRP-2 gene is deleted in some P. falciparum isolates (Gamboa et 
al., 2010; Sepúlveda et al., 2017), a rapid quantification method for PfHRP-2 after a patient 
has been diagnosed with a P. falciparum infection may aid in determining if the patient’s illness 
would become CM. This will allow correct treatment to be administrated to the patients (Seydel 
et al., 2012; Dvorin, 2017; Sinha et al., 2015). 
 The administration of the correct anti-malaria treatment for infected patients will reduce 
the unnecessary use of drugs. This is important as it would reduce malaria  parasite drug 
resistance which is thought to be due to the misuse of the these anti-malarials.  
6.1.1. Determining the thermal stability of three malaria antigens, protein-protein 
interactions of antigens and antibodies; anti-malaria drugs interacting with 
rPfLDH and rPfGAPDH. (Chapter 2) 
Krause et al., (2017) showed that PfGAPDH has potential as a diagnostic marker for a P. 
falciparum malaria infection. A new P. falciparum malaria diagnostic marker is needed as the 
gene for PfHRP-2 is no longer present in some isolates. Therefore, the aim in Chapter 2 was 
to compare the thermal stability of rPfGAPDH, rPfLDH and rPfHRP-2. All three proteins were 
recombinantly expressed as His6-tag fusion proteins and purified using Ni2+-chelate affinity 
chromatography.  
The thermal stability of the three recombinant proteins were tested using DSF. 
rPfGAPDH was found to be more stable than rPfLDH. rPfHRP-2 Tm could not be evaluated as 
the denaturation profile of rPfHRP-2 did not produce a transition peak. The stability of 
rPfGAPDH was fortunate as stable antigens are better diagnostic targets and antigens should 
be heat stable for RDT quality controls (Lon et al., 2005).  
 Using DSF, rPfLDH and rPfHRP-2 interactions with their respective antibodies were 
analysed for two reasons: (i) Firstly to see if a protein-protein interaction can be followed using 
DSF (ii) and secondly to see if the antigen-antibody complex is more stable than either of the 
individual species. The largest Tm shifts were observed at pH 4 where both anti-rPfLDH IgY 
and rPfHRP-2 IgY were stabilised in the presence of the respective antigens and showed that 
DSF can be used to monitor protein-protein interactions.  
 Initially DSF was developed by Pantoliano et al., (2001) to screen small ligands for drug 
discovery. Therefore, using DSF different anti-malaria drugs were tested with rPfLDH and 
rPfGAPDH. Chloroquine and quinine did not interfere with fluorescence signal in the assay and 
resulted in a positive Tm shift for rPfLDH indicating it bound to and stabilised it, while rPfGAPDH 
had a negative shift in Tm indicating it was destabilised.  
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Following experimental work, molecular docking studies were carried out. The Schrodinger 
molecular docking suite (2018-2), showed both quinine and chloroquine bound to PfLDH and 
PfGAPDH in the co-factor binding sites. The in silico docking studies showed the bonds in the 
co-factor binding site bind to motifs on the drugs. This information may be useful for new drug 
development as it indicates which amino acids are involved in drug binding. Chloroquine and 
quinine are important to look for the design of new drugs (Wells et al., 2015).   
6.1.2. Comparing the thermal stability of polyclonal antibodies and the optimal 
conjugation method for chicken IgY (Chapter 3). 
Since most RDT’s are not stable above 30°C (Gillet et al., 2011), there is a need to find 
stable antibodies to use in malaria diagnostics tests. Thermodynamic (ΔµG, ΔµH, ΔµS) 
unfolding energy of Chicken IgY was analysed and compared to rabbit IgG, mouse IgG, 
crocodile IgY and IgM using DSF (Wright et al., 2017). Chicken IgY was found to be the most 
stable from the thermodynamic parameters. DSF analysis of a 28-year-old chicken IgY sample, 
showed that the sample had similar Tm to a sample of freshly isolated chicken IgY indicating 
chicken IgY can be stored for long periods of time with minimal degradation.  
The data supports the workshop held by the European centre for the validation of alternate 
method (ECVAM) which suggested testing if chicken IgY can be used to replace monoclonal 
antibodies  (Schade et al., 1996). Polyclonal antibodies offer higher sensitivity in detecting 
antigens compared to monoclonal antibodies but have lower specificity (Lipman et al., 2005). 
 Different conjugating methods were analysed for the coupling of chicken IgY to HRPC. 
Glutaraldehyde conjugation was shown to work best for chicken IgY. This was useful since it 
provides a method for effective coupling of HRPC to chicken IgY to be used as immunological 
reagents.   
6.1.3. Detection of PfHRP-2 using two copper-based assays 
Two assays were developed based on PfHRP-2  high binding to Cu ions to detect and 
quantify PfHRP-2. The first assay was based on reducing Cu2+ to Cu+. The Cu+ is a potent 
inhibitor of HRPC and PfHRP-2 present binds Cu+ allowing HRPC to remain active. The assay 
was termed the Cu+-HRPC-TMB assay. The assay detected rPfHRP-2 in an aqueous solution, 
in a saliva spoked sample (by a mechanism not understood) and rPfHRP-2 coated directly into 
the wells of a microtiter plate. The second assay was Cu2+ catalysing the oxidation of TMB by 
generating RCl-. The presence of PfHRP-2 binds and removes Cu2+, therefore preventing the 
oxidation of TMB. The assay was termed the Cu2+-RCl- -TMB assay. The Cu+-HRPC-TMB 
assay detected rPfHRP-2 in an aqueous solution, in a saliva spiked sample (by a mechanism 
not understood) and rPfHRP-2 coated directly into wells of a microtiter plate. Both assays did 
not work in an ELISA based format, for reasons we were not able to explain.  
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The theory was if PfHRP-2 could be quantified using either of the Cu based assays, it could 
be further developed into a field test for quantifying PfHRP-2 therefore, prevents detecting the 
potential for an uncomplicated malaria infection progressing to a CM infection. 
Since both Cu based assays did not work, chemiluminescence using HRPC was also 
tested, unfortunately the assay was less sensitive then the colorimetric assay. It should be 
noted that high concentrations of PfHRP-2 is not a definitive indication of a P. falciparum 
malaria infected patient’s conditioning worsening to CM but rather a precautionary marker 
(Seydel et al., 2012). 
6.1.4. A stability buffer for storing dilute solutions of HRPC    
During optimisation of the Cu+-HRPC-TMB assay, low concentrations of HRPC lost activity 
in short periods of time. Therefore, a stability buffer was developed which was a Tris-HCl buffer 
(50 mM; pH 8.0; 20% (v/v) MeOH; 50 mM Ca2+). The buffer allowed 0.5 ng HRPC to maintain 
70% activity over 3 months and even allowed HRPC to remain significantly more stable at 
37°C after 20 hours compared to HRPC in Tris-HCl (50 mM; pH 8). 
6.2.1. Further work for the DSF assay  
To determine the Tm of proteins that did not produce transitions in the DSF assay, 
alternative dyes can be considered such as CFC and BFC which are thiol probes. Protein 
stability should be obtained using DSC and this data can be compared to the current DSF data 
to measure the suitability of DSF.  
The DSF assay showed it could follow the interaction between two proteins. Protein-
protein interactions can be further investigated with other proteins and compared to more 
commonly used biophysical techniques such as surface plasma resonance, dynamic light 
scattering or isothermal titration calorimetry. This will confirm if DSF is accurate at determining 
protein-protein interactions and expand the DSF assay.  
6.2.2. Further work on thermodynamic data  
Chicken IgY and Rabbit IgG polyclonal antibodies could be raised against the same 
antigen. Thermodynamic parameters of both antibodies should be calculated following. Both 
antibodies can be stored at different temperatures (4°C, 25°C, 37°C and 50°C) and the stability 
of the antibodies should be compared. 
The thermodynamic stability of different species polyclonal antibodies can be 
calculated using DSF and compared to chicken IgY. Commonly used IgG molecules that could 
be tested are sheep IgG, horse IgG, bovine IgG and goat IgG. 
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6.2.3. Further work for the conjugation of chicken IgY to HRPC  
The glutaraldehyde method to conjugate chicken IgY to HRPC can be improved by 
separating non-coupled IgY from IgY-HRPC. This can be done using gel filtration 
chromatography. Higher activity HRPC can be  coupled to chicken IgY, to allow for the 
conjugate to have higher sensitivity.  
6.2.4. Further work for the HRPC-Cu+-TMB assay  
Na-ascorbate absorbs at 255 nm, when Na-ascorbate is oxidised by Cu2+ the 
absorbance at 255 nm decreases. If PfHRP-2 is present it could potentially bind Cu2+, 
therefore preventing Na-ascorbate oxidation. The decrease in absorbance at 255 nm 
indicates the presence of PfHRP-2.  
6.2.5. Further work for the HRPC stability buffer  
Different activity HRPC storage stability can be measured in the Tris-HCl buffer (50 
mM; pH 8.0; 20% (v/v) MeOH; 50 mM Ca2+), as well as testing the stability of a HRPC 
conjugate in the buffer.  
6.3. Conclusion  
This study initially aimed to develop a diagnostic test for PfHRP-2 based on its high 
affinity for Cu ions. Unfortunately, both developed assays were unable to detect rPfHRP-2 in 
the ELISA based format. However, the study identified rPfGAPDH as thermally more stable 
than rPfLDH and showed that DSF has more potential than just drug screening. Interestingly, 
chicken IgY is a very stable molecule and is best coupled with HRPC using glutaraldehyde. 
The study provided some data for diagnostic reagents for malaria RDT’s 
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8. APPENDIX A: INFORMATION ON APPENDICES 
The following Tables (Table 1-18) show the data and calculations used to obtain the ΔµG, used to make the equations in Table 3.4. The Tables 
represent all five antibodies tested. Equations for the data are present in the materials and methods at the beginning of Chapter 3 and has also 
been reported by Wright et al., (2017). 
Table A.1: Crocodile IgM data calculated from equations 1 – 5 (Chapter 3). First replicate.  
Fmin 
Crocodile 
IgM 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf Ku  T   
T in 
kelvin ΔµG 
38.82 38.831 0.011 2.98 0.004 0.996 0.004 0.996 0.0036 57.1 273 330.1 15456.01 
38.82 38.887 0.067 2.98 0.022 0.978 0.022 0.978 0.0229 57.4 273 330.4 10370.63 
38.82 38.941 0.121 2.98 0.041 0.959 0.041 0.959 0.0424 57.7 273 330.7 8693.39 
38.82 38.983 0.163 2.98 0.055 0.945 0.055 0.945 0.0579 58 273 331 7839.14 
38.82 39.040 0.220 2.98 0.074 0.926 0.074 0.926 0.0797 58.3 273 331.3 6967.17 
38.82 39.135 0.315 2.98 0.106 0.894 0.106 0.894 0.1184 58.6 273 331.6 5883.59 
38.82 39.262 0.442 2.98 0.148 0.852 0.148 0.852 0.1742 58.9 273 331.9 4822.05 
38.82 39.404 0.584 2.98 0.196 0.804 0.196 0.804 0.2435 59.2 273 332.2 3901.53 
38.82 39.511 0.691 2.98 0.232 0.768 0.232 0.768 0.3018 59.5 273 332.5 3311.80 
38.82 39.642 0.822 2.98 0.276 0.724 0.276 0.724 0.3807 59.8 273 332.8 2672.44 
38.82 39.784 0.964 2.98 0.323 0.677 0.323 0.677 0.4782 60.1 273 333.1 2043.54 
38.82 39.935 1.115 2.98 0.374 0.626 0.374 0.626 0.5981 60.4 273 333.4 1425.01 
38.82 40.071 1.251 2.98 0.420 0.580 0.420 0.580 0.7234 60.7 273 333.7 898.50 
38.82 40.196 1.376 2.98 0.462 0.538 0.462 0.538 0.8582 61 273 334 424.70 
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Table A.2: Crocodile IgM data calculated from equations 1 – 5 (Chapter 3). Second replicate.  
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf Ku                         T 273 
T in 
kelvin ΔµG 
37.42 37.473 0.053 3.6 0.0147 0.985 0.0147 0.985 0.0149 57.1 273 330.1 11543.46 
37.42 37.525 0.105 3.6 0.0292 0.971 0.0292 0.971 0.0301 57.4 273 330.4 9623.79 
37.42 37.597 0.177 3.6 0.0492 0.951 0.0492 0.951 0.0517 57.7 273 330.7 8144.40 
37.42 37.666 0.246 3.6 0.0683 0.932 0.0683 0.932 0.0733 58 273 331 7190.81 
37.42 37.766 0.346 3.6 0.0962 0.904 0.0962 0.904 0.1064 58.3 273 331.3 6171.21 
37.42 37.870 0.45 3.6 0.1250 0.875 0.1250 0.875 0.1429 58.6 273 331.6 5365.13 
37.42 37.987 0.567 3.6 0.1576 0.842 0.1576 0.842 0.1870 58.9 273 331.9 4626.57 
37.42 38.113 0.693 3.6 0.1925 0.808 0.1925 0.808 0.2384 59.2 273 332.2 3960.94 
37.42 38.254 0.834 3.6 0.2317 0.768 0.2317 0.768 0.3016 59.5 273 332.5 3314.35 
37.42 38.396 0.976 3.6 0.2710 0.729 0.2710 0.729 0.3717 59.8 273 332.8 2738.48 
37.42 38.555 1.135 3.6 0.3152 0.685 0.3152 0.685 0.4602 60.1 273 333.1 2149.41 
37.42 38.718 1.298 3.6 0.3606 0.639 0.3606 0.639 0.5641 60.4 273 333.4 1587.40 
37.42 38.892 1.472 3.6 0.4089 0.591 0.4089 0.591 0.6919 60.7 273 333.7 1022.12 
37.42 39.073 1.653 3.6 0.4591 0.541 0.4591 0.541 0.8486 61 273 334 455.78 
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Table A.3: Crocodile IgM data calculated from equations 1 – 5 (Chapter 3). Third replicate.  
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf Ku  T   
T in 
kelvin ΔµG 
38.09 38.135 0.045 3.58 0.0125 0.987 0.0125 0.987 0.0127 57.1 273 330.1 11985.93 
38.09 38.190 0.1 3.58 0.0280 0.972 0.0280 0.972 0.0288 57.4 273 330.4 9744.79 
38.09 38.245 0.155 3.58 0.0433 0.957 0.0433 0.957 0.0452 57.7 273 330.7 8512.23 
38.09 38.329 0.239 3.58 0.0667 0.933 0.0667 0.933 0.0714 58 273 331 7263.32 
38.09 38.421 0.331 3.58 0.0926 0.907 0.0926 0.907 0.1020 58.3 273 331.3 6287.48 
38.09 38.522 0.432 3.58 0.1208 0.879 0.1208 0.879 0.1374 58.6 273 331.6 5473.27 
38.09 38.645 0.555 3.58 0.1551 0.845 0.1551 0.845 0.1836 58.9 273 331.9 4677.96 
38.09 38.762 0.672 3.58 0.1877 0.812 0.1877 0.812 0.2311 59.2 273 332.2 4046.68 
38.09 38.901 0.811 3.58 0.2266 0.773 0.2266 0.773 0.2929 59.5 273 332.5 3394.56 
38.09 39.063 0.973 3.58 0.2719 0.728 0.2719 0.728 0.3735 59.8 273 332.8 2725.36 
38.09 39.209 1.119 3.58 0.3126 0.687 0.3126 0.687 0.4547 60.1 273 333.1 2182.92 
38.09 39.373 1.283 3.58 0.3583 0.642 0.3583 0.642 0.5584 60.4 273 333.4 1615.41 
38.09 39.530 1.44 3.58 0.4022 0.598 0.4022 0.598 0.6729 60.7 273 333.7 1099.42 
38.09 39.709 1.619 3.58 0.4523 0.548 0.4523 0.548 0.8260 61 273 334 531.01 
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Table A.4: Crocodile IgY (first transition peak) data calculated from equations 1 – 5 (Chapter 3). First replicate.  
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) T    
T in 
kelvin ΔµG 
6.77 6.786 0.016 3.09 0.005 0.995 0.005 0.995 0.005 59.8 273 332.8 14499.20 
6.77 6.802 0.032 3.09 0.010 0.990 0.010 0.990 0.010 60.1 273 333.1 12647.19 
6.77 6.832 0.062 3.09 0.020 0.980 0.020 0.980 0.020 60.4 273 333.4 10782.89 
6.77 6.866 0.096 3.09 0.031 0.969 0.031 0.969 0.032 60.7 273 333.7 9552.47 
6.77 6.904 0.134 3.09 0.043 0.957 0.043 0.957 0.045 61 273 334 8591.90 
6.77 6.940 0.170 3.09 0.055 0.945 0.055 0.945 0.058 61.3 273 334.3 7905.24 
6.77 6.989 0.219 3.09 0.071 0.929 0.071 0.929 0.076 61.6 273 334.6 7165.38 
6.77 7.043 0.273 3.09 0.088 0.912 0.088 0.912 0.097 61.9 273 334.9 6503.10 
6.77 7.112 0.342 3.09 0.111 0.889 0.111 0.889 0.125 62.2 273 335.2 5804.60 
6.77 7.181 0.411 3.09 0.133 0.867 0.133 0.867 0.153 62.5 273 335.5 5231.87 
6.77 7.268 0.498 3.09 0.161 0.839 0.161 0.839 0.192 62.8 273 335.8 4608.30 
6.77 7.367 0.597 3.09 0.193 0.807 0.193 0.807 0.239 63.1 273 336.1 3995.88 
6.77 7.477 0.707 3.09 0.229 0.771 0.229 0.771 0.297 63.4 273 336.4 3397.62 
6.77 7.593 0.823 3.09 0.266 0.734 0.266 0.734 0.363 63.7 273 336.7 2836.37 
6.77 7.727 0.957 3.09 0.310 0.690 0.310 0.690 0.449 64 273 337 2246.02 
6.77 7.876 1.106 3.09 0.358 0.642 0.358 0.642 0.558 64.3 273 337.3 1638.72 
6.77 8.031 1.261 3.09 0.408 0.592 0.408 0.592 0.690 64.6 273 337.6 1043.24 
6.77 8.184 1.414 3.09 0.458 0.542 0.458 0.542 0.843 64.9 273 337.9 478.58 
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Table A.5: Crocodile IgY (second transition peak) data calculated from equations 1 – 5 (Chapter 3). Second replicate.  
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) Tm    
T in 
kelvin ΔµG 
8.84 8.984 0.144 3.18 0.045 0.955 0.045 0.955 0.047 66.4 273 339.4 8609.66 
8.84 9.125 0.285 3.18 0.090 0.910 0.090 0.910 0.098 66.7 273 339.7 6552.13 
8.84 9.254 0.414 3.18 0.130 0.870 0.130 0.870 0.150 67 273 340 5370.94 
8.84 9.373 0.533 3.18 0.168 0.832 0.168 0.832 0.201 67.3 273 340.3 4534.43 
8.84 9.482 0.642 3.18 0.202 0.798 0.202 0.798 0.253 67.6 273 340.6 3892.48 
8.84 9.592 0.752 3.18 0.236 0.764 0.236 0.764 0.310 67.9 273 340.9 3322.74 
8.84 9.689 0.849 3.18 0.267 0.733 0.267 0.733 0.364 68.2 273 341.2 2864.08 
8.84 9.792 0.952 3.18 0.299 0.701 0.299 0.701 0.427 68.5 273 341.5 2415.77 
8.84 9.892 1.052 3.18 0.331 0.669 0.331 0.669 0.494 68.8 273 341.8 2001.96 
8.84 9.998 1.158 3.18 0.364 0.636 0.364 0.636 0.573 69.1 273 342.1 1583.73 
8.84 10.104 1.264 3.18 0.397 0.603 0.397 0.603 0.659 69.4 273 342.4 1186.06 
8.84 10.210 1.370 3.18 0.431 0.569 0.431 0.569 0.757 69.7 273 342.7 792.92 
8.84 10.323 1.483 3.18 0.466 0.534 0.466 0.534 0.873 70 273 343 386.02 
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Table A.6: Crocodile IgY (first transition peak) data calculated from equations 1 – 5 (Chapter 3). Third replicate. 
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) T  273 
T in 
kelvin ΔµG 
6.97 6.979 0.009 2.7 0.003 0.997 0.003 0.997 0.003 59.8 273 332.8 15872.83 
6.97 6.999 0.029 2.7 0.011 0.989 0.011 0.989 0.011 60.1 273 333.1 12500.96 
6.97 7.020 0.050 2.7 0.018 0.982 0.018 0.982 0.019 60.4 273 333.4 11023.30 
6.97 7.046 0.076 2.7 0.028 0.972 0.028 0.972 0.029 60.7 273 333.7 9813.92 
6.97 7.071 0.101 2.7 0.037 0.963 0.037 0.963 0.039 61 273 334 9021.89 
6.97 7.101 0.131 2.7 0.048 0.952 0.048 0.952 0.051 61.3 273 334.3 8280.24 
6.97 7.138 0.168 2.7 0.062 0.938 0.062 0.938 0.066 61.6 273 334.6 7543.36 
6.97 7.190 0.220 2.7 0.082 0.918 0.082 0.918 0.089 61.9 273 334.9 6743.38 
6.97 7.246 0.276 2.7 0.102 0.898 0.102 0.898 0.114 62.2 273 335.2 6059.29 
6.97 7.308 0.338 2.7 0.125 0.875 0.125 0.875 0.143 62.5 273 335.5 5423.99 
6.97 7.383 0.413 2.7 0.153 0.847 0.153 0.847 0.181 62.8 273 335.8 4776.65 
6.97 7.465 0.495 2.7 0.183 0.817 0.183 0.817 0.225 63.1 273 336.1 4173.08 
6.97 7.557 0.587 2.7 0.217 0.783 0.217 0.783 0.278 63.4 273 336.4 3583.65 
6.97 7.661 0.691 2.7 0.256 0.744 0.256 0.744 0.344 63.7 273 336.7 2986.85 
6.97 7.775 0.805 2.7 0.298 0.702 0.298 0.702 0.425 64 273 337 2398.68 
6.97 7.893 0.923 2.7 0.342 0.658 0.342 0.658 0.520 64.3 273 337.3 1836.64 
6.97 8.027 1.057 2.7 0.391 0.609 0.391 0.609 0.643 64.6 273 337.6 1239.05 
6.97 8.173 1.203 2.7 0.446 0.554 0.446 0.554 0.804 64.9 273 337.9 613.33 
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Table A.7: Crocodile IgY (second transition peak) data calculated from equations 1 – 5 (Chapter 3). First replicate. 
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) T    
T in 
kelvin ΔµG 
8.62 8.755 0.135 3.16 0.043 0.957 0.043 0.957 0.045 66.1 273 339.1 8767.52 
8.62 8.885 0.265 3.16 0.084 0.916 0.084 0.916 0.091 66.4 273 339.4 6751.80 
8.62 9.013 0.393 3.16 0.125 0.875 0.125 0.875 0.142 66.7 273 339.7 5508.83 
8.62 9.117 0.497 3.16 0.157 0.843 0.157 0.843 0.187 67 273 340 4742.44 
8.62 9.222 0.602 3.16 0.191 0.809 0.191 0.809 0.235 67.3 273 340.3 4092.91 
8.62 9.327 0.707 3.16 0.224 0.776 0.224 0.776 0.288 67.6 273 340.6 3523.10 
8.62 9.427 0.807 3.16 0.256 0.744 0.256 0.744 0.343 67.9 273 340.9 3031.09 
8.62 9.522 0.902 3.16 0.285 0.715 0.285 0.715 0.399 68.2 273 341.2 2605.43 
8.62 9.617 0.997 3.16 0.315 0.685 0.315 0.685 0.461 68.5 273 341.5 2199.99 
8.62 9.716 1.096 3.16 0.347 0.653 0.347 0.653 0.531 68.8 273 341.8 1797.03 
8.62 9.818 1.198 3.16 0.379 0.621 0.379 0.621 0.611 69.1 273 342.1 1402.74 
8.62 9.915 1.295 3.16 0.410 0.590 0.410 0.590 0.695 69.4 273 342.4 1037.10 
8.62 10.005 1.385 3.16 0.438 0.562 0.438 0.562 0.780 69.7 273 342.7 707.10 
8.62 10.098 1.478 3.16 0.468 0.532 0.468 0.532 0.879 70 273 343 368.23 
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Table A.8: Crocodile IgY (first transition peak) data calculated from equations 1 – 5 (Chapter 3). Second replicate. 
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) T  273 
T in 
kelvin ΔµG 
6.8 6.808 0.008 2.96 0.003 0.997 0.003 0.997 0.003 59.8 273 332.8 16526.80 
6.8 6.830 0.030 2.96 0.010 0.990 0.010 0.990 0.010 60.1 273 333.1 12676.65 
6.8 6.847 0.047 2.96 0.016 0.984 0.016 0.984 0.016 60.4 273 333.4 11465.02 
6.8 6.875 0.075 2.96 0.025 0.975 0.025 0.975 0.026 60.7 273 333.7 10133.39 
6.8 6.909 0.109 2.96 0.037 0.963 0.037 0.963 0.038 61 273 334 9063.88 
6.8 6.947 0.147 2.96 0.050 0.950 0.050 0.950 0.052 61.3 273 334.3 8200.34 
6.8 6.992 0.192 2.96 0.065 0.935 0.065 0.935 0.069 61.6 273 334.6 7419.59 
6.8 7.048 0.248 2.96 0.084 0.916 0.084 0.916 0.091 61.9 273 334.9 6666.97 
6.8 7.111 0.311 2.96 0.105 0.895 0.105 0.895 0.117 62.2 273 335.2 5974.05 
6.8 7.184 0.384 2.96 0.130 0.870 0.130 0.870 0.149 62.5 273 335.5 5309.29 
6.8 7.264 0.464 2.96 0.157 0.843 0.157 0.843 0.186 62.8 273 335.8 4696.00 
6.8 7.354 0.554 2.96 0.187 0.813 0.187 0.813 0.230 63.1 273 336.1 4101.44 
6.8 7.456 0.656 2.96 0.222 0.778 0.222 0.778 0.285 63.4 273 336.4 3512.30 
6.8 7.568 0.768 2.96 0.259 0.741 0.259 0.741 0.350 63.7 273 336.7 2936.30 
6.8 7.694 0.894 2.96 0.302 0.698 0.302 0.698 0.432 64 273 337 2349.04 
6.8 7.831 1.031 2.96 0.348 0.652 0.348 0.652 0.535 64.3 273 337.3 1756.67 
6.8 7.975 1.175 2.96 0.397 0.603 0.397 0.603 0.658 64.6 273 337.6 1173.31 
6.8 8.127 1.327 2.96 0.448 0.552 0.448 0.552 0.813 64.9 273 337.9 581.93 
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Table A.9: Crocodile IgY (second transition peak) data calculated from equations 1 – 5 (Chapter 3). Third replicate. 
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) T    
T in 
kelvin ΔµG 
8.73 8.873 0.143 3.14 0.045 0.955 0.045 0.955 0.048 66.4 273 339.4 8589.90 
8.73 9.010 0.280 3.14 0.089 0.911 0.089 0.911 0.098 66.7 273 339.7 6561.78 
8.73 9.128 0.398 3.14 0.127 0.873 0.127 0.873 0.145 67 273 340 5454.75 
8.73 9.244 0.514 3.14 0.164 0.836 0.164 0.836 0.196 67.3 273 340.3 4617.01 
8.73 9.355 0.625 3.14 0.199 0.801 0.199 0.801 0.249 67.6 273 340.6 3942.52 
8.73 9.466 0.736 3.14 0.235 0.765 0.235 0.765 0.306 67.9 273 340.9 3353.28 
8.73 9.573 0.843 3.14 0.268 0.732 0.268 0.732 0.367 68.2 273 341.2 2844.63 
8.73 9.671 0.941 3.14 0.300 0.700 0.300 0.700 0.428 68.5 273 341.5 2408.18 
8.73 9.775 1.045 3.14 0.333 0.667 0.333 0.667 0.499 68.8 273 341.8 1976.05 
8.73 9.882 1.152 3.14 0.367 0.633 0.367 0.633 0.580 69.1 273 342.1 1551.17 
8.73 9.988 1.258 3.14 0.401 0.599 0.401 0.599 0.668 69.4 273 342.4 1148.40 
8.73 10.098 1.368 3.14 0.436 0.564 0.436 0.564 0.772 69.7 273 342.7 736.46 
8.73 10.201 1.471 3.14 0.468 0.532 0.468 0.532 0.881 70 273 343 360.52 
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Table A.10: Mouse IgG data calculated from equations 1 – 5 (Chapter 3). First replicate. 
 Fm 
PfLDH 
IgY 
Fluoro 
data F- F min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf)   T  
T in 
kelvin ΔGµ 
5.101 5.103 0.002 2.986 0.001 0.999 0.001 0.999 0.001 273 57.4 330.4 20638.11 
5.101 5.103 0.002 2.986 0.001 0.999 0.001 0.999 0.001 273 57.7 330.7 19508.61 
5.101 5.103 0.002 2.986 0.001 0.999 0.001 0.999 0.001 273 58 331 19583.5 
5.101 5.103 0.002 2.986 0.001 0.999 0.001 0.999 0.001 273 58.3 331.3 19706.54 
5.101 5.108 0.007 2.986 0.002 0.998 0.002 0.998 0.002 273 58.6 331.6 16819.41 
5.101 5.110 0.009 2.986 0.003 0.997 0.003 0.997 0.003 273 58.9 331.9 16140.01 
5.101 5.108 0.007 2.986 0.002 0.998 0.002 0.998 0.002 273 59.2 332.2 16758.53 
5.101 5.109 0.008 2.986 0.003 0.997 0.003 0.997 0.003 273 59.5 332.5 16253.62 
5.101 5.101 0.000 2.986 0.000 1.000 0.000 1.000 0.000 273 59.8 332.8 24152.5 
5.101 5.106 0.005 2.986 0.002 0.998 0.002 0.998 0.002 273 60.1 333.1 17761.85 
5.101 5.109 0.008 2.986 0.003 0.997 0.003 0.997 0.003 273 60.4 333.4 16356.6 
5.101 5.116 0.015 2.986 0.005 0.995 0.005 0.995 0.005 273 60.7 333.7 14757.08 
5.101 5.121 0.020 2.986 0.007 0.993 0.007 0.993 0.007 273 61 334 13899.81 
5.101 5.124 0.023 2.986 0.008 0.992 0.008 0.992 0.008 273 61.3 334.3 13495.53 
5.101 5.125 0.024 2.986 0.008 0.992 0.008 0.992 0.008 273 61.6 334.6 13349.32 
5.101 5.134 0.033 2.986 0.011 0.989 0.011 0.989 0.011 273 61.9 334.9 12551.5 
5.101 5.139 0.038 2.986 0.013 0.987 0.013 0.987 0.013 273 62.2 335.2 12133.92 
5.101 5.146 0.045 2.986 0.015 0.985 0.015 0.985 0.015 273 62.5 335.5 11688.54 
5.101 5.146 0.045 2.986 0.015 0.985 0.015 0.985 0.015 273 62.8 335.8 11679.64 
5.101 5.150 0.049 2.986 0.016 0.984 0.016 0.984 0.017 273 63.1 336.1 11456.79 
5.101 5.159 0.058 2.986 0.020 0.980 0.020 0.980 0.020 273 63.4 336.4 10955.03 
161 
5.101 5.173 0.072 2.986 0.024 0.976 0.024 0.976 0.025 273 63.7 336.7 10359.52 
5.101 5.186 0.085 2.986 0.029 0.971 0.029 0.971 0.029 273 64 337 9885.79 
5.101 5.194 0.093 2.986 0.031 0.969 0.031 0.969 0.032 273 64.3 337.3 9638.15 
5.101 5.205 0.104 2.986 0.035 0.965 0.035 0.965 0.036 273 64.6 337.6 9338.21 
5.101 5.221 0.120 2.986 0.040 0.960 0.040 0.960 0.042 273 64.9 337.9 8927.16 
5.101 5.239 0.138 2.986 0.046 0.954 0.046 0.954 0.048 273 65.2 338.2 8519.11 
5.101 5.253 0.152 2.986 0.051 0.949 0.051 0.949 0.054 273 65.5 338.5 8232.71 
5.101 5.269 0.168 2.986 0.056 0.944 0.056 0.944 0.060 273 65.8 338.8 7943.55 
5.101 5.287 0.186 2.986 0.062 0.938 0.062 0.938 0.066 273 66.1 339.1 7644.59 
5.101 5.306 0.205 2.986 0.069 0.931 0.069 0.931 0.074 273 66.4 339.4 7363.85 
5.101 5.327 0.226 2.986 0.076 0.924 0.076 0.924 0.082 273 66.7 339.7 7072.66 
5.101 5.348 0.247 2.986 0.083 0.917 0.083 0.917 0.090 273 67 340 6797.59 
5.101 5.369 0.268 2.986 0.090 0.910 0.090 0.910 0.098 273 67.3 340.3 6559.88 
5.101 5.402 0.301 2.986 0.101 0.899 0.101 0.899 0.112 273 67.6 340.6 6192.73 
5.101 5.439 0.338 2.986 0.113 0.887 0.113 0.887 0.128 273 67.9 340.9 5830.93 
5.101 5.475 0.374 2.986 0.125 0.875 0.125 0.875 0.143 273 68.2 341.2 5517.11 
5.101 5.516 0.415 2.986 0.139 0.861 0.139 0.861 0.161 273 68.5 341.5 5179.17 
5.101 5.563 0.462 2.986 0.155 0.845 0.155 0.845 0.183 273 68.8 341.8 4829.21 
5.101 5.614 0.513 2.986 0.172 0.828 0.172 0.828 0.208 273 69.1 342.1 4471.87 
5.101 5.671 0.570 2.986 0.191 0.809 0.191 0.809 0.236 273 69.4 342.4 4109.01 
5.101 5.723 0.622 2.986 0.208 0.792 0.208 0.792 0.263 273 69.7 342.7 3802.04 
5.101 5.775 0.674 2.986 0.226 0.774 0.226 0.774 0.291 273 70 343 3518.08 
5.101 5.833 0.732 2.986 0.245 0.755 0.245 0.755 0.325 273 70.3 343.3 3209.13 
5.101 5.898 0.797 2.986 0.267 0.733 0.267 0.733 0.364 273 70.6 343.6 2886.60 
5.101 5.965 0.864 2.986 0.289 0.711 0.289 0.711 0.407 273 70.9 343.9 2570.57 
5.101 6.029 0.928 2.986 0.311 0.689 0.311 0.689 0.451 273 71.2 344.2 2277.53 
5.101 6.099 0.998 2.986 0.334 0.666 0.334 0.666 0.502 273 71.5 344.5 1974.48 
5.101 6.173 1.072 2.986 0.359 0.641 0.359 0.641 0.560 273 71.8 344.8 1663.81 
5.101 6.256 1.155 2.986 0.387 0.613 0.387 0.613 0.631 273 72.1 345.1 1323.34 
162 
5.101 6.338 1.237 2.986 0.414 0.586 0.414 0.586 0.708 273 72.4 345.4 993.05 
5.101 6.419 1.318 2.986 0.441 0.559 0.441 0.559 0.790 273 72.7 345.7 676.85 
5.101 6.506 1.405 2.986 0.471 0.529 0.471 0.529 0.889 273 73 346 338.95 
 
Table A.11: Mouse IgG data calculated from equations 1 – 5 (Chapter 3). Second replicate. 
 Fm 
PfLDH 
IgY 
Fluoro 
data F- F min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf)   T  
T in 
kelvin ΔGµ 
5.431 5.433 0.002 2.716 0.001 0.999 0.001 0.999 0.001 273 61.3 334.3 20225.53 
5.431 5.434 0.003 2.716 0.001 0.999 0.001 0.999 0.001 273 61.6 334.6 18974.62 
5.431 5.443 0.012 2.716 0.005 0.995 0.005 0.995 0.005 273 61.9 334.9 15024.75 
5.431 5.450 0.019 2.716 0.007 0.993 0.007 0.993 0.007 273 62.2 335.2 13813.81 
5.431 5.451 0.020 2.716 0.007 0.993 0.007 0.993 0.007 273 62.5 335.5 13679.52 
5.431 5.458 0.027 2.716 0.010 0.990 0.010 0.990 0.010 273 62.8 335.8 12820.89 
5.431 5.473 0.042 2.716 0.015 0.985 0.015 0.985 0.016 273 63.1 336.1 11603.08 
5.431 5.483 0.052 2.716 0.019 0.981 0.019 0.981 0.020 273 63.4 336.4 10988.63 
5.431 5.490 0.059 2.716 0.022 0.978 0.022 0.978 0.022 273 63.7 336.7 10644.62 
5.431 5.496 0.065 2.716 0.024 0.976 0.024 0.976 0.025 273 64 337 10370.96 
5.431 5.509 0.078 2.716 0.029 0.971 0.029 0.971 0.029 273 64.3 337.3 9883.54 
5.431 5.526 0.095 2.716 0.035 0.965 0.035 0.965 0.036 273 64.6 337.6 9311.31 
5.431 5.535 0.104 2.716 0.038 0.962 0.038 0.962 0.040 273 64.9 337.9 9061.43 
5.431 5.548 0.117 2.716 0.043 0.957 0.043 0.957 0.045 273 65.2 338.2 8729.47 
5.431 5.568 0.137 2.716 0.050 0.950 0.050 0.950 0.053 273 65.5 338.5 8265.57 
5.431 5.584 0.153 2.716 0.056 0.944 0.056 0.944 0.060 273 65.8 338.8 7940.90 
5.431 5.609 0.178 2.716 0.066 0.934 0.066 0.934 0.070 273 66.1 339.1 7484.58 
163 
5.431 5.628 0.197 2.716 0.072 0.928 0.072 0.928 0.078 273 66.4 339.4 7195.66 
5.431 5.652 0.221 2.716 0.081 0.919 0.081 0.919 0.089 273 66.7 339.7 6841.96 
5.431 5.680 0.249 2.716 0.091 0.909 0.091 0.909 0.101 273 67 340 6489.65 
5.431 5.711 0.280 2.716 0.103 0.897 0.103 0.897 0.115 273 67.3 340.3 6116.95 
5.431 5.742 0.311 2.716 0.115 0.885 0.115 0.885 0.129 273 67.6 340.6 5791.37 
5.431 5.785 0.354 2.716 0.130 0.870 0.130 0.870 0.150 273 67.9 340.9 5379.74 
5.431 5.821 0.390 2.716 0.144 0.856 0.144 0.856 0.168 273 68.2 341.2 5067.16 
5.431 5.865 0.434 2.716 0.160 0.840 0.160 0.840 0.190 273 68.5 341.5 4716.06 
5.431 5.911 0.480 2.716 0.177 0.823 0.177 0.823 0.215 273 68.8 341.8 4373.13 
5.431 5.966 0.535 2.716 0.197 0.803 0.197 0.803 0.245 273 69.1 342.1 3998.96 
5.431 6.020 0.589 2.716 0.217 0.783 0.217 0.783 0.277 273 69.4 342.4 3655.40 
5.431 6.078 0.647 2.716 0.238 0.762 0.238 0.762 0.313 273 69.7 342.7 3313.92 
5.431 6.135 0.704 2.716 0.259 0.741 0.259 0.741 0.350 273 70 343 2993.60 
5.431 6.196 0.765 2.716 0.282 0.718 0.282 0.718 0.392 273 70.3 343.3 2671.90 
5.431 6.265 0.834 2.716 0.307 0.693 0.307 0.693 0.443 273 70.6 343.6 2327.19 
5.431 6.331 0.900 2.716 0.331 0.669 0.331 0.669 0.496 273 70.9 343.9 2006.99 
5.431 6.395 0.964 2.716 0.355 0.645 0.355 0.645 0.550 273 71.2 344.2 1710.61 
5.431 6.465 1.034 2.716 0.381 0.619 0.381 0.619 0.615 273 71.5 344.5 1392.72 
5.431 6.539 1.108 2.716 0.408 0.592 0.408 0.592 0.689 273 71.8 344.8 1069.48 
5.431 6.617 1.186 2.716 0.437 0.563 0.437 0.563 0.775 273 72.1 345.1 730.46 
5.431 6.706 1.275 2.716 0.469 0.531 0.469 0.531 0.885 273 72.4 345.4 351.59 
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Table A.12: Mouse IgG data calculated from equations 1 – 5 (Chapter 3). Third replicate. 
 Fm 
PfLDH 
IgY 
Fluoro 
data F- F min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf)   T  
T in 
kelvin ΔGµ 
5.264 5.264 0.000 3.014 0.000 1.000 0.000 1.000 0.000 273 61.3 334.3 29995.51 
5.264 5.269 0.005 3.014 0.002 0.998 0.002 0.998 0.002 273 61.6 334.6 17934.12 
5.264 5.275 0.011 3.014 0.004 0.996 0.004 0.996 0.004 273 61.9 334.9 15596.90 
5.264 5.279 0.015 3.014 0.005 0.995 0.005 0.995 0.005 273 62.2 335.2 14812.40 
5.264 5.290 0.026 3.014 0.009 0.991 0.009 0.991 0.009 273 62.5 335.5 13261.40 
5.264 5.297 0.033 3.014 0.011 0.989 0.011 0.989 0.011 273 62.8 335.8 12576.95 
5.264 5.301 0.037 3.014 0.012 0.988 0.012 0.988 0.012 273 63.1 336.1 12289.45 
5.264 5.310 0.046 3.014 0.015 0.985 0.015 0.985 0.015 273 63.4 336.4 11675.51 
5.264 5.315 0.051 3.014 0.017 0.983 0.017 0.983 0.017 273 63.7 336.7 11345.71 
5.264 5.326 0.062 3.014 0.020 0.980 0.020 0.980 0.021 273 64 337 10837.75 
5.264 5.336 0.072 3.014 0.024 0.976 0.024 0.976 0.024 273 64.3 337.3 10419.54 
5.264 5.345 0.081 3.014 0.027 0.973 0.027 0.973 0.028 273 64.6 337.6 10084.07 
5.264 5.359 0.095 3.014 0.031 0.969 0.031 0.969 0.033 273 64.9 337.9 9625.64 
5.264 5.376 0.112 3.014 0.037 0.963 0.037 0.963 0.039 273 65.2 338.2 9142.06 
5.264 5.390 0.126 3.014 0.042 0.958 0.042 0.958 0.044 273 65.5 338.5 8808.36 
5.264 5.411 0.147 3.014 0.049 0.951 0.049 0.951 0.051 273 65.8 338.8 8364.85 
5.264 5.432 0.168 3.014 0.056 0.944 0.056 0.944 0.059 273 66.1 339.1 7980.64 
5.264 5.454 0.190 3.014 0.063 0.937 0.063 0.937 0.067 273 66.4 339.4 7616.73 
5.264 5.477 0.213 3.014 0.071 0.929 0.071 0.929 0.076 273 66.7 339.7 7280.82 
5.264 5.502 0.238 3.014 0.079 0.921 0.079 0.921 0.086 273 67 340 6942.11 
5.264 5.532 0.268 3.014 0.089 0.911 0.089 0.911 0.098 273 67.3 340.3 6586.75 
165 
5.264 5.568 0.304 3.014 0.101 0.899 0.101 0.899 0.112 273 67.6 340.6 6196.90 
5.264 5.603 0.339 3.014 0.113 0.887 0.113 0.887 0.127 273 67.9 340.9 5851.51 
5.264 5.638 0.374 3.014 0.124 0.876 0.124 0.876 0.142 273 68.2 341.2 5540.51 
5.264 5.682 0.418 3.014 0.139 0.861 0.139 0.861 0.161 273 68.5 341.5 5183.98 
5.264 5.731 0.467 3.014 0.155 0.845 0.155 0.845 0.184 273 68.8 341.8 4818.54 
5.264 5.785 0.521 3.014 0.173 0.827 0.173 0.827 0.209 273 69.1 342.1 4456.34 
5.264 5.831 0.567 3.014 0.188 0.812 0.188 0.812 0.232 273 69.4 342.4 4161.37 
5.264 5.884 0.620 3.014 0.206 0.794 0.206 0.794 0.259 273 69.7 342.7 3850.92 
5.264 5.938 0.674 3.014 0.224 0.776 0.224 0.776 0.288 273 70 343 3549.87 
5.264 6.002 0.738 3.014 0.245 0.755 0.245 0.755 0.325 273 70.3 343.3 3212.56 
5.264 6.067 0.803 3.014 0.266 0.734 0.266 0.734 0.363 273 70.6 343.6 2892.84 
5.264 6.134 0.870 3.014 0.289 0.711 0.289 0.711 0.406 273 70.9 343.9 2580.62 
5.264 6.199 0.935 3.014 0.310 0.690 0.310 0.690 0.449 273 71.2 344.2 2288.58 
5.264 6.276 1.012 3.014 0.336 0.664 0.336 0.664 0.506 273 71.5 344.5 1952.86 
5.264 6.349 1.085 3.014 0.360 0.640 0.360 0.640 0.562 273 71.8 344.8 1650.48 
5.264 6.430 1.166 3.014 0.387 0.613 0.387 0.613 0.631 273 72.1 345.1 1320.82 
5.264 6.511 1.247 3.014 0.414 0.586 0.414 0.586 0.706 273 72.4 345.4 1001.21 
5.264 6.597 1.333 3.014 0.442 0.558 0.442 0.558 0.793 273 72.7 345.7 665.28 
5.264 6.682 1.418 3.014 0.470 0.530 0.470 0.530 0.888 273 73 346 340.44 
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Table A.13: Rabbit IgG data calculated from equations 1 – 5 (Chapter 3). First replicate. 
 Fm 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf)   T  
T in 
Kelvin  ΔµG 
5.44 5.452 0.012 3.52 0.003 0.997 0.003 0.997 0.004 273 63.7 336.7 15828.71 
5.44 5.456 0.016 3.52 0.004 0.996 0.004 0.996 0.005 273 64 337 15137.12 
5.44 5.468 0.028 3.52 0.008 0.992 0.008 0.992 0.008 273 64.3 337.3 13494.28 
5.44 5.485 0.045 3.52 0.013 0.987 0.013 0.987 0.013 273 64.6 337.6 12212.83 
5.44 5.498 0.058 3.52 0.016 0.984 0.016 0.984 0.017 273 64.9 337.9 11490.41 
5.44 5.518 0.078 3.52 0.022 0.978 0.022 0.978 0.023 273 65.2 338.2 10663.51 
5.44 5.532 0.092 3.52 0.026 0.974 0.026 0.974 0.027 273 65.5 338.5 10196.26 
5.44 5.547 0.107 3.52 0.030 0.970 0.030 0.970 0.031 273 65.8 338.8 9760.72 
5.44 5.574 0.134 3.52 0.038 0.962 0.038 0.962 0.040 273 66.1 339.1 9101.36 
5.44 5.593 0.153 3.52 0.043 0.957 0.043 0.957 0.045 273 66.4 339.4 8723.59 
5.44 5.624 0.184 3.52 0.052 0.948 0.052 0.948 0.055 273 66.7 339.7 8181.59 
5.44 5.651 0.211 3.52 0.060 0.940 0.060 0.940 0.064 273 67 340 7784.43 
5.44 5.680 0.240 3.52 0.068 0.932 0.068 0.932 0.073 273 67.3 340.3 7394.98 
5.44 5.714 0.274 3.52 0.078 0.922 0.078 0.922 0.084 273 67.6 340.6 7004.67 
5.44 5.754 0.314 3.52 0.089 0.911 0.089 0.911 0.098 273 67.9 340.9 6586.29 
5.44 5.791 0.351 3.52 0.100 0.900 0.100 0.900 0.111 273 68.2 341.2 6244.27 
5.44 5.833 0.393 3.52 0.112 0.888 0.112 0.888 0.126 273 68.5 341.5 5885.27 
5.44 5.875 0.435 3.52 0.124 0.876 0.124 0.876 0.141 273 68.8 341.8 5565.73 
5.44 5.931 0.491 3.52 0.140 0.860 0.140 0.860 0.162 273 69.1 342.1 5174.01 
5.44 5.983 0.543 3.52 0.154 0.846 0.154 0.846 0.182 273 69.4 342.4 4846.52 
5.44 6.040 0.600 3.52 0.171 0.829 0.171 0.829 0.206 273 69.7 342.7 4508.05 
167 
5.44 6.099 0.659 3.52 0.187 0.813 0.187 0.813 0.230 273 70 343 4185.45 
5.44 6.162 0.722 3.52 0.205 0.795 0.205 0.795 0.258 273 70.3 343.3 3869.22 
5.44 6.236 0.796 3.52 0.226 0.774 0.226 0.774 0.292 273 70.6 343.6 3512.66 
5.44 6.311 0.871 3.52 0.248 0.752 0.248 0.752 0.329 273 70.9 343.9 3179.23 
5.44 6.383 0.943 3.52 0.268 0.732 0.268 0.732 0.366 273 71.2 344.2 2877.04 
5.44 6.464 1.024 3.52 0.291 0.709 0.291 0.709 0.411 273 71.5 344.5 2550.48 
5.44 6.546 1.106 3.52 0.314 0.686 0.314 0.686 0.458 273 71.8 344.8 2236.35 
5.44 6.634 1.194 3.52 0.339 0.661 0.339 0.661 0.514 273 72.1 345.1 1911.96 
5.44 6.729 1.289 3.52 0.366 0.634 0.366 0.634 0.578 273 72.4 345.4 1574.98 
5.44 6.821 1.381 3.52 0.392 0.608 0.392 0.608 0.646 273 72.7 345.7 1257.87 
5.44 6.911 1.471 3.52 0.418 0.582 0.418 0.582 0.718 273 73 346 953.36 
5.44 7.002 1.562 3.52 0.444 0.556 0.444 0.556 0.798 273 73.3 346.3 651.20 
5.44 7.095 1.655 3.52 0.470 0.530 0.470 0.530 0.887 273 73.6 346.6 345.02 
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Table A.14: Rabbit IgG data calculated from equations 1 – 5 (Chapter 3). Second replicate. 
 Fm 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf)   T  
T in 
Kelvin   ΔµG 
5.74 5.742 0.002 3.54 0.001 0.999 0.001 0.999 0.001 273 60.7 333.7 20409.65 
5.74 5.744 0.004 3.54 0.001 0.999 0.001 0.999 0.001 273 61 334 19053.42 
5.74 5.747 0.007 3.54 0.002 0.998 0.002 0.998 0.002 273 61.3 334.3 17479.49 
5.74 5.754 0.014 3.54 0.004 0.996 0.004 0.996 0.004 273 61.6 334.6 15481.57 
5.74 5.764 0.024 3.54 0.007 0.993 0.007 0.993 0.007 273 61.9 334.9 13914.51 
5.74 5.774 0.034 3.54 0.010 0.990 0.010 0.990 0.010 273 62.2 335.2 12939.39 
5.74 5.775 0.035 3.54 0.010 0.990 0.010 0.990 0.010 273 62.5 335.5 12887.80 
5.74 5.781 0.041 3.54 0.011 0.989 0.011 0.989 0.012 273 62.8 335.8 12450.21 
5.74 5.790 0.050 3.54 0.014 0.986 0.014 0.986 0.014 273 63.1 336.1 11890.28 
5.74 5.793 0.053 3.54 0.015 0.985 0.015 0.985 0.015 273 63.4 336.4 11726.52 
5.74 5.798 0.058 3.54 0.016 0.984 0.016 0.984 0.017 273 63.7 336.7 11478.52 
5.74 5.804 0.064 3.54 0.018 0.982 0.018 0.982 0.019 273 64 337 11178.54 
5.74 5.814 0.074 3.54 0.021 0.979 0.021 0.979 0.021 273 64.3 337.3 10798.25 
5.74 5.827 0.087 3.54 0.025 0.975 0.025 0.975 0.025 273 64.6 337.6 10327.69 
5.74 5.840 0.100 3.54 0.028 0.972 0.028 0.972 0.029 273 64.9 337.9 9929.60 
5.74 5.857 0.117 3.54 0.033 0.967 0.033 0.967 0.034 273 65.2 338.2 9499.54 
5.74 5.876 0.136 3.54 0.038 0.962 0.038 0.962 0.040 273 65.5 338.5 9069.67 
5.74 5.897 0.157 3.54 0.044 0.956 0.044 0.956 0.046 273 65.8 338.8 8649.49 
5.74 5.915 0.175 3.54 0.049 0.951 0.049 0.951 0.052 273 66.1 339.1 8337.94 
169 
5.74 5.941 0.201 3.54 0.057 0.943 0.057 0.943 0.060 273 66.4 339.4 7933.63 
5.74 5.967 0.227 3.54 0.064 0.936 0.064 0.936 0.068 273 66.7 339.7 7573.41 
5.74 5.993 0.253 3.54 0.071 0.929 0.071 0.929 0.077 273 67 340 7253.92 
5.74 6.016 0.276 3.54 0.078 0.922 0.078 0.922 0.084 273 67.3 340.3 6994.51 
5.74 6.052 0.312 3.54 0.088 0.912 0.088 0.912 0.097 273 67.6 340.6 6613.91 
5.74 6.083 0.343 3.54 0.097 0.903 0.097 0.903 0.107 273 67.9 340.9 6322.93 
5.74 6.123 0.383 3.54 0.108 0.892 0.108 0.892 0.121 273 68.2 341.2 5987.75 
5.74 6.166 0.426 3.54 0.120 0.880 0.120 0.880 0.137 273 68.5 341.5 5651.71 
5.74 6.212 0.472 3.54 0.133 0.867 0.133 0.867 0.154 273 68.8 341.8 5319.69 
5.74 6.263 0.523 3.54 0.148 0.852 0.148 0.852 0.173 273 69.1 342.1 4985.08 
5.74 6.325 0.585 3.54 0.165 0.835 0.165 0.835 0.198 273 69.4 342.4 4613.96 
5.74 6.376 0.636 3.54 0.180 0.820 0.180 0.820 0.219 273 69.7 342.7 4328.08 
5.74 6.441 0.701 3.54 0.198 0.802 0.198 0.802 0.247 273 70 343 3990.74 
5.74 6.507 0.767 3.54 0.217 0.783 0.217 0.783 0.277 273 70.3 343.3 3667.46 
5.74 6.571 0.831 3.54 0.235 0.765 0.235 0.765 0.307 273 70.6 343.6 3374.10 
5.74 6.648 0.908 3.54 0.256 0.744 0.256 0.744 0.345 273 70.9 343.9 3045.12 
5.74 6.724 0.984 3.54 0.278 0.722 0.278 0.722 0.385 273 71.2 344.2 2733.41 
5.74 6.797 1.057 3.54 0.299 0.701 0.299 0.701 0.426 273 71.5 344.5 2446.30 
5.74 6.878 1.138 3.54 0.321 0.679 0.321 0.679 0.474 273 71.8 344.8 2142.56 
5.74 6.961 1.221 3.54 0.345 0.655 0.345 0.655 0.527 273 72.1 345.1 1839.75 
5.74 7.049 1.309 3.54 0.370 0.630 0.370 0.630 0.587 273 72.4 345.4 1532.13 
5.74 7.139 1.399 3.54 0.395 0.605 0.395 0.605 0.653 273 72.7 345.7 1224.70 
5.74 7.224 1.484 3.54 0.419 0.581 0.419 0.581 0.722 273 73 346 936.97 
5.74 7.311 1.571 3.54 0.444 0.556 0.444 0.556 0.798 273 73.3 346.3 651.05 
5.74 7.407 1.667 3.54 0.471 0.529 0.471 0.529 0.890 273 73.6 346.6 335.03 
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Table A.15: Rabbit IgG data calculated from equations 1 – 5 (Chapter 3). Third replicate. 
 Fm 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf)   T  
T in 
Kelvin ΔµG 
5.75 5.756 0.006 3.18 0.002 0.998 0.002 0.998 0.002 273 60.7 333.7 17632.25 
5.75 5.756 0.006 3.18 0.002 0.998 0.002 0.998 0.002 273 61 334 17525.28 
5.75 5.764 0.014 3.18 0.004 0.996 0.004 0.996 0.004 273 61.3 334.3 15151.17 
5.75 5.766 0.016 3.18 0.005 0.995 0.005 0.995 0.005 273 61.6 334.6 14703.43 
5.75 5.772 0.022 3.18 0.007 0.993 0.007 0.993 0.007 273 61.9 334.9 13831.49 
5.75 5.781 0.031 3.18 0.010 0.990 0.010 0.990 0.010 273 62.2 335.2 12907.33 
5.75 5.783 0.033 3.18 0.010 0.990 0.010 0.990 0.010 273 62.5 335.5 12721.49 
5.75 5.789 0.039 3.18 0.012 0.988 0.012 0.988 0.012 273 62.8 335.8 12274.51 
5.75 5.793 0.043 3.18 0.014 0.986 0.014 0.986 0.014 273 63.1 336.1 11985.81 
5.75 5.799 0.049 3.18 0.015 0.985 0.015 0.985 0.016 273 63.4 336.4 11629.60 
5.75 5.802 0.052 3.18 0.016 0.984 0.016 0.984 0.017 273 63.7 336.7 11463.10 
5.75 5.811 0.061 3.18 0.019 0.981 0.019 0.981 0.020 273 64 337 11019.13 
5.75 5.820 0.070 3.18 0.022 0.978 0.022 0.978 0.023 273 64.3 337.3 10628.54 
5.75 5.830 0.080 3.18 0.025 0.975 0.025 0.975 0.026 273 64.6 337.6 10257.72 
5.75 5.846 0.096 3.18 0.030 0.970 0.030 0.970 0.031 273 64.9 337.9 9755.56 
5.75 5.861 0.111 3.18 0.035 0.965 0.035 0.965 0.036 273 65.2 338.2 9347.88 
5.75 5.871 0.121 3.18 0.038 0.962 0.038 0.962 0.040 273 65.5 338.5 9080.29 
5.75 5.885 0.135 3.18 0.043 0.957 0.043 0.957 0.044 273 65.8 338.8 8769.49 
5.75 5.903 0.153 3.18 0.048 0.952 0.048 0.952 0.050 273 66.1 339.1 8420.43 
5.75 5.922 0.172 3.18 0.054 0.946 0.054 0.946 0.057 273 66.4 339.4 8082.70 
171 
5.75 5.950 0.200 3.18 0.063 0.937 0.063 0.937 0.067 273 66.7 339.7 7637.07 
5.75 5.967 0.217 3.18 0.068 0.932 0.068 0.932 0.073 273 67 340 7387.80 
5.75 5.995 0.245 3.18 0.077 0.923 0.077 0.923 0.083 273 67.3 340.3 7029.90 
5.75 6.029 0.279 3.18 0.088 0.912 0.088 0.912 0.096 273 67.6 340.6 6626.99 
5.75 6.066 0.316 3.18 0.099 0.901 0.099 0.901 0.110 273 67.9 340.9 6249.18 
5.75 6.104 0.354 3.18 0.111 0.889 0.111 0.889 0.125 273 68.2 341.2 5892.34 
5.75 6.145 0.395 3.18 0.124 0.876 0.124 0.876 0.142 273 68.5 341.5 5545.69 
5.75 6.181 0.431 3.18 0.135 0.865 0.135 0.865 0.157 273 68.8 341.8 5268.82 
5.75 6.224 0.474 3.18 0.149 0.851 0.149 0.851 0.175 273 69.1 342.1 4952.57 
5.75 6.263 0.513 3.18 0.161 0.839 0.161 0.839 0.193 273 69.4 342.4 4690.98 
5.75 6.309 0.559 3.18 0.176 0.824 0.176 0.824 0.213 273 69.7 342.7 4401.65 
5.75 6.359 0.609 3.18 0.192 0.808 0.192 0.808 0.237 273 70 343 4106.04 
5.75 6.413 0.663 3.18 0.209 0.791 0.209 0.791 0.263 273 70.3 343.3 3807.27 
5.75 6.471 0.721 3.18 0.227 0.773 0.227 0.773 0.293 273 70.6 343.6 3503.69 
5.75 6.542 0.792 3.18 0.249 0.751 0.249 0.751 0.332 273 70.9 343.9 3156.37 
5.75 6.610 0.860 3.18 0.270 0.730 0.270 0.730 0.371 273 71.2 344.2 2841.40 
5.75 6.691 0.941 3.18 0.296 0.704 0.296 0.704 0.420 273 71.5 344.5 2483.32 
5.75 6.767 1.017 3.18 0.320 0.680 0.320 0.680 0.470 273 71.8 344.8 2164.64 
5.75 6.843 1.093 3.18 0.344 0.656 0.344 0.656 0.524 273 72.1 345.1 1855.33 
5.75 6.926 1.176 3.18 0.370 0.630 0.370 0.630 0.587 273 72.4 345.4 1529.07 
5.75 7.010 1.260 3.18 0.396 0.604 0.396 0.604 0.656 273 72.7 345.7 1211.05 
5.75 7.089 1.339 3.18 0.421 0.579 0.421 0.579 0.728 273 73 346 914.28 
5.75 7.166 1.416 3.18 0.445 0.555 0.445 0.555 0.803 273 73.3 346.3 631.67 
5.75 7.251 1.501 3.18 0.472 0.528 0.472 0.528 0.894 273 73.6 346.6 322.48 
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Table A.16: Chicken IgY data calculated from equations 1 – 5 (Chapter 3). First replicate. 
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) T  
T in 
kelvin ΔGµ 
9.37 9.401 0.031 19.5 0.002 0.998 0.002 0.998 0.002 62.2 273 335.2 17995.27 
9.37 9.421 0.051 19.5 0.003 0.997 0.003 0.997 0.003 62.5 273 335.5 16595.49 
9.37 9.438 0.068 19.5 0.003 0.997 0.003 0.997 0.003 62.8 273 335.8 15806.05 
9.37 9.438 0.068 19.5 0.003 0.997 0.003 0.997 0.004 63.1 273 336.1 15800.20 
9.37 9.447 0.077 19.5 0.004 0.996 0.004 0.996 0.004 63.4 273 336.4 15464.12 
9.37 9.483 0.113 19.5 0.006 0.994 0.006 0.994 0.006 63.7 273 336.7 14407.64 
9.37 9.540 0.170 19.5 0.009 0.991 0.009 0.991 0.009 64 273 337 13268.15 
9.37 9.559 0.189 19.5 0.010 0.990 0.010 0.990 0.010 64.3 273 337.3 12983.31 
9.37 9.588 0.218 19.5 0.011 0.989 0.011 0.989 0.011 64.6 273 337.6 12584.07 
9.37 9.620 0.250 19.5 0.013 0.987 0.013 0.987 0.013 64.9 273 337.9 12205.67 
9.37 9.690 0.320 19.5 0.016 0.984 0.016 0.984 0.017 65.2 273 338.2 11506.95 
9.37 9.747 0.377 19.5 0.019 0.981 0.019 0.981 0.020 65.5 273 338.5 11048.33 
9.37 9.815 0.445 19.5 0.023 0.977 0.023 0.977 0.023 65.8 273 338.8 10581.70 
9.37 9.879 0.509 19.5 0.026 0.974 0.026 0.974 0.027 66.1 273 339.1 10205.95 
9.37 9.956 0.586 19.5 0.030 0.970 0.030 0.970 0.031 66.4 273 339.4 9804.58 
9.37 10.054 0.684 19.5 0.035 0.965 0.035 0.965 0.036 66.7 273 339.7 9362.35 
9.37 10.165 0.795 19.5 0.041 0.959 0.041 0.959 0.042 67 273 340 8930.28 
9.37 10.271 0.901 19.5 0.046 0.954 0.046 0.954 0.048 67.3 273 340.3 8564.89 
9.37 10.389 1.019 19.5 0.052 0.948 0.052 0.948 0.055 67.6 273 340.6 8205.98 
9.37 10.541 1.171 19.5 0.060 0.940 0.060 0.940 0.064 67.9 273 340.9 7795.89 
9.37 10.721 1.351 19.5 0.069 0.931 0.069 0.931 0.074 68.2 273 341.2 7369.27 
173 
9.37 10.912 1.542 19.5 0.079 0.921 0.079 0.921 0.086 68.5 273 341.5 6970.61 
9.37 11.133 1.763 19.5 0.090 0.910 0.090 0.910 0.099 68.8 273 341.8 6561.05 
9.37 11.380 2.010 19.5 0.103 0.897 0.103 0.897 0.115 69.1 273 342.1 6154.68 
9.37 11.629 2.259 19.5 0.116 0.884 0.116 0.884 0.131 69.4 273 342.4 5786.90 
9.37 11.940 2.570 19.5 0.132 0.868 0.132 0.868 0.152 69.7 273 342.7 5371.51 
9.37 12.276 2.906 19.5 0.149 0.851 0.149 0.851 0.175 70 273 343 4968.97 
9.37 12.664 3.294 19.5 0.169 0.831 0.169 0.831 0.203 70.3 273 343.3 4547.67 
9.37 13.056 3.686 19.5 0.189 0.811 0.189 0.811 0.233 70.6 273 343.6 4161.13 
9.37 13.477 4.107 19.5 0.211 0.789 0.211 0.789 0.267 70.9 273 343.9 3778.32 
9.37 13.975 4.605 19.5 0.236 0.764 0.236 0.764 0.309 71.2 273 344.2 3359.37 
9.37 14.487 5.117 19.5 0.262 0.738 0.262 0.738 0.356 71.5 273 344.5 2960.62 
9.37 15.074 5.704 19.5 0.293 0.707 0.293 0.707 0.413 71.8 273 344.8 2532.08 
9.37 15.650 6.280 19.5 0.322 0.678 0.322 0.678 0.475 72.1 273 345.1 2136.04 
9.37 16.286 6.916 19.5 0.355 0.645 0.355 0.645 0.550 72.4 273 345.4 1719.30 
9.37 16.939 7.569 19.5 0.388 0.612 0.388 0.612 0.634 72.7 273 345.7 1308.42 
9.37 17.647 8.277 19.5 0.424 0.576 0.424 0.576 0.738 73 273 346 875.79 
9.37 18.361 8.991 19.5 0.461 0.539 0.461 0.539 0.856 73.3 273 346.3 449.35 
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Table A.17: Chicken IgY data calculated from equations 1 – 5 (Chapter 3). Second replicate. 
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min 
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is: Pf 
Ku= 
(pu/pf) T 273 
T in 
kelvin ΔGµ 
9.53 9.548 0.018 20.2 0.001 0.999 0.001 0.999 0.001 62.2 273 335.2 19599.96 
9.53 9.571 0.041 20.2 0.002 0.998 0.002 0.998 0.002 62.5 273 335.5 17263.14 
9.53 9.581 0.051 20.2 0.003 0.997 0.003 0.997 0.003 62.8 273 335.8 16683.62 
9.53 9.595 0.065 20.2 0.003 0.997 0.003 0.997 0.003 63.1 273 336.1 16035.19 
9.53 9.600 0.070 20.2 0.003 0.997 0.003 0.997 0.003 63.4 273 336.4 15849.90 
9.53 9.631 0.101 20.2 0.005 0.995 0.005 0.995 0.005 63.7 273 336.7 14830.50 
9.53 9.663 0.133 20.2 0.007 0.993 0.007 0.993 0.007 64 273 337 14050.04 
9.53 9.698 0.168 20.2 0.008 0.992 0.008 0.992 0.008 64.3 273 337.3 13404.81 
9.53 9.741 0.211 20.2 0.010 0.990 0.010 0.990 0.011 64.6 273 337.6 12771.38 
9.53 9.781 0.251 20.2 0.012 0.988 0.012 0.988 0.013 64.9 273 337.9 12294.20 
9.53 9.827 0.297 20.2 0.015 0.985 0.015 0.985 0.015 65.2 273 338.2 11827.09 
9.53 9.898 0.368 20.2 0.018 0.982 0.018 0.982 0.019 65.5 273 338.5 11222.87 
9.53 9.962 0.432 20.2 0.021 0.979 0.021 0.979 0.022 65.8 273 338.8 10774.15 
9.53 10.041 0.511 20.2 0.025 0.975 0.025 0.975 0.026 66.1 273 339.1 10297.03 
9.53 10.111 0.581 20.2 0.029 0.971 0.029 0.971 0.030 66.4 273 339.4 9931.03 
9.53 10.200 0.670 20.2 0.033 0.967 0.033 0.967 0.034 66.7 273 339.7 9524.37 
9.53 10.306 0.776 20.2 0.038 0.962 0.038 0.962 0.040 67 273 340 9105.01 
9.53 10.419 0.889 20.2 0.044 0.956 0.044 0.956 0.046 67.3 273 340.3 8709.33 
9.53 10.548 1.018 20.2 0.050 0.950 0.050 0.950 0.053 67.6 273 340.6 8315.97 
9.53 10.706 1.176 20.2 0.058 0.942 0.058 0.942 0.062 67.9 273 340.9 7891.38 
175 
9.53 10.889 1.359 20.2 0.067 0.933 0.067 0.933 0.072 68.2 273 341.2 7459.16 
9.53 11.105 1.575 20.2 0.078 0.922 0.078 0.922 0.085 68.5 273 341.5 7013.71 
9.53 11.329 1.799 20.2 0.089 0.911 0.089 0.911 0.098 68.8 273 341.8 6608.48 
9.53 11.548 2.018 20.2 0.100 0.900 0.100 0.900 0.111 69.1 273 342.1 6252.90 
9.53 11.815 2.285 20.2 0.113 0.887 0.113 0.887 0.128 69.4 273 342.4 5863.04 
9.53 12.121 2.591 20.2 0.128 0.872 0.128 0.872 0.147 69.7 273 342.7 5460.51 
9.53 12.488 2.958 20.2 0.146 0.854 0.146 0.854 0.172 70 273 343 5027.80 
9.53 12.860 3.330 20.2 0.165 0.835 0.165 0.835 0.197 70.3 273 343.3 4631.40 
9.53 13.278 3.748 20.2 0.186 0.814 0.186 0.814 0.228 70.6 273 343.6 4226.58 
9.53 13.738 4.208 20.2 0.208 0.792 0.208 0.792 0.263 70.9 273 343.9 3817.65 
9.53 14.243 4.713 20.2 0.233 0.767 0.233 0.767 0.304 71.2 273 344.2 3404.90 
9.53 14.790 5.260 20.2 0.260 0.740 0.260 0.740 0.352 71.5 273 344.5 2989.99 
9.53 15.394 5.864 20.2 0.290 0.710 0.290 0.710 0.409 71.8 273 344.8 2562.99 
9.53 16.022 6.492 20.2 0.321 0.679 0.321 0.679 0.474 72.1 273 345.1 2144.72 
9.53 16.689 7.159 20.2 0.354 0.646 0.354 0.646 0.549 72.4 273 345.4 1722.64 
9.53 17.375 7.845 20.2 0.388 0.612 0.388 0.612 0.635 72.7 273 345.7 1305.65 
9.53 18.120 8.590 20.2 0.425 0.575 0.425 0.575 0.740 73 273 346 866.63 
9.53 18.864 9.334 20.2 0.462 0.538 0.462 0.538 0.859 73.3 273 346.3 437.51 
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Table A.  18: Chicken IgY data calculated from equations 1 – 5 (Chapter 3). Third replicate. 
Fmin 
PfLDH 
IgY 
Fluoro 
data 
F- F 
min  
Fmax-
Fmin 
(F-
Fmin)/Fmax-
Fmin) 
1-(F-
Fmin)/Fmax-
Fmin) 
(F-
Fmin)/Fmax-
Fmin) 
Therefore 
Pu is:  Pf 
Ku= 
(pu/pf) T  
T in 
kelvin ΔGµ 
11.13 11.152 0.022 19.4 0.001 0.999 0.001 0.999 0.001 63.1 273 336.1 18902.25 
11.13 11.181 0.051 19.4 0.003 0.997 0.003 0.997 0.003 63.4 273 336.4 16614.64 
11.13 11.230 0.100 19.4 0.005 0.995 0.005 0.995 0.005 63.7 273 336.7 14719.80 
11.13 11.252 0.122 19.4 0.006 0.994 0.006 0.994 0.006 64 273 337 14197.38 
11.13 11.253 0.123 19.4 0.006 0.994 0.006 0.994 0.006 64.3 273 337.3 14178.97 
11.13 11.275 0.145 19.4 0.007 0.993 0.007 0.993 0.008 64.6 273 337.6 13715.68 
11.13 11.296 0.166 19.4 0.009 0.991 0.009 0.991 0.009 64.9 273 337.9 13347.54 
11.13 11.356 0.226 19.4 0.012 0.988 0.012 0.988 0.012 65.2 273 338.2 12483.13 
11.13 11.398 0.268 19.4 0.014 0.986 0.014 0.986 0.014 65.5 273 338.5 12013.85 
11.13 11.460 0.330 19.4 0.017 0.983 0.017 0.983 0.017 65.8 273 338.8 11431.31 
11.13 11.530 0.400 19.4 0.021 0.979 0.021 0.979 0.021 66.1 273 339.1 10887.30 
11.13 11.609 0.479 19.4 0.025 0.975 0.025 0.975 0.025 66.4 273 339.4 10376.75 
11.13 11.692 0.562 19.4 0.029 0.971 0.029 0.971 0.030 66.7 273 339.7 9921.81 
11.13 11.765 0.635 19.4 0.033 0.967 0.033 0.967 0.034 67 273 340 9570.68 
11.13 11.895 0.765 19.4 0.039 0.961 0.039 0.961 0.041 67.3 273 340.3 9033.02 
11.13 12.030 0.900 19.4 0.046 0.954 0.046 0.954 0.049 67.6 273 340.6 8563.31 
11.13 12.202 1.072 19.4 0.055 0.945 0.055 0.945 0.058 67.9 273 340.9 8047.12 
11.13 12.354 1.224 19.4 0.063 0.937 0.063 0.937 0.067 68.2 273 341.2 7655.31 
11.13 12.552 1.422 19.4 0.073 0.927 0.073 0.927 0.079 68.5 273 341.5 7203.88 
11.13 12.751 1.621 19.4 0.084 0.916 0.084 0.916 0.091 68.8 273 341.8 6805.92 
11.13 12.977 1.847 19.4 0.095 0.905 0.095 0.905 0.105 69.1 273 342.1 6404.62 
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11.13 13.226 2.096 19.4 0.108 0.892 0.108 0.892 0.121 69.4 273 342.4 6010.44 
11.13 13.529 2.399 19.4 0.124 0.876 0.124 0.876 0.141 69.7 273 342.7 5580.65 
11.13 13.854 2.724 19.4 0.140 0.860 0.140 0.860 0.163 70 273 343 5167.04 
11.13 14.247 3.117 19.4 0.161 0.839 0.161 0.839 0.191 70.3 273 343.3 4719.52 
11.13 14.631 3.501 19.4 0.180 0.820 0.180 0.820 0.220 70.6 273 343.6 4322.99 
11.13 15.081 3.951 19.4 0.204 0.796 0.204 0.796 0.256 70.9 273 343.9 3899.17 
11.13 15.559 4.429 19.4 0.228 0.772 0.228 0.772 0.296 71.2 273 344.2 3485.95 
11.13 16.117 4.987 19.4 0.257 0.743 0.257 0.743 0.346 71.5 273 344.5 3039.84 
11.13 16.695 5.565 19.4 0.287 0.713 0.287 0.713 0.402 71.8 273 344.8 2611.26 
11.13 17.300 6.170 19.4 0.318 0.682 0.318 0.682 0.466 72.1 273 345.1 2188.64 
11.13 17.938 6.808 19.4 0.351 0.649 0.351 0.649 0.541 72.4 273 345.4 1766.05 
11.13 18.616 7.486 19.4 0.386 0.614 0.386 0.614 0.628 72.7 273 345.7 1335.45 
11.13 19.333 8.203 19.4 0.423 0.577 0.423 0.577 0.733 73 273 346 895.23 
11.13 20.067 8.937 19.4 0.461 0.539 0.461 0.539 0.854 73.3 273 346.3 454.10 
1 
 
